Trading Analysis Report: LLY¶

Analysis date: 2026-10-03
Rating: Overweight
Generated: 2026-10-04 19:36:02
TradingAgents 0.6.0: anthropic, deep claude-opus-5-5, quick claude-opus-5-5
Analysts: market, sentiment, news, fundamentals; research debate rounds 5, risk debate rounds 5
Data vendors: core_stock_apis yfinance, technical_indicators yfinance, fundamental_data sec_edgar,yfinance, news_data yfinance, macro_data fred, prediction_markets polymarket

I. Analyst Team Reports¶

Market Analyst¶

Current Price: 1142.85 USD Price As Of: 2026-10-02

LLY (Eli Lilly and Company, NYSE): technical analysis¶

Analysis date is 2026-10-03, a Saturday. The last completed session was Friday 2026-10-02, and the next is Monday 2026-10-05.

Bottom line: LLY's long-term uptrend is intact, but it has moved sideways for about six weeks and the short-term signals turned down after a failed breakout on 9/30. At 1142.85 it sits in the lower-middle of its trading range, which is a poor spot for a new trade. The better entries are near the range floor (1107–1118) or on a daily close above 1217.65.

0. Data check¶

Verified bar for 2026-10-02: Open 1153.82, High 1164.92, Low 1136.66, Close 1142.85, Volume 2,052,300.
The two data sources agree. Every indicator that appears in both the indicator tool and the verified snapshot matches: 50-day average 1176.28, MACD −2.93, RSI 43.05, ATR 31.91.
The daily z-score is consistent with the Bollinger Bands. (1142.85 − 1151.22) ÷ 21.75 ≈ −0.38, which matches the z-score tool. There are no conflicts to flag.
Labels: anything marked derived or est. is my own arithmetic on the tool's prices, not a tool output.

1. Indicators chosen and why¶

The stock is moving sideways after a strong uptrend and just failed a breakout. So the indicators need to separate the long-term trend from short-term noise, show whether the market is trending or ranging, size risk, and check whether volume supports the moves.

SuperTrend. Trend direction and a stop level on the weekly, monthly and daily charts. It shows how the timeframes disagree.
50-day simple moving average. The medium-term trend line that price just failed to hold.
MACD. Momentum turns and crossovers. The snapshot adds the signal line and histogram.
RSI. Momentum level and divergences at the edges of the range.
ADX. Whether the market is trending or ranging.
ATR. Average daily move, used for stop distance and position size.
OBV (on-balance volume). Whether volume confirms the moves within the range.
Z-score. How stretched price is from its average on each timeframe.

The verified snapshot also supplied the 200-day average, the 10-day exponential average, the Bollinger Bands, and the MACD signal and histogram.

Not retrieved: +DI/−DI (which would show ADX direction), TD-9, MFI and VWMA. These are listed as gaps in section 11.

2. Price structure: a narrowing range after a big rally¶

The prior rally was large. Price rose from a 848.53 close on 4/29 to a 1280.34 close on 8/19, about +50.9%. The intraday high that day was 1292.65. Today's price is 10.7% below the 8/19 closing high.
Highs are falling while lows hold. The high dropped from 1292.65 on 8/19 to 1215.00 on 9/30. The floor stayed level:
Early August lows were 1107.56 (8/3) and 1107.57 (8/4). Price bounced to a 1168.19 close on 8/5.
September lows were 1113.55 (9/8) and 1113.29 (9/11). Price bounced to a 1138.28 close on 9/14 and reached 1184.78 by 9/28.
Monthly closes have gone flat: 1147.20 in July, 1156.73 in August and 1157.08 in September. August left a long upper wick of about 136 points (high 1292.65 against a 1156.73 close), meaning sellers pushed price well off the high.
The 9/30 failed breakout:
Price opened at 1186.49 and rose to 1215.00, above the 9/24 swing high of 1197.79.
It then closed at 1157.08, in the bottom 3% of the day's range.
It was an outside day: its high and low both exceeded the 9/29 bar (1192.94 / 1168.47).
The range was 59.73, about 1.8 times the ATR and the widest daily range since 8/5.
Volume was 3.41M, about 1.5 times the 20-day average of roughly 2.26M (derived). Apart from the 9/18 expiration session, that was the heaviest volume since 8/19. This is a sign of selling into strength.
Follow-through:
10/1 closed at 1149.85.
10/2 was another outside day: a high of 1164.92 (above the 10/1 high of 1158.72) and a low of 1136.66 (below 1139.85). It closed at 1142.85, in the bottom 22% of its range, so an intraday rally was sold.
The weekly bar looks bearish. The week opened at 1180.30, spiked to 1215.00 and closed at 1142.85. That close is below the prior week's 1144.50 open, so it erased all of that week's gain: −40.61, or −3.43%, week over week.
On closing prices, price has given back about 61% of the September rebound (1115.70 → 1184.78 → 1142.85).

3. Trend: the timeframes disagree¶

SuperTrend (when timeframes conflict, the weekly carries the most weight, then monthly, then daily):

Timeframe	Direction	Stop line	Close vs. stop
Weekly (primary)	UP	979.50	+16.68%
Monthly (background)	UP	781.18	+46.30%
Daily (entry timing)	DOWN	1217.65	−6.14%

The weekly and monthly trends are up. The daily trend is in a correction.
The daily stop line appears unchanged since the 9/11 low (derived). 1217.65 equals the 9/11 bar's midpoint (1122.37) plus 3 × ATR (31.76).
The 9/30 spike stopped 2.65 points short of that line (1215.00 against 1217.65). A daily close above 1217.65 would flip the daily trend up and put all three timeframes in agreement.

Moving averages: price sits below every short and medium average but above the 200-day.

Average	Value	Price vs. average
200-day	1071.34	+6.67%
20-day (Bollinger middle)	1151.22	−0.73%
10-day exponential	1160.38	−1.51%
50-day	1176.28	−2.84%

The 50-day average has flattened. It peaked at 1190.35 on 9/4 and has held around 1176–1178 since 9/22.
Price failed to reclaim it. Price closed below the 50-day for 19 sessions (8/27 to 9/23). It closed above for four sessions (9/24 to 9/29), then lost it again on 9/30.
The averages are converging (derived, assuming price stays near 1143):
The 50-day slips to about 1171 within five sessions, because the 7/24–7/30 closes leaving the window are mostly above 1190.
The 20-day rises to about 1155, because the 9/4–9/11 lows leave its window.
The 200-day keeps rising to about 1075 by mid-October, because the closes leaving its window are the 12/16–12/30/2025 closes of 1036.78–1074.56.

4. Momentum: rolling over¶

MACD is about to cross bearish.
MACD is −2.93 against a signal line of −3.59, so the histogram is +0.67.
MACD bottomed at −18.20 on 9/11. It turned positive only on 9/29 (+0.89), then fell to −0.05, −1.36 and −2.93.
So MACD failed to hold above zero, and its 9/29 peak was far below the 8/24 peak of 21.81.
Est.: by standard MACD arithmetic, a close below about 1150 on 10/5 would likely turn the histogram negative (a bearish signal-line cross). A close above about 1150 would delay it.
RSI is falling and below 50.
It is at 43.05, down 13 points from 56.05 on 9/29.
Since 8/4 it has stayed between 35.50 (9/11) and 65.23 (8/19). It was never overbought at the high or oversold at the low, which is normal for a range.
At the 9/11 retest of the floor (close 1115.70), RSI made a lower low than at the 8/4 low (35.50 against 40.23 at a close of 1114.08). The retest was weaker, so there was no bullish divergence.
What to watch: if a third test of 1107–1115 comes with RSI holding above about 35.5, that would be a bullish divergence.

5. Trend strength (ADX): mostly a ranging market¶

ADX is 23.94, below the 25 level that marks a real trend. It was above 25 on only 5 of the 43 sessions since 8/4: the 8/20–8/25 cluster, peaking at 27.33, and 9/30 at 25.06.
It hit 4.98 on 9/18, an extremely trendless reading.
The rise into 9/30 most likely measured the late-September upswing. On 9/30 the move above the prior high (+22.06) was larger than the move below the prior low (−13.20) (derived), so ADX counted that day as upward pressure even though it closed as a bearish reversal. ADX therefore isn't confirming a new downtrend. Direction can't be verified without +DI/−DI.
Implication: range trading suits this market better than trend-following.

6. Volatility (ATR and Bollinger Bands)¶

ATR is 31.91, or 2.79% of price. That is down about 25% from 42.72 on 8/6. It bottomed at 29.48 on 9/18 and ticked up to 33.22 on the 9/30 reversal.
Stop distances: 1× ATR = 31.91, 1.5× = 47.87, 2× = 63.82.
The Bollinger Bands match the range closely:
Lower band 1107.71, middle 1151.22, upper 1194.72.
Band width is 87.01, or 7.56% of the middle.
Price sits at about 40% of the way from the lower band to the upper band.
The lower band is about the same level as the August lows (1107.56). The upper band is about the same level as the late-September highs (1192.94–1197.79).

7. Volume (OBV): no sign of accumulation¶

OBV is 345.81M. It fell 9.29M over the four lower closes since 9/28, giving back about 54% of the rebound's OBV gain.
OBV didn't confirm the August high. It reached 357.01M on 8/19 at a 1280.34 close, below the 357.66M reached on 7/28 at a 1218.91 close.
It made a lower low on the September retest: 337.85M on 9/11 against 342.54M on 8/4, at about the same price.
The 9/11 → 9/28 OBV rebound (+17.25M) is overstated. On 9/18, 4.54M shares traded on a close only 0.49 higher. That is likely third-Friday options expiration flow (inference).
Volume was heavier on the way down than the way up (derived). The 8/26–9/11 decline averaged about 2.44M shares a day. The 9/14–9/29 rally averaged about 2.04M excluding 9/18.

8. Stretch (z-score): nothing is stretched¶

Readings: weekly −0.37, monthly +1.07, daily −0.38.
No timeframe is beyond ±2, so there is no statistical case for a snap-back in either direction.
LLY is fairly valued on the weekly and daily charts. Any edge has to come from the range boundaries, not mean reversion.

9. Overall read¶

Long term (bullish): the weekly and monthly SuperTrend are up, and price is above a rising 200-day average.
Medium term (sideways): the 50-day average is flat, ADX has been below 25 on 38 of 43 sessions, and three monthly closes were flat.
Short term (bearish): the daily SuperTrend is down, and the 9/30 failed breakout came on heavy volume. Price is below the 10-day, 20-day and 50-day averages. MACD is close to a bearish cross, RSI is at 43 and falling, and OBV is falling.
Overall: neutral, leaning bearish in the near term, inside a long-term uptrend. At 1142.85 price is about 35 points (1.1 ATR) above the floor and about 52 points (1.6 ATR) below the upper band. That gives a poor reward-to-risk ratio for a new trade. Another agent should make the final trade decision.

10. Trade setups for LLY¶

The 10/5 pivot is about 1150–1151 (20-day average plus the estimated MACD crossover level). - A close above it delays the bearish cross. The next hurdles are 1160.38 (10-day exponential average) and 1164.92 (the 10/2 high). - A close below 1136.66 points to 1130.50–1134.41 (the 9/14–9/21 lows), then 1107–1115.

A. Buy at the range floor (base case; best reward-to-risk) - Entry: 1110–1120 (1115 used below). - Confirm with: a close back above about 1115, RSI above 35.5, OBV holding above 337.85M, and the MACD histogram turning up. - Stop: about 1090, which is roughly half an ATR below 1107.56. - Targets: 1151 (≈1.4× risk), about 1171–1176 (≈2.2–2.4×), and 1195 (≈3.2×). - Caution: the stop is less than one ATR away. Either use smaller size, or put the stop under the 200-day (about 1065) at half size.

B. Buy a breakout (follows the trend; lower payoff ratio) - Trigger: a daily close above 1217.65, which also clears the 1215.00 rejection high. - Confirm with: ADX above 25, MACD above 0, RSI above 60, and volume above about 2.3M. - Targets: 1247.66 (the 7/7 high), then 1280.34–1292.65. - Stop: 1.5× ATR (about 48 points) below entry. - Payoff: about 1.3–1.5× risk to the old highs. The real upside comes from trailing the stop if price makes new highs.

C. Range breakdown (mainly a risk-management trigger) - Trigger: a daily close below about 1107 (the August lows and the lower band). - Next levels: the rising 200-day at about 1071–1075. - For holders: a close below the 200-day is the first real warning to the long-term trend. The weekly stop at 979.50 is the final line.

D. Short-term short (against the weekly trend; half size) - Entry: fade rallies into 1165–1195 (10/2 high, 50-day average, late-September highs) after a rejection candle. - Stop: above 1218. - Targets: 1137, then 1115. That pays about 1.3–1.5× risk from 1176 and about 2–3× from 1185–1195.

Position sizing: risking 1% of $100k ($1,000) allows about 20 shares with a 1.5× ATR stop (about $22.9k position), or about 15 shares with a 2× ATR stop.

11. Risks and gaps¶

Price gaps can jump stops (inference). The highest-volume days in the data produced large moves:
10/30/2025 (6.04M shares): +3.8%.
2/4/2026 (7.12M): opened at 1069.95 against a 998.64 prior close, a +7.1% gap, closed +10.3%, then fell 7.8% the next day.
4/30/2026 (8.24M): +9.8%.
8/5/2026 (6.45M): +4.9%.
Downside gaps happen too. 7/30/2026 opened at 1172.35 against a 1208.29 prior close, a −3.0% gap.
Earnings may fall inside a normal swing-trade holding period. The big-volume days above look like quarterly earnings releases. If that pattern holds, the next is likely in late October or early November. Check the calendar.
Indicator gaps: without +DI/−DI, ADX direction is unconfirmed. TD-9, MFI and VWMA were not pulled.
Projections are estimates. The moving-average drift and the MACD crossover level assume a flat price; they are not tool outputs.

12. Summary table¶

Area	Item	Verified value (10/02)	What it shows	What to do
Price	Close	1142.85	Lower-middle of the 1107–1195 range (about 40% up from the lower band)	Middle of range: poor reward-to-risk for new trades
Trend (weekly)	SuperTrend	UP, stop 979.50 (+16.68%)	Long-term uptrend intact	Prefer buying dips to shorting breakdowns
Trend (monthly)	SuperTrend	UP, stop 781.18 (+46.30%)	Long-term background is bullish	Background only
Trend (daily)	SuperTrend	DOWN, stop 1217.65 (−6.14%)	Short-term correction; 9/30 high stopped 2.65 below the line	Close above 1217.65 = all-timeframe buy signal
Long-term average	200-day	1071.34 (+6.67%)	Rising (est. about 1075 by mid-October)	Deep support; long-term trend warning line
Medium average	50-day	1176.28 (−2.84%)	Flat; failed reclaim 9/24–9/29, lost 9/30	Resistance, drifting to about 1171
Short averages	10-day exp. / 20-day	1160.38 / 1151.22	Price below both	First hurdle at 1150–1160
Momentum	MACD / signal / histogram	−2.93 / −3.59 / +0.67	Rolling over after failing to hold above zero	Bearish cross likely if 10/5 closes below about 1150 (est.)
Momentum	RSI	43.05	Down from 56.05; range 35.5–65.2	Neutral to bearish; above 35.5 at support = divergence
Trend strength	ADX	23.94	Below 25 on 38 of 43 sessions	Trade the range; trend signals are unreliable
Volatility	ATR	31.91 (2.79%)	Down 25% from 42.72 on 8/6	Stops: 1.5× = 47.87, 2× = 63.82
Volatility	Bollinger Bands	1107.71 / 1151.22 / 1194.72	Bands match the range	Buy near lower band, fade near upper band while ADX is below 25
Volume	OBV	345.81M	Down 9.29M since 9/28; lower low on 9/11; didn't confirm 8/19 high	No buying signal; watch 337.85M
Volume	9/30 reversal	3.41M (about 1.5× average)	Selling into strength at the failed breakout	Respect selling pressure at 1185–1218
Stretch	Z-score weekly / monthly / daily	−0.37 / +1.07 / −0.38	Nothing stretched	No snap-back edge
Support	Levels	1136.66 → 1130.50–1134.41 → 1107.56–1113.55 → 1071.34	Floor held on 8/3–8/4 and 9/8–9/11	Buy zone 1107–1118, stop about 1090
Resistance	Levels	1151–1160 → 1176.28 → 1184.78–1197.79 → 1215.00–1217.65 → 1280.34–1292.65	Several layers of selling	Fade 1185–1195 short-term; buy above 1217.65
Event risk	Big-volume gap days	+7.1% gap on 2/4/26; −3.0% gap on 7/30/26	Next likely late Oct / early Nov (inferred; verify)	Size positions for gaps
Overall	—	—	Neutral, near-term bearish tilt inside a long-term uptrend	Wait for the range edges or a daily close above 1217.65

Sentiment Analyst¶

Overall Sentiment: Mildly Bullish (Score: 6.0/10) Confidence: Low

LLY sentiment for 2026-09-26 to 2026-10-03 (now = Saturday 2026-10-03) leans constructive. The support comes from hard, company-specific news: an FDA label expansion for Jaypirca and several positive obesity/diabetes data headlines (Foundayo, EloraTZP). The retail layer is far more two-sided than its 13-to-1 tag ratio suggests, and retail posters describe a down week for the stock despite the good news. Net: Mildly Bullish (6.0/10).

Confidence is low per methodology, for three reasons: - Reddit returned a placeholder. - The news feed is headline-only. - The StockTwits sample spans only ~32 hours, 46% of posts lead with other cashtags, and one user wrote 18% of them.

The read on hard events is sturdier than the retail read. Weigh this alongside fundamentals and technicals; it is not a price call.

1. Source-by-source breakdown¶

News — Yahoo Finance (18 headlines; headlines only, no article bodies) - LLY-specific positive events (5 headlines): - (a) Jaypirca (pirtobrutinib) won an expanded FDA indication in previously untreated CLL/SLL. Both the company release (PR Newswire: 'the first-and-only approved non-covalent BTK inhibitor ... for certain patients with previously untreated CLL/SLL') and MT Newswires carried it. It is the week's only hard regulatory event. It moves Jaypirca into the treatment-naive setting and diversifies the story beyond incretins. The 'certain patients' wording implies a defined subset whose size the headlines do not reveal. - (b) TheStreet: 'Eli Lilly’s Foundayo delivers diabetes surprise in late-stage study'. The framing reads positive, but the headline does not say what the surprise was. - © Zacks: 'LLY Highlights New Efficacy Data From Foundayo and EloraTZP Studies'. - (d) Simply Wall St.: 'Eli Lilly (LLY) Reported Strong Phase 2b And Phase 3 Obesity Trial Data'. - A FiercePharma link shared on StockTwits identifies Foundayo as Lilly's launched oral GLP-1, tracked against Novo's Wegovy pill. Judging by its name and the CNBC excerpts quoted on StockTwits, EloraTZP appears to be an amylin agent layered on tirzepatide (inference). - Bullish opinion pieces (2): 24/7 Wall St. 'Prediction: Eli Lilly Could Be the Next $2 Trillion Drugmaker', and TIKR 'Eli Lilly Stock Is Up 7% in 2026 as Its Obesity Pipeline Expands' with a 2030 outlook. A +7% YTD gain is modest for a name attracting $2T calls; the narrative is running ahead of the share price. - LLY-adjacent negative (2 headlines, 1 event): Lilly ended its cancer collaboration with Foghorn Therapeutics. Headlines: 'FHTX Stock Extends Sell-Off After Lilly Collaboration Ends — Wedbush Slashes Target By 80%' (Stocktwits) and 'Foghorn Therapeutics layoffs' (Quartz). The damage falls mainly on the partner. For LLY it reads as minor oncology pipeline pruning. - Competitive context (1): Motley Fool on Novo Nordisk striking 'nearly $4 billion in 2 deals'. LLY's main obesity rival is buying pipeline. - Ambiguous (4): - 'Top Midday Decliners' and its 'Correction' (MT Newswires): constituents are not visible. The decliner may be FHTX given its concurrent sell-off; LLY's inclusion cannot be confirmed. - Motley Fool's Fed piece ('These 3 Stocks Win Either Way', filed under healthcare) may feature LLY; this is unverifiable. - Pharma Voice's '3 drug targets pharma is betting on next' is industry-level. - Noise (4): MarketBeat 'Income Stocks Under $30' (LLY trades ~$1,143 per a StockTwits post, so it is not a featured name), the WSJ ex-executive estate sale, a Benzinga inheritance/advisor story, and CFO Dive on chief AI officers. - Net news tone: positive and event-driven. 7 of 18 headlines are LLY-specific and positive-leaning. The set contains no LLY-specific negative event (safety signal, regulatory setback, guidance cut, downgrade or target cut) and no analyst rating action on LLY.

StockTwits (28 most-recent messages) - Headline stats: 13 Bullish (46%), 1 Bearish (4%), 14 unlabeled (50%). That is 93/7 among labeled posts, nominally in the ≥90/10 over-extension zone. - Coverage: posts span only 2026-10-02 14:27Z to 2026-10-03 22:12Z (~32 hours). 20 are from Friday 10-02 (mostly intraday) and 8 from Saturday 10-03 with the market closed. This is a ~1.3-day snapshot, not the 7-day window. There are 21 unique users; @biolover alone wrote 5 posts. - Cross-tag contamination: 13 of 28 posts lead with a different cashtag (VKTX, LXRX, GPCR, ABCL, AMGN, ALT, MANE, FHTX, SPY). 9 of the 13 Bullish tags sit on those posts. - Audit of the 13 Bullish tags: - 2 are clean LLY-bullish calls: @flychicken1991's automated-style Jaypirca note ('Impact: Positive (88%) ... the approved treatment setting creates an additional revenue opportunity for Jaypirca') and @holamasgrande's obesity-demand quip ('Everyone so fat and over nourished they need injections $LLY'). - 2 are weak: @Acho5280 tagged Bullish while exiting ('Exit for a swing since yest3rday ah, 1% gain. GL longs'), and @dick3 wrote '$LLY could buy out with pocket change'. - 5 promote other names and actively argue against LLY. @biolover wrote four of them: 'VK2735 is better than all $LLY has'; a CNBC quote that 10.8% to 27% of combo patients 'discontinued treatment due to side effects, compared with the 2.9% of people on tirz[epatide]'; a rejection of the view that 'Lilly took the market and no competition long term'; and a plug for the VKTX CEO's VK2735-vs-TZP/retatrutide comparison. The fifth is @macrossluvsrobotech's 'The Amylin Trap' ('up to 27% of patients dropping out from severe nausea/vomiting'). - 1 casts LLY as a deep-pocketed acquirer (@PolarBear1 on ABCL). - 3 are a news share or off-topic (amylin basket, LXRX, AMGN). - The single Bearish tag (@JackedNicholson) targets $ALT, arguing its financing leaves it outgunned against LLY and NVO. That implicitly concedes LLY's strength. No Bearish tag is directed at LLY. - Unlabeled posts (14): - Constructive (3): @BSinvest ('this has the chance to become the next Apple and Nvidia', while conceding 'You already missed the lottery ticket time'); @KcWatermark73 ('Lilly at $1,143 with a $1.1T market cap won on efficacy (retatrutide: 29% weight loss)', a promotional video post with unverified figures); and @jewell69, who is long LLY as the 'opposite position' to fast-food promotions. - Cautious on price (2): @blueyuki86 ('why this was climbing for 3 weeks to dump this week') and @Jimsonlima ('bounce off the uptrend line or breaking below? I believe it will break if 1150 is not reclaimed'). - Competitor-skeptical (1): @biolover on reading VKTX trial hints. - Information shares (6): Jaypirca link, FHTX headline, CNBC amylin story, FiercePharma oral GLP-1 launch tracker, a Fidelity-as-top-holder note, and a $MANE 'takeover note' citing an Endpoints rumor of existing Lilly interest. - Noise (2): @MikeBob15. - Content-adjusted stance: - By message: ~8 constructive vs ~8 skeptical/cautious vs 12 neutral/off-topic. - By unique user: 8 constructive vs 4 skeptical. 5 of the 8 skeptical messages come from one VKTX promoter. - By day: Friday's 20 posts skewed skeptical (7 vs 4) as the CNBC tolerability story circulated. The 8 weekend posts skewed constructive (4 vs 1), suggesting the week's drawdown has not dented long-horizon conviction. - The 93% tag ratio is an artefact of cross-tagging, not LLY-specific euphoria. The usual contrarian over-extension warning therefore carries little weight here.

Reddit (r/wallstreetbets, r/stocks, r/investing) - No data: skipped because sentiment_include_reddit is disabled in config. All three subreddits are silent in this dataset, so the StockTwits read cannot be cross-checked against longer-form retail discussion.

2. Cross-source divergences and alignments¶

Aligned on catalysts: both sources surface the same four stories (the Jaypirca approval, Foundayo, the amylin/EloraTZP combination and the Foghorn exit). There is no hidden retail narrative the news has missed.
Aligned on leadership: both treat LLY as the obesity benchmark. News: 'Next $2 Trillion Drugmaker', 'Obesity Pipeline Expands'. StockTwits: 'won on efficacy', LLY as presumed acquirer of ABCL/MANE, and small-cap bulls measuring VK2735 against tirzepatide and retatrutide. Even LLY's critics treat it as the bar to beat.
Divergence 1 — good news, weak tape: headlines delivered an FDA approval and several positive readouts. Yet retail asks why the stock was 'climbing for 3 weeks to dump this week'. A Saturday post puts it at ~$1,143, below a $1,150 pivot and testing an uptrend line. These prices are retail-reported and unverified; no price/volume feed was provided. Two explanations are plausible but unconfirmed: the prior run priced in the news, or the market weighted EloraTZP tolerability and competitive noise over headline efficacy.
Divergence 2 — headline vs detail on EloraTZP: news frames it as 'efficacy data'. StockTwits surfaces CNBC's 10-02 tolerability detail: dose-dependent discontinuations of 10.8%–27% vs 2.9%, with Lilly aiming 'to improve how well patients tolerate the combo regimen in later studies'. This is the one area where the more granular source is less favorable than the headlines.
Divergence 3 — tags vs content: 93% labeled-bullish versus a roughly even 8-vs-8 content split by message.
Divergence 4 — time horizon: long-horizon framing is uniformly bullish ('$2 Trillion', 2030 outlook, 'next Apple and Nvidia'). Short-horizon commentary is cautious: the 1,150 reclaim, an uptrend-line test, a swing trader banking 1% and leaving. TIKR's +7% YTD sits awkwardly beside the $2T narrative, suggesting the market wants proof before re-rating.
Timing nuance: StockTwits timestamps show the Jaypirca approval circulating from ~19:15Z on Friday 10-02 (~3:15pm ET), in the last hour of the session. The price may not have fully absorbed it before the weekend.

3. Dominant narrative themes¶

The next-generation obesity race (dominant in both sources):
Oral GLP-1: Foundayo's launch trajectory vs the Wegovy pill, plus late-stage diabetes data.
Amylin layering: EloraTZP efficacy vs tolerability, Lilly vs Novo per CNBC on 10-02. A retail summary cites ~23% weight loss for the combinations.
Retatrutide: 29% weight loss cited, unverified.
Retail sub-theme: secular obesity demand (fast-food ads, 'need injections').
Competitive challenge, largely promoter-driven: VKTX, GPCR, KLRA, LXRX and ALT bulls define their theses against LLY. Novo's ~$4B in deals adds institutional-grade competitive context.
Diversification beyond incretins: Jaypirca moving into previously untreated CLL/SLL.
Capital allocation: pruning (the Foghorn exit) alongside acquirer chatter (ABCL speculation, the MANE/Endpoints rumor) and a 'pocket change' view of the balance sheet.
Mega-cap valuation tension: a $1.1T market cap and $2T / Apple-Nvidia comparisons against a modest +7% YTD and a technically fragile tape.

4. Catalysts and risks¶

Catalysts (upside): - First full-session reaction to the late-Friday Jaypirca approval (next session Monday 10-05). - Foundayo prescription-trajectory data vs the Wegovy pill (tracked by FiercePharma; no figures in this dataset), and detail on what the diabetes 'surprise' was. - Later-stage amylin-combo studies aimed at better tolerability; further retatrutide and obesity readouts. - BD/M&A with LLY as acquirer (rumor-level only: MANE via Endpoints, ABCL speculation). - Macro: the Fed-rates article frames certain stocks as winners 'either way'; LLY's inclusion is unconfirmed. - Not in the data: no earnings date, guidance update or analyst rating action. Confirm the Q3 reporting calendar independently.

Risks (downside): - Combo tolerability (10.8%–27% vs 2.9% discontinuations) could cap the perceived value of amylin layering. Competitor bulls are already using it. - Competition: Novo's deal-making, the oral GLP-1 launch race, and promoter claims of VK2735 superiority (unverified, largely from one poster). - Technical: retail flags $1,150 as the level to reclaim and an uptrend line under test. A break could trigger momentum selling, and swing traders are already taking profits. - Expectation risk: '$2 Trillion' and 'next Apple and Nvidia' framing sets a high bar against modest YTD performance. - Partner terminations (Foghorn): minor for LLY, but they signal oncology reprioritization. - Information risk: the news is headline-only, so the direction and size of the 'surprise' and 'strong' data are unverified. The 'Top Midday Decliners' constituents are unknown.

5. Key sentiment signals¶

Signal	Direction	Source	Supporting evidence
Jaypirca FDA label expansion (previously untreated CLL/SLL)	Bullish	News (PR Newswire, MT Newswires); StockTwits (@flychicken1991, @focafoca99)	'first-and-only approved non-covalent BTK inhibitor'; 'Impact: Positive (88%)'; circulated ~3:15pm ET Friday, possibly not fully priced
Foundayo late-stage diabetes data	Bullish (headline-only)	News (TheStreet, Zacks)	'delivers diabetes surprise in late-stage study'; 'new efficacy data'
Obesity pipeline strength	Bullish	News (Simply Wall St., Zacks); StockTwits (@KcWatermark73)	'Strong Phase 2b And Phase 3 Obesity Trial Data'; 'won on efficacy (retatrutide: 29% weight loss)'
EloraTZP / amylin-combo tolerability	Bearish	StockTwits (@biolover, @macrossluvsrobotech citing CNBC 10-02)	10.8%–27% discontinued for side effects vs 2.9% on tirzepatide; 'The Amylin Trap'
Long-term valuation narrative	Bullish	News (24/7 Wall St., TIKR); StockTwits (@BSinvest)	'Next $2 Trillion Drugmaker'; 2030 outlook; 'next Apple and Nvidia'
YTD performance vs narrative	Mixed	News (TIKR)	'Up 7% in 2026', modest relative to $2T framing
Short-term price action	Bearish	StockTwits (@blueyuki86, @Jimsonlima, @KcWatermark73, @Acho5280)	'climbing for 3 weeks to dump this week'; 'will break if 1150 is not reclaimed'; ~$1,143 cited; swing exit at +1%
Competitive pressure	Mildly Bearish	StockTwits (@biolover ×5); News (Motley Fool on Novo)	'VK2735 is better than all $LLY has'; Novo 'nearly $4 billion in 2 deals'
LLY as acquirer / balance-sheet strength	Mildly Bullish	StockTwits (@PolarBear1, @dick3, @itsphd)	'could buy out with pocket change'; MANE takeover rumor via Endpoints
Foghorn collaboration ended	Neutral (partner-centric)	News (Stocktwits, Quartz)	FHTX sell-off, Wedbush target cut 80%, Foghorn layoffs
'Top Midday Decliners' (×2)	Unknown	News (MT Newswires)	Constituents not visible; LLY inclusion unconfirmed
StockTwits tag ratio	Nominally Bullish (inflated)	StockTwits	13 Bullish / 1 Bearish / 14 unlabeled; 9 of 13 Bullish tags on posts led by other tickers; sole Bearish tag targets $ALT
StockTwits content-adjusted stance	Mixed, mildly constructive	StockTwits	~8 constructive vs ~8 skeptical messages; 8 vs 4 unique users; Friday skeptical (7 vs 4), weekend constructive (4 vs 1)
Reddit	No data	Reddit (disabled)	`sentiment_include_reddit` off; no subreddit read

News Analyst¶

LLY: Weekly news and macro report (as of 2026-10-03)¶

Eli Lilly and Company (NYQ: LLY), Healthcare / Drug Manufacturers – General. News covers 2026-09-26 to 2026-10-03; macro data is FRED, latest prints through Oct 1–2.

1. Summary¶

LLY's own news this week was positive. There were three items:
New late-stage data for Foundayo in diabetes. TheStreet called it a "surprise"; Zacks and Simply Wall St. framed it positively.
Phase 2b obesity data for the EloraTZP combination.
FDA approval of Jaypirca for previously untreated CLL/SLL. That opens the largest segment of the BTK-inhibitor market.

The one negative-sounding item, Lilly ending its Foghorn collaboration, hurt Foghorn (FHTX), not LLY. - The main risk to LLY is interest rates, not earnings. - The Fed raised rates 25bp on Sept 16: the effective fed funds rate went from 3.63% to 3.88%. That was its first hike since July 2023. - The 10Y Treasury reached 5.29% on Sept 30, a level last seen before the 2008 crisis. - From Aug 25 to Sept 30, about 94% of the 10Y's +65bp rise came from real (inflation-adjusted) yields. The 10Y TIPS went from 2.32% to 2.93%, while inflation expectations stayed near 2.35%. - Rising real yields hurt high-valuation stocks whose value depends on profits far in the future, and that describes LLY. - Friday, Oct 2 brought relief. September payrolls grew only +29K and unemployment rose to 4.2%. Expectations of more hikes faded, Treasury yields eased and stocks rallied. Right now, weak economic data means lower yields, which helps stocks like LLY. - Credit markets are showing stress. High-yield bond spreads widened from 2.60% to 3.24%, including +51bp in the last six trading days. The VIX is only about 16.4, so stock volatility hasn't caught up. Oil (WTI about $96, +69% this year, driven by the Iran war) is the main driver of inflation and the Fed. - Late October has several big events close together: September CPI (mid-October), the FOMC (Oct 27–28), LLY's Q3 earnings (historically around Oct 30, not confirmed) and Q3 GDP.

2. Company news (LLY)¶

2.1 Obesity and diabetes drugs: Foundayo and EloraTZP data (positive)¶

Headlines: "Eli Lilly's Foundayo delivers diabetes surprise in late-stage study" (TheStreet); "LLY Highlights New Efficacy Data From Foundayo and EloraTZP Studies" (Zacks); "Eli Lilly (LLY) Reported Strong Phase 2b And Phase 3 Obesity Trial Data" (Simply Wall St.).
What the drugs likely are. I inferred this from the names; the headlines don't give the molecules or any efficacy numbers.
Foundayo is most likely the oral GLP-1 orforglipron.
EloraTZP is most likely eloralintide (an amylin drug) combined with tirzepatide.
Why it matters.
Good diabetes data widens Foundayo's market. A pill is cheaper to make and easier to scale than injections, which helps against supply limits and GLP-1 price cuts.
A strong amylin + tirzepatide combination gives Lilly a next-generation product to answer Novo's amylin strategy.
Trading read: this supports the long-term case, but the news came out Oct 1–2 and is probably mostly in the price. The next steps are full data presentations (ObesityWeek is usually early November) and launch numbers at Q3.

2.2 Cancer: Jaypirca approved for untreated CLL/SLL (positive)¶

The FDA expanded Jaypirca (pirtobrutinib), "the first-and-only approved non-covalent BTK inhibitor," to certain adult patients with previously untreated CLL/SLL (PR Newswire, MT Newswires).
Jaypirca moves from later-line use into first-line treatment, the largest part of this market, against Brukinsa, Calquence and Imbruvica. That gives LLY a real growth source outside obesity drugs.
The phrase "certain patients" suggests limits on the label. How broad it is will decide how fast sales grow.

2.3 Foghorn collaboration ended (neutral for LLY)¶

Lilly ended its cancer collaboration with Foghorn Therapeutics. FHTX shares kept falling, Wedbush cut its price target by about 80%, and Foghorn announced layoffs.
This doesn't matter financially for LLY; it shows Lilly focusing its spending. For small biotech partners, losing Lilly can threaten survival.
⚠️ Two MT Newswires "Top Midday Decliners" items (one a correction) were tagged to LLY. They appeared next to the FHTX story, so they probably refer to Foghorn. The agent with price data should check how LLY traded on Oct 1–2.

2.4 Competition: Novo Nordisk did about $4B in two deals (mildly negative, long-term)¶

LLY's main obesity rival is buying drug candidates from outside (Motley Fool). That isn't a near-term threat to LLY's market share, but Novo is restocking for the next round of obesity drugs from 2027 on.

2.5 Sentiment (bullish but crowded)¶

"Eli Lilly Stock Is Up 7% in 2026" (TIKR). That is a modest gain given the strong drug news, which fits a drag from rates and lower GLP-1 prices.
Other bullish pieces: "Could Be the Next $2 Trillion Drugmaker" (24/7 Wall St.), and LLY listed among stocks that "win either way" on the Fed (Motley Fool). With retail commentary this one-sided, the trade is crowded if the macro turns.
Background from before this week (my prior knowledge, not this week's tools): under the Nov-2025 pricing deal with the U.S. administration, Lilly cut GLP-1 prices in exchange for wider coverage and relief from tariffs. So 2026 trades lower prices for higher volume; compare the two at Q3.
Not relevant to the stock: a former executive's $39.5M Wyoming estate sale (WSJ), an article on chief AI officers, and a personal-finance column.

3. Macro backdrop (FRED data)¶

3.1 The Fed is raising rates again¶

The daily effective fed funds rate rose from 3.63% to 3.88% on Sept 17. That means a 25bp hike at the Sept 15–16 meeting, with an implied target range of 3.75–4.00%.
This reverses part of the late-2025 cuts. The monthly rate fell from 4.09% in Oct 2025 to 3.64% in Jan 2026, then stayed flat through August.
What markets expect next. Prediction-market odds were not available, so I used Treasury yields as a rough guide:

Maturity	Sept 28	Oct 1
3-month bill	4.28%	4.17% (about 30bp above fed funds)
1-year	4.59%	4.44%
2-year	4.92%	4.78%

At the Sept 28 peak, markets priced roughly one more full hike soon, plus more later. That had already eased before Friday's jobs report, which eased it further. These gaps overstate expectations somewhat, because of how bill yields are quoted and the extra yield investors demand for longer maturities.

3.2 Bond yields: driven by real yields, not inflation fears¶

Series	Recent	Earlier	Change
10Y nominal	5.24% (Oct 1); peak 5.29% (Sept 30)	4.13% (Oct 2025); 4.63% (Aug 13)	+111bp over the year; +66bp since mid-August
10Y TIPS (real yield)	2.88% (Oct 1); peak 2.93%	2.32% (Aug 25)	+61bp to the peak; highest since 2008
10Y breakeven (expected inflation)	2.36% (Oct 2)	2.32% (Aug 25)	+4bp
10Y minus 2Y	0.45% (Oct 2)	0.20% (Sept 21)	Long yields rose faster into month-end; short yields fell more after the jobs miss

Bond investors aren't pricing runaway inflation. They are demanding a higher real return for holding long bonds.
That is the worst mix for high-valuation stocks whose value sits in distant profits, such as LLY's obesity business through 2030 and beyond.

3.3 Inflation: led by energy, with core firming slightly¶

Headline CPI was +3.35% year over year in August.
Month-over-month: +0.87% in March and +0.64% in April when oil spiked, −0.42% in June, then +0.40% in August.
Core CPI (excluding food and energy) was +2.45% year over year, but +0.29% in August alone (about 3.5% annualized). That partly supports Yahoo Finance's "The Iran war is driving inflation higher — and it's not just because of oil."
Core PCE was +3.0% year over year (+0.25% in August). This is the Fed's preferred measure, and it is a full point above the 2% target.
Medical-care CPI was only +1.56% year over year (−0.25% in August). Healthcare prices are not rising much, which fits continued pressure on drug and GLP-1 prices.

3.4 Jobs and growth: few hires, few layoffs¶

Payrolls: +29K in September; the three-month average is about +51K.
Unemployment: 4.2%, up from 4.1%.
Initial jobless claims: 197K (week ending Sept 26), so there is no wave of layoffs.
Real GDP: about +2.5% annualized in Q1 2026 and about +2.2% in Q2. Growth held up through mid-year; Q3 is not out yet.
Consumer sentiment (University of Michigan): 51.7 in August, after a record low of 44.8 in May.
Rates commentary: Moody's economist Mark Zandi warns that higher rates are "already damaging the economy."

3.5 Oil and the Iran war¶

Date	WTI price
Jan 6	$56.97
Apr 7 (first spike, began early March)	$114.58
Early August	about $77
Sept 15 (second spike)	$107.02
Sept 29	$96.16 (+69% this year)

Prices are jumping on headlines: −$10.65 on Sept 25, then +$14.14 on Sept 28.
September averaged about $97, versus about $84 in August (+16%). September headline CPI (mid-October) will likely be hot. The core number will decide how hawkish the Oct 27–28 Fed meeting is.

3.6 Risk appetite, the dollar and financial conditions¶

High-yield bond spreads: 2.60% (Aug 28) to 3.24% (Oct 1). This is the clearest stress signal in the data.
VIX: 16.39 (Oct 1), so stock volatility is lagging the credit market.
Chicago Fed financial conditions index: −0.548 (Sept 25). Conditions are still loose but have tightened three weeks in a row.
Dollar: the broad dollar index rose 2.1% from Sept 9 to Sept 25. That slightly reduces the dollar value of LLY's growing overseas sales.

3.7 Prediction markets¶

Polymarket odds were withheld for 2026-10-03 because the tool has no historical snapshots. Section 3.1 uses Treasury yields instead.

4. How the macro affects LLY¶

Channel	Effect	Comment
Real yields / discount rate	❌ Main headwind	A high valuation plus profits weighted far in the future make LLY very rate-sensitive. The 10Y TIPS is the indicator to watch.
Preference for quality, defensive stocks	✅ Relative support	Steady, non-cyclical earnings growth should beat cyclical stocks if credit stress spreads. The stock can still fall in absolute terms.
Weak data lowers yields	✅ Near-term help	Weak jobs → lower yields → support for long-horizon growth stocks (the Oct 2 rally).
Consumer stress (self-pay obesity patients)	⚠️ Modest risk	High fuel prices and weak sentiment could reduce cash-pay demand. Ask about it at Q3.
Strong dollar	⚠️ Mild headwind	Overseas sales are a growing share (e.g., Mounjaro outside the U.S.).
Drug pricing	⚠️ Ongoing headwind	Medical CPI is +1.6% a year, and GLP-1s trade lower price for volume. No new pricing or tariff news this week.

A historical comparison (from my prior knowledge): in the 2022 rate shock, LLY rose about 32% while the S&P 500 fell about 19%, because tirzepatide news outweighed the macro. The drug news is positive again now. But at about a $1T market value, with most investors already bullish, each new result moves the stock less, so rates matter more than they did in 2022.

5. Upcoming events (approximate dates; confirm)¶

Timing	Event	Why it matters for LLY
~Oct 14–15	September CPI	Energy will likely push it up. A hot core number would revive hike expectations, which pressures LLY's valuation.
Oct 27–28	FOMC	Hold or a second hike. The Fed's guidance on future moves matters more than the decision.
~Oct 29	Q3 GDP (first estimate)	Whether the story is steady growth or stagflation.
~Oct 30 (not confirmed)	LLY Q3 earnings	Zepbound/Mounjaro volume vs. price, Foundayo launch numbers, Jaypirca's first-line launch, full-year guidance, currency effects.
Early November	October jobs (~Nov 6); Novo Q3; ObesityWeek	Job trend; read-across from the main competitor; full obesity data.
Ongoing	Iran war and oil news	The main source of inflation surprises, which drive the Fed and LLY's valuation.

6. Scenarios¶

Bull case: Data stays weak and/or oil falls on de-escalation. The 10Y TIPS drops back toward 2.5–2.6% and the Fed signals a pause. LLY's valuation recovers, and the drug news plus a strong Q3 drive outperformance.
Base case: The 10Y stays roughly between 5.0% and 5.3%. LLY trades mostly on its own news, with the drug news offsetting the rate drag. The stock stays in a range into Q3, with volatility around CPI, the FOMC and earnings.
Bear case: Hot September core CPI and another oil spike lead markets to price a second hike in October or December. The 10Y TIPS goes above 3% and high-yield spreads above 3.5%. Long-horizon growth stocks get marked down broadly, and LLY falls despite good fundamentals. It gets worse if Q3 shows GLP-1 price cuts outpacing volume growth.

7. Takeaways for the trading agent¶

Watch the 10Y TIPS yield as the main macro signal for LLY.
Above about 3.0% (now 2.88%, peak 2.93%) is a headwind.
A move back toward about 2.6%, where it was before Sept 23, would help.
Tell a rate-driven drop apart from a broken thesis. This week's three drug and regulatory events improved LLY's fundamentals. A decline driven by rates is a valuation move, not a change in the story, which matters for when to enter and how much.
Plan around the late-October cluster. CPI, the FOMC and LLY's Q3 fall within about two weeks. Buying in stages, or using options with capped risk, may be safer than a full-size position before the CPI release. Check option prices with the options/price agent.
Expect hot headline CPI; the core number decides. If core rises 0.3% or more again in a month, hike odds and real yields likely rise, which is negative for LLY near term. A hot headline with soft core will probably be looked past.
Use high-yield spreads as the alarm. Above about 3.5% would signal broad selling. LLY should hold up better than riskier growth stocks but could still fall.
LLY vs. Novo: LLY's lead keeps widening (oral GLP-1, the amylin combination, cancer drugs), while Novo is buying to catch up. That favors LLY over NVO, but many investors already hold that view.

8. Caveats and data gaps¶

My tools have no price, volume or valuation data. Please check LLY's Oct 1–2 moves, where it sits relative to its 50- and 200-day moving averages, and its forward P/E against a 5.2% 10Y yield.
News came as headlines only. Efficacy numbers, the exact Jaypirca label and the identities of Foundayo and EloraTZP are inferred.
LLY news for Sept 12–26 was unavailable. The news source returns only a sample of recent articles, so no results doesn't mean nothing happened.
The S&P 500 series couldn't be retrieved from FRED, and prediction-market odds were withheld.
Event dates are estimates based on past patterns and the published Fed calendar.

9. Key points¶

#	Theme	Key evidence	Signal for LLY	Confidence	What to watch
1	Obesity/diabetes drugs	Foundayo Phase 3 diabetes "surprise"; EloraTZP Phase 2b; "strong" data (TheStreet, Zacks, Simply Wall St.)	🟢 Bullish, medium term	Medium-high (headlines only)	Full data / ObesityWeek; Foundayo launch numbers at Q3
2	Cancer drugs	Jaypirca approved for untreated CLL/SLL; only approved non-covalent BTK inhibitor	🟢 Bullish	High	Label limits; first-line sales vs. Brukinsa/Calquence
3	Partnerships	Foghorn deal ended; FHTX fell, Wedbush target −80%	⚪ Neutral	High	Confirm "Top Midday Decliners" refers to FHTX, not LLY
4	Competition	Novo about $4B in two deals	🟠 Mildly bearish, long term	Medium	Novo Q3 (early Nov); its amylin programs
5	Sentiment	+7% this year (TIKR); "$2T drugmaker" articles	⚪ Neutral / crowded	Medium	Whether good news still lifts the stock
6	Fed	Fed funds 3.63% → 3.88% on Sept 17 (first hike since Jul 2023)	🔴 Bearish for valuation	High	FOMC Oct 27–28
7	Rates (main driver)	10Y peak 5.29%, 5.24% Oct 1; TIPS peak 2.93%; breakeven 2.36%	🔴 Bearish, biggest macro risk	High	TIPS above 3.0% bearish; below 2.6% bullish
8	Inflation	CPI 3.35% y/y; core CPI 2.45% (+0.29% in Aug); core PCE 3.0%	🔴 Bearish through the Fed	High	September CPI ~Oct 14–15 (core ≥0.3% is hawkish)
9	Jobs and growth	Payrolls +29K; unemployment 4.2%; claims 197K; Q2 GDP ~2.2%	🟢 Near-term bullish (weak data, lower yields)	High	Q3 GDP ~Oct 29; October jobs ~Nov 6
10	Oil and Iran war	WTI $96 (+69% this year); September average ~$97 vs. ~$84 in August	🔴 Bearish through inflation and the Fed	High	Escalation or ceasefire news
11	Credit and risk	High-yield spreads 2.60% → 3.24% (+51bp in 6 days); VIX 16.4; financial conditions −0.55	🟠 Holds up relatively, but absolute risk	High	High-yield spreads above 3.5%
12	Dollar	Broad dollar +2.1% (Sept 9–25)	🟠 Mildly bearish	Medium	Currency effects in Q3 and Q4 guidance
13	Drug pricing	Medical CPI +1.56% y/y, −0.25% in August	🟠 Ongoing headwind	Medium	GLP-1 price vs. volume at Q3
14	Event risk	CPI → FOMC → LLY Q3 (~Oct 30, not confirmed) within ~2 weeks	⚠️ Higher volatility	Medium (dates not confirmed)	Positions with capped risk
—	Overall	Strong company news vs. pressure from rising real yields; relief on Oct 2	Fundamentals 🟢 / Macro 🔴 / Near-term tone 🟢	—	10Y TIPS and September CPI decide the direction

Fundamentals Analyst¶

LLY (Eli Lilly and Company): Fundamental Analysis Report¶

As of: 2026-10-03 | Exchange: NYSE (NYQ) | Classification: Healthcare / Drug Manufacturers – General Latest filed period: Q2 2026 (quarter ended 2026-06-30), from SEC EDGAR filings as filed on or before 2026-10-03. Figures are in USD millions unless noted.

1. Data coverage and caveats¶

No new periodic filing came out in the past week. The newest statements are for Q2 2026, so LLY's fundamentals this week are the same as in its Q2 2026 quarterly report (10-Q). The next update is Q3 2026 results. Based on past timing (Oct 30 in 2024 and 2025), that should be around late October or early November 2026; the tools do not confirm a date.
The vendor withheld some data because it can't supply values as of a past date: market cap, valuation multiples, the 52-week range, the profile snapshot, and all insider transactions. Another agent needs to supply these.
LLY doesn't report these as separate items in its SEC data feed: gross profit, operating income, total liabilities, debt, and capex (missing from 2023 on). Where I derived them, I used:
Gross profit = Revenue − Cost of revenue
Total liabilities = Total assets − Equity
Q4 = Full year − first nine months
A rough free-cash-flow figure ("OCF + ICF") = operating cash flow + investing cash flow. It is conservative because investing cash flow also includes acquisitions and investment purchases.
The history has a break in 2016. From 2016 on, figures are restated to exclude Elanco, the animal-health business separated in 2019. Years 2007–2015 are as originally reported and include Elanco, so they don't compare directly.

2. Company profile¶

Eli Lilly is a large US drugmaker based in Indianapolis. According to company disclosures through 2025, growth comes mainly from its GLP-1/GIP diabetes and obesity drug, tirzepatide, sold as Mounjaro (type 2 diabetes) and Zepbound (obesity). The rest of the portfolio covers oncology, immunology and neuroscience. These tools don't provide sales by product or segment, so how concentrated revenue is in tirzepatide can't be measured here.

3. Income statement¶

3a. Quarterly trend¶

Quarter	Revenue	YoY	QoQ	Gross Profit	Gross Margin	Net Income	NI YoY	Net Margin	Diluted EPS
Q1'25	12,729	+45.2%	−5.9%	10,504	82.5%	2,759	+23.0%	21.7%	$3.06
Q2'25	15,558	+37.6%	+22.2%	13,110	84.3%	5,661	+90.8%	36.4%	$6.29
Q3'25	17,601	+53.9%	+13.1%	14,593	82.9%	5,582	+475%	31.7%	$6.21
Q4'25 (derived)	19,291	+42.5%	+9.6%	15,920	82.5%	6,638	+50.5%	34.4%	~$7.39
Q1'26	19,799	+55.5%	+2.6%	16,222	81.9%	7,396	+168%	37.4%	$8.26
Q2'26	22,974	+47.7%	+16.0%	19,706	85.8%	7,095	+25.3%	30.9%	$7.94

What stands out: - Very fast growth at very large scale. Revenue has grown 37–56% year over year (YoY) for six straight quarters. Q2'26 added $3,175M quarter over quarter (QoQ), the largest one-quarter dollar increase in the series. Q1'26 had slowed to +2.6% QoQ, so Q2 was a sharp re-acceleration. - Record gross margin of 85.8% in Q2'26. Cost of revenue fell 8.6% QoQ (3,577 → 3,268) while revenue rose 16%. Q1'26's 81.9% was the weak point. - First half of 2026 (H1'26) vs H1'25: revenue $42,773M (+51.2%), net income $14,491M (+72.1%), diluted EPS $16.20 (+73.3%).

3b. Annual and trailing-twelve-month (TTM) trend¶

FY	Revenue	YoY	Gross Margin	Net Income	Net Margin	Diluted EPS	Operating CF	Investing CF	OCF + ICF
2020	24,540	+9.9%	77.7%	6,194	25.2%	$6.79	6,500	−2,259	4,241
2021	28,318	+15.4%	74.2%	5,582	19.7%	$6.12	7,366	−2,868	4,498
2022	28,541	+0.8%	76.8%	6,245	21.9%	$6.90	7,586	−3,763	3,823
2023	34,124	+19.6%	79.2%	5,240	15.4%	$5.80	4,240	−7,153	−2,913
2024	45,043	+32.0%	81.3%	10,590	23.5%	$11.71	8,818	−9,302	−484
2025	65,179	+44.7%	83.0%	20,640	31.7%	$22.95	16,813	−10,972	5,841
TTM to Q2'26	79,665	+49.6%	83.4%	26,711	33.5%	$29.80	28,083	−25,097	2,986

Revenue grew 2.28× from 2022 to 2025, a 31.7% three-year compound annual growth rate (CAGR); the five-year CAGR (2020–25) is 21.6%. Growth has sped up every year since 2022.
Strong operating leverage. All costs below gross profit (R&D, sales and admin, acquired R&D, taxes) fell from 63.9% of revenue in 2023 to 57.8% in 2024, 51.4% in 2025 and 49.9% TTM.
TTM diluted EPS is $29.80, up about 95% YoY (prior-year TTM was $15.30). TTM net income is up 93.6%.

3c. Key watch item: Q2 2026 GAAP earnings didn't keep up with revenue¶

In Q2'26, revenue rose $3,175M and gross profit rose $3,484M QoQ, but net income fell $301M (−4.1%).
Costs below gross profit jumped $3,785M QoQ to $12,611M, or 54.9% of revenue. That compares with 44.6% in Q1'26 and 47.9–51.2% in the three quarters before.
Most likely cause (my inference, needs checking in the 10-Q): one-time charges for in-process R&D bought in acquisitions.
Q2'26 had a $15.4B investing outflow, and long-term assets rose $15.9B.
LLY has taken this kind of GAAP hit before: a net loss in Q3'23, only $970M of net income in Q3'24, and a depressed Q1'25.
Other possible causes are launch spending, a step-up in R&D, or a higher tax rate.
Rough size: if Q2's cost ratio had matched Q1'26, net income would have been about $2.4B higher (about $2.65 per share). Using the prior four-quarter average ratio, it would have been about $1.6B higher (about $1.80 per share). That points to an illustrative adjusted Q2 EPS of about $9.70–10.60, versus GAAP $7.94.
Why it matters for traders: if the charge was one-time, GAAP EPS understates LLY's earning power. If it is recurring, the margin path resets lower.

4. Balance sheet¶

Period end	Total Assets	Current Assets	Cash	Current Liab.	Total Liab. (derived)	Equity	Current Ratio	Liab/Equity
2023-12-31	64,006	25,727	2,819	27,293	53,234	10,772	0.94	4.94×
2024-12-31	78,715	32,740	3,268	28,376	64,443	14,272	1.15	4.52×
2025-06-30	100,923	49,854	3,376	39,020	82,650	18,273	1.28	4.52×
2025-12-31	112,476	55,629	7,268	35,228	85,941	26,535	1.58	3.24×
2026-03-31	116,576	54,835	5,282	36,634	85,378	31,198	1.50	2.74×
2026-06-30	142,283	64,672	8,950	47,741	108,404	33,879	1.35	3.20×

Total assets grew 122% since December 2023. Q2'26 alone added $25.7B:
long-term assets +$15.9B, which roughly matches the $15.4B investing outflow (acquisitions and/or plants and equipment);
non-cash current assets +$6.2B (receivables and inventory supporting growth);
cash +$3.7B.
Liabilities rose $23.0B in Q2'26: $11.1B current and $11.9B long-term. Together with the +$8.4B financing inflow, this suggests Q2 spending was largely paid for with new debt. Debt detail isn't in the data, so this needs confirming in the 10-Q.
The leverage improvement partly reversed. Liabilities-to-equity fell from 4.52× (December 2024) to 2.74× (March 2026), then rose back to 3.20×. The current ratio fell from 1.50 to 1.35, and working capital fell to $16.9B from $20.4B at year-end 2025.
Equity was $33.9B, up 85% YoY, with book value of about $38 per share. In Q2, equity grew only $2.7B against $7.1B of net income. That implies about $4.4B went to dividends, buybacks or other equity reductions, up from about $2.7B in Q1. This is worth checking.
LLY has historically kept little cash on hand ($1.7–3.8B over 2019–2024). Today's $9.0B of cash covers only about 19% of current liabilities, so the company leans on operating cash flow and on borrowing.

5. Cash flow¶

Quarter	Operating CF	Investing CF	OCF + ICF	Financing CF	OCF / Net Income
Q1'25	1,666	−3,353	−1,687	+1,380	0.60×
Q2'25	3,087	−1,834	+1,253	−1,245	0.55×
Q3'25	8,835	−2,983	+5,852	+531	1.58×
Q4'25	3,225	−2,802	+423	−2,879	0.49×
Q1'26	5,333	−3,916	+1,417	−3,470	0.72×
Q2'26	10,690	−15,396	−4,706	+8,426	1.51×

Operating cash flow has risen sharply: $4.2B in FY23, $8.8B in FY24, $16.8B in FY25 and $28.1B TTM. H1'26 operating cash flow was $16.0B, 3.4× H1'25, and Q2'26's $10.7B is a record.
Earnings are backed by cash. TTM operating cash flow is 1.05× net income, though quarters are uneven (0.49× to 1.58×).
Spending has jumped. TTM investing outflows were $25.1B, or 31.5% of revenue. So OCF + ICF is only +$3.0B TTM, and −$3.3B for H1'26. FY25 was +$5.8B.
Because capex isn't reported separately, plant and equipment spending can't be separated from acquisitions. The next agent should pull capex from the 10-Q.

Return on equity (ROE) is about 100% on average equity (TTM). That figure is inflated by a small equity base: equity was cut to $2.5B by the 2019 Elanco split-off, plus buybacks. It is not a clean comparison with peers.
Return on assets is about 22–23% TTM. Asset turnover is about 0.68×.
Diluted share count is about 894M, down 0.7% YoY from about 900M. Buybacks are modest, so EPS growth is almost entirely from the business itself.

7. Long-run history¶

2008: net loss of $2.07B from acquisition and litigation charges.
2014: revenue fell 15% after patent expirations. Revenue then stayed flat at about $18–22B (restated) through 2019.
2017: net loss of $204M from the US tax-reform charge.
2019: net income was inflated by the gain on the Elanco disposal.
2023 onward: the GLP-1 era. Gross margin rose every year, from 74.2% (2021) to 83.0% (2025).

8. Valuation framework (the tools provided no price)¶

Substitute the live quote. Market cap below assumes about 894M diluted shares.

Hypothetical price	Implied market cap	P/E on TTM EPS ($29.80)	P/E on H1'26 annualized ($32.40)	Price/sales on TTM revenue
$800	~$715B	26.8×	24.7×	9.0×
$900	~$804B	30.2×	27.8×	10.1×
$1,000	~$894B	33.6×	30.9×	11.2×
$1,100	~$983B	36.9×	34.0×	12.3×
$1,200	~$1,072B	40.3×	37.0×	13.5×

A company growing revenue about 50% with expanding margins usually trades at a premium. The real question is whether the growth lasts. If Q2's costs prove to be one-time, P/E on adjusted run-rate earnings is lower than the GAAP figures above.

9. Insider activity¶

Withheld by the vendor, so no conclusion is possible. Context for whoever pulls the Form 4 filings: Lilly Endowment, a large long-term holder, sells shares on a routine basis. Those sales usually carry little signal. Discretionary open-market trades by officers and directors are more informative.

10. Fundamental read and what to watch (the trade decision is left to the next agent)¶

Strengths - Roughly 48% YoY growth on a $23B quarter. - Record 85.8% gross margin. - Costs below gross profit falling steadily as a share of revenue. - $28.1B TTM operating cash flow. - TTM EPS up about 95%.

Risks - The $3.8B QoQ cost spike in Q2. - Liabilities up $23B in one quarter, apparently debt-funded. - Heavy spending leaves little free cash flow (OCF + ICF negative in H1'26). - Dependence on tirzepatide, plus pricing, policy and competitive risk. These can't be measured with these tools. - Valuation is unknown.

Q3 2026 levels to watch (prior-year Q3 revenue was $17,601M, the toughest comparison of the year): - Revenue: - Flat QoQ at about $23.0B would mean only +30.5% YoY. - Keeping ≥40% YoY needs ≥$24.6B (+7.3% QoQ); keeping ≥45% needs ≥$25.5B (+11.1% QoQ). - YoY growth will likely look slower even if the business stays strong, so judge the quarter on QoQ dollars. - Gross margin: holding ≥83% is healthy (TTM 83.4%). A drop to ≤82% would repeat Q1'26. - Costs below gross profit: a return to about 45–48% of revenue would confirm Q2 was one-time. Staying near 55% would mean a lasting step-up in spending. - Balance sheet: further growth in liabilities, the current ratio holding ≥1.3, and whether capex is disclosed.

Summary table¶

Area	Key metric	Value	Trend / signal	Trader takeaway
Data freshness	Latest filing	Q2'26 (to 2026-06-30)	No new filings in the past week	Fundamentals unchanged this week; Q3'26 report (late Oct/early Nov, expected) is the next catalyst
Growth	Q2'26 revenue	$22,974M	+47.7% YoY, +16.0% QoQ (record +$3.2B)	Momentum re-accelerated after a soft Q1
Growth	TTM revenue	$79,665M	+49.6% YoY; FY25 $65,179M (+44.7%)	Very fast growth at scale
Margins	Gross margin	85.8% Q2'26; 83.4% TTM	Up from 74.2% in 2021	Pricing power and scale; Q2 level may not repeat
Earnings	Q2'26 net income / EPS	$7,095M / $7.94	+25% YoY but −4% QoQ	GAAP lagged revenue; see cost spike
Earnings	TTM EPS	$29.80	+95% YoY; H1'26 $16.20 (+73%)	Earnings power still compounding
Red flag	Costs below gross profit	$12,611M (54.9% of revenue)	+$3.8B QoQ (Q1'26: 44.6%)	Likely one-time acquisition charges; verify. Adjusted Q2 EPS ≈ $9.70–10.60 (illustrative)
Cash	TTM operating cash flow	$28,083M	1.05× net income; H1'26 3.4× H1'25	Earnings are backed by cash
Cash	TTM investing cash flow	−$25,097M	Q2'26 alone −$15,396M	Heavy spending on acquisitions and plants
Cash	OCF + ICF	+$2,986M TTM; −$3,289M H1'26	Thin or negative	Shareholder returns depend partly on debt
Balance sheet	Total assets	$142,283M	+$25.7B QoQ; +122% since Dec'23	Rapid expansion
Balance sheet	Total liabilities (derived)	$108,404M	+$23.0B QoQ; Q2 financing +$8.4B	Leverage rising again; check debt in 10-Q
Balance sheet	Equity / Liab-to-equity	$33,879M / 3.20×	Equity +85% YoY; leverage up from 2.74×	Balance sheet improved, then partly reversed
Liquidity	Current ratio / cash	1.35 / $8,950M	Down from 1.50	Adequate; little cash held by design
Returns	ROE / ROA (TTM)	~100% / ~22%	Very high	ROE inflated by small equity base
Shares	Diluted count	~894M	−0.7% YoY	EPS growth comes from the business, not buybacks
Valuation	P/E at $1,000 (illustrative)	33.6× TTM; 30.9× H1 annualized	No price provided	Plug in the live quote
Insiders	Form 4 activity	Withheld	n/a	Next agent to check; routine Lilly Endowment sales carry little signal
Next print	Q3'26 revenue vs $17,601M prior-year Q3	Flat QoQ = +30.5% YoY; ≥$24.6B needed for ≥40%	Toughest comparison of the year	Expect slower YoY growth; judge on QoQ dollars, margins and cost normalization

II. Research Team Decision¶

Bull Researcher¶

Bull Analyst: # Bull Opening: LLY. The business keeps compounding while the stock waits.

The bear hasn't spoken yet, so I'll lay out the case and answer the arguments I expect.

Start with one mismatch. LLY's trailing EPS is up about 95% year over year, H1'26 EPS is up 73%, and the stock is up roughly 7% in 2026. When fundamentals run that far ahead of price, either the business is about to break or rising rates have temporarily drowned out the story. The data points to rates, and that is the opportunity.

1. Growth re-accelerated¶

Q2'26 revenue was $22.97B, up 47.7% YoY. The $3.2B added versus Q1 is the largest quarter-over-quarter dollar gain in the data. It is the sixth straight quarter of 37–56% growth, on a trailing base of about $80B.
Gross margin hit a record 85.8%. This came in the same year Lilly deliberately cut GLP-1 prices to gain volume. If price cuts were eroding the franchise, margins would show it first, and they are rising instead: 74.2% in 2021, 83.0% in 2025, 85.8% in Q2.
Profitability is improving structurally. All costs below gross profit fell from 63.9% of revenue in 2023 to 49.9% over the trailing twelve months. Net margin rose from 15.4% to 33.5% over the same period.
The cash is real. Operating cash flow went from $8.8B in FY24 to $16.8B in FY25 to $28.1B trailing, about 1.05x net income. Q2 alone produced a record $10.7B.
The EPS growth is organic. Diluted shares fell only 0.7%, so buybacks are not driving it.

Q3 does face the year's toughest comparison ($17.6B a year earlier). But Lilly has added about $1.85B of revenue per quarter on average over the last four quarters. Repeat that and Q3 lands near $24.8B, about +41% YoY, which clears the 40% bar. Judge the quarter on dollars, not percentages.

2. The moat widened on three fronts in one week¶

Foundayo. Lilly's launched oral GLP-1 posted late-stage diabetes data, headlined as a positive "surprise." A pill is cheaper to make and easier to scale than an injection. That answers both supply limits and lower net pricing.
EloraTZP. This is an amylin drug layered on tirzepatide, and it produced Phase 2b obesity data. It is Lilly's answer to Novo's amylin strategy, and retatrutide is still coming behind it.
Jaypirca. It won FDA approval in previously untreated CLL/SLL. It is the only approved non-covalent BTK inhibitor, and this moves it into the largest part of the BTK market.
This is real diversification beyond obesity and diabetes.
The "certain patients" wording means the label's breadth will set the sales ramp.
The news crossed the wires around 3:15pm ET Friday, so Monday is the first full session to digest it.

Meanwhile, Novo is spending about $4B on two deals to restock its pipeline, which is what catching up looks like. Even small-cap bulls on StockTwits pitch their names against tirzepatide. Notice also what did not happen this week: no LLY safety signal, no guidance cut, no downgrade, no price-target cut.

3. The valuation has already absorbed the rate shock¶

At $1,142.85 and about 894M diluted shares, LLY is worth roughly $1.02T. That is about 38x trailing GAAP EPS and about 35x H1'26 EPS annualized.

The multiple has already compressed. In late December the stock traded around $1,037–1,075, against the $22.95 it went on to earn for FY25. That is roughly 45–47x, so a 15–18% de-rating has already happened while the business accelerated.
Time works for the bull. Suppose Q3 EPS only matches Q2's $7.94, which was held down by one-time charges, and replaces Q3'25's $6.21. The trailing P/E then falls to about 36x at today's price.
Stress test. Build a cautious FY26 floor where H2 simply repeats H1's GAAP EPS, with no sequential growth: $32.40, up 41%. Then assume growth collapses in 2027:

FY27 EPS (scenario arithmetic, not a forecast)	Price at 30x	Price at 35x
+15% → $37.26	~$1,118 (−2%)	~$1,304 (+14%)
+25% → $40.50	~$1,215 (+6%)	~$1,418 (+24%)

In the worst cell, growth drops from +73% to +15% and the multiple compresses another 22%, and the stock is still only down about 2%. That is a margin of safety for a company growing about 50%.

Where I expect the bear to push, and why it doesn't hold¶

"Real yields are at 2008 levels, and LLY's value sits in distant future profits." This is the bear's best argument, so I'll take it directly.

The stock already withstood the shock. September brought the first Fed hike since 2023, and the 10-year TIPS yield reached 2.93%, the highest since 2008. LLY's monthly close went from $1,156.73 to $1,157.08, and the $1,107–1,114 floor held on its retest.
The 9/30 reversal tracks rates. It happened on the same day the 10-year Treasury peaked at 5.29%. That points to a rate-driven sell-off, not a broken thesis.
The "distant profits" label doesn't fit. Lilly earns $26.7B a year today.
A 2.6% trailing earnings yield looks thin next to a 2.9% TIPS yield. But the TIPS real yield is fixed, while Lilly's earnings grew 73% in H1.
On my no-growth FY26 floor, the earnings yield is already about 2.8%. At +25% in FY27, it is about 3.5% on today's price.
The macro may be turning. The 2-year yield was already 14bp below its Sept 28 high before Friday's +29K payrolls print. Moody's Mark Zandi says higher rates are "already damaging the economy."
Credit stress favors LLY. If high-yield spreads keep widening (2.60% → 3.24% so far), money tends to move toward steady, non-cyclical growth.
2022 is a precedent. In that rate shock, LLY rose about 32% while the S&P 500 fell about 19%. The macro desk is right that headlines move a $1T stock less now, which is why my case rests on earnings rather than headlines.
One concession: September CPI (around Oct 14–15) is a real near-term risk. That affects how I size the entry, not whether the thesis holds.

"Q2 earnings fell while revenue rose, and the balance sheet is taking on debt."

The earnings dip has a likely one-time cause. Q2 net income did fall 4.1% from Q1, as costs below gross profit jumped $3.8B. But the same quarter shows a $15.4B investing outflow and $15.9B of new long-term assets.
Lilly routinely expenses acquired in-process R&D (pipeline drugs bought from other companies) through GAAP earnings. That pattern produced a net loss in Q3'23, only $970M of net income in Q3'24, and a weak Q1'25.
Normalize the cost ratio and Q2 EPS comes out at roughly $9.70–10.60 rather than $7.94. That figure is illustrative; the 10-Q will confirm, but the pattern fits.
The balance sheet is stronger than at end-2023. Liabilities are 3.20x equity, down from 4.94x then, and equity is up 85% YoY.
This is investment, not distress. Raising $8.4B of new financing to put $15B into plants or pipeline, while generating $28B a year of operating cash, is playing offense.

"The chart broke."

The short-term tape is weak. The daily trend indicator (SuperTrend) is down, and the 9/30 reversal on 3.41M shares was real selling.
But one session shouldn't be over-read. 9/30 was also quarter-end, when rebalancing flows run heavy. The intraday spike stopped just 2.65 points short of turning every timeframe's trend signal up.
The bigger picture is a range, not a downtrend.
ADX has been below 25 on 38 of 43 sessions, which means no strong trend in either direction.
The weekly and monthly trends are up, and price is above a rising 200-day average.
Nothing is stretched: price sits close to its average on both weekly and daily charts (z-scores of −0.37 and −0.38).
Average daily range (ATR) has narrowed about 25% heading into a busy catalyst window.
This floor has launched rallies before. LLY closed at $1,114.08 on 8/4. It rose 4.9% the next session, on what looks like the Q2 earnings report, and closed at $1,280 by 8/19, about +15% in two weeks. The four high-volume sessions the technical team flags as likely earnings days closed +3.8%, +10.3%, +9.8% and +4.9%.

"Competition, and the amylin 'trap.'"

The dropout rates came from a dose-finding trial. EloraTZP's 10.8–27% discontinuation rates rose with dose in a Phase 2b study. Finding a tolerable dose and titration schedule is exactly what Phase 2b is for, and Lilly says it aims to improve tolerability in later studies.
The comparison flatters Lilly. The 2.9% comparator was tirzepatide, which is Lilly's own core drug. That headline really shows how well tolerated the base franchise is.
The skepticism is concentrated. Five of the eight skeptical StockTwits messages came from one Viking Therapeutics (VKTX) promoter.

"It's crowded."

The 93% bullish tag ratio is misleading. Nine of the 13 bullish tags sit on posts that lead with other tickers.
Actual sentiment is roughly even. Reading the content, constructive and skeptical messages are about balanced, and weekend posts leaned constructive.
Price doesn't reflect euphoria. A stock up 7% this year while EPS is up about 95% is not priced for a crowded trade.

How I'd own LLY: buy, in stages¶

Start a core position now. The late-October cluster favors being in before it, not after. It includes Q3 earnings (around Oct 30, unconfirmed), ObesityWeek in early November, Foundayo launch numbers and the Jaypirca first-line rollout.
Add at $1,107–1,118 if the floor is retested. Ideally RSI holds above 35.5 there, which would be a bullish divergence.
Add again on a daily close above $1,217.65, where every timeframe's trend signal turns up.
Size for gaps. ATR is about $32, and gaps run both ways: the 2/4 jump gave back 7.8% the next day.
Know the risk lines.
A sustained break below the rising 200-day average (about $1,071–1,075) is the point to re-examine the thesis.
The weekly SuperTrend at $979.50 is the structural line.
Reward-to-risk: the prior highs ($1,280–1,293) are 12–13% above today's price. A stop under the floor at about $1,090 is 4.6% below it. That is roughly 2.6:1 for an investor aiming at the old highs, not a range trader capped at $1,195.

My challenge to the bear¶

To be bearish on LLY here, you have to argue one of two things:

A business adding about $3B of revenue a quarter at an 86% gross margin is about to stall.
A multiple that has already compressed 15–18% this year must compress much further while earnings grow 40% or more.

Which one are you arguing, and what's your evidence? Bull Analyst: # Bull Rebuttal: LLY. Your downside needs every bad assumption at once

You've made the best bear case available: the business compounds, the multiple shrinks, and the stock goes nowhere. I'll grant what the data supports. But your downside only appears when several worst cases happen together. And Lilly's weakest non-Q1 quarter would already meet the revenue part of your buy trigger.

What I concede¶

The +95% TTM figure flatters. Its base includes two quarters hit by one-time charges, so I'll use first-half (H1) and revenue figures from here.
One session proves nothing. That covers my 9/30 read and your 10/1–10/2 read.
The near-term tape is weak. The 9/30 rejection and the lower low in on-balance volume (OBV) are real.
EloraTZP's dropout rates are a genuine Phase 2b question.
Margin expansion is slowing from its 2024–25 pace.
2022 is a weaker precedent for a $1T company.
Your "why pay mid-range?" point partly lands. I'm shrinking the first tranche (section 7).

1. "Routine or one-time": pick one, and growth holds either way¶

You said a charge can't be both routine and one-time. Agreed, so pick one:

How you treat the charges	H1'25 EPS	H1'26 EPS	Growth
Routine: keep them all (each half has one heavy-cost quarter)	$9.35	$16.20	+73%
One-time: strip both out (desk's illustrative Q2 adjustment)	~$11.18	~$18.0–18.9	~+61–69%
Your mix: strip last year's charge, treat this year's jump as permanent	~$11.18	$16.20	~+45%

Normalized H1'25 restates Q1'25 at Q2'25's cost ratio (derived).

Your 26% Q2 growth figure is the one comparison where the heavy-cost quarter sits only on today's side. That's the move you accused me of, in reverse.
Even your mix gives about +45%, close to H1's 51% revenue growth. That's what "EPS converges toward revenue growth" looks like when revenue is growing about 50%.
The Q2 jump looks like a one-off, not a new run-rate.
Costs below gross profit rose $3.79B (+43%) in one quarter. The next-largest quarterly rise in the data is $1.56B.
Operating budgets don't jump 43% in three months; one-off charges do. Lilly has booked three such quarters since 2023.
Your asset-matching test doesn't settle it either way. Liabilities rose $23B in Q2. Even if all the new financing and all the shareholder payouts had been new debt, about $10B of that increase came from something else. Large non-cash items were moving the balance sheet. The 10-Q will decide.
Cash flow undercuts the receivables worry. Q2 operating cash flow was a record $10.7B, 1.51× net income, despite a $6.2B build in receivables and inventory.
When revenue is pulled forward, cash lags earnings. Q2 showed the opposite.
If the $3.8B cost jump had been cash spent on launches or R&D, operating cash flow would have fallen with earnings. It didn't.
Compare margins like for like. You set a six-month change against full-year changes. Comparing H1 with H1:
Costs below gross profit fell from 53.7% to 50.1% of revenue.
Net margin rose from 29.8% to 33.9%.
Expansion slowed from about 8 points a year to about 4. It didn't stall.

2. Q3: your bar sits at Lilly's weakest non-Q1 quarter¶

My average isn't skewed. You say my $1.85B average quarterly gain leans on Q2's $3.2B and Q1's $0.5B. The median of the same four quarters is $1.87B.
Only the Q1s are soft. In six quarters of data, the only weak sequential quarters were the two Q1s (−5.9% and +2.6%), the usual first-quarter pattern in U.S. pharma. Every other quarter added $1.69B–3.18B.
Repeat the weakest of those ($1.69B, in Q4'25) and Q3 revenue is $24.66B, +40.1% year over year. That sits on your $24.6B buy line and above your $24.2B "slowest growth" line.
Stack all three of your worries: zero sequential growth, Q1's 81.9% gross margin, and Q2's 54.9% cost ratio made permanent. Q3 EPS still comes out around $6.94 (derived), above Q3'25's $6.21. Trailing EPS rises either way.

3. Valuation: your −14% needs a panic multiple on stale earnings¶

Your 33x is the year's panic low.
It came during April's oil spike: WTI hit $114.58 on Apr 7, and March CPI rose 0.87% in a single month.
The stock rose 51% from there.
Anchoring on that low is the start-date choice you charged me with, pointed the other way.
Today's 38x sits about five turns above that low and five below August's high.
Earnings are about to rise. Q3'25's $6.21 drops out of trailing EPS at the next report:

Q3 outcome (derived)	Q3 EPS	New TTM EPS	At 33x (April low)	At 38x (today)
Your stack: flat revenue, 81.9% gross margin, 54.9% cost ratio	~$6.94	~$30.53	~$1,007 (−12%)	~$1,160 (+1.5%)
My base: +$1.85B revenue, 83.4% gross margin, 50% cost ratio	~$9.28	~$32.87	~$1,085 (−5%)	~$1,249 (+9%)

Your −14% only happens if the panic multiple returns and earnings stand still. After Q3, my base case at your multiple lands near the 200-day average.

By your own yardstick, the stock isn't expensive.
You called 30x for 15% growth a PEG ratio of 2.
Apply that test to today's 38x, using the growth you expect EPS to converge toward: 30% on your flat Q3, 41% on my base.
That gives a PEG of about 0.9–1.3.
TIPS can't grow; LLY's earnings can. Ten-year TIPS pay 2.88% real with zero growth. On your own 30% growth case, LLY's earnings yield on today's price is about 3.4% next year. Comparing my stress case with a Treasury's base case only proves that stress cases are stressful.
Your "third outcome" already happened this year.
So far in 2026, trailing EPS is up 30%, the multiple is down 18%, and the stock is up 7%.
Repeat that next year on your 30% growth case, and the stock still gains about 7%.
For the stock to go nowhere, the multiple has to fall from 38x to about 29.5x within twelve months.
Novo isn't a template. Its slide came with repeated guidance cuts and lost market share to tirzepatide (background, like your point). LLY's week brought no guidance cut, no downgrade and no price-target cut.

4. Rates and this week's tape¶

Most of the week's drop came before the good news. About two-thirds of the 40.6-point loss came on 9/29–9/30, ending on the day the 10-year yield peaked at 5.29%. The trial headlines landed Oct 1–2.
The news days cost 14 points, less than half of one average day's range (ATR about 32 points).
10/2 had a stock-specific drag. CNBC's EloraTZP tolerability story ran that day, and Friday's posts turned skeptical as it spread (sentiment desk). The market was digesting a mixed Phase 2b readout; that doesn't show it refusing to pay for good news.
September was the real test. It brought the first Fed hike since 2023 and the highest real yields since 2008. LLY's monthly close went from $1,156.73 to $1,157.08, and the floor held.
The calendar cuts both ways.
The 2-year yield had already fallen 14bp before payrolls.
Payrolls then came in at +29K, with unemployment up to 4.2%.
Headline CPI will be hot; everyone knows what oil did in September. The macro desk says core CPI will decide, and that a hot headline with soft core will probably be looked past.

5. Margins, cash and leverage: widen the window¶

Gross margin: your own H1 figure makes my point. H1'26 was 84.0%, against 83.0% in FY25 and 81.3% in FY24, in the year Lilly cut GLP-1 prices. I'll concede Q2's 85.8% may not repeat.
Trading price for volume is tested in dollars. Q2 gross profit rose $6.6B (+50%) year over year.
Demand held up in bad conditions. Consumer sentiment hit a record low of 44.8 in May, and oil spiked in April. That was Q2, Lilly's record sequential quarter. A 2.1% move in the dollar is small against roughly 50% growth.
Cash: your measure (operating plus investing cash flow) treats acquisitions as running costs. That's why the fundamentals desk calls it conservative.
Before Q2's single $15.4B outflow, the trailing figure was +$8.9B.
Operating cash flow is $28.1B, up 67% from FY25.
Leverage: you measured from March. Year over year, liabilities-to-equity fell from 4.52x to 3.20x, and the current ratio rose from 1.28 to 1.35. The $8.4B raised equals under four months of operating cash flow.

6. Pipeline: the amylin "trap" catches the challenger¶

EloraTZP: the 10.8–27% dropout range comes from dose-finding, which is Phase 2b's job.
Your framing concedes something bigger: the benchmark in that trial was Lilly's own tirzepatide, at 2.9% dropout.
Amylin layering is Novo's strategy too, and CNBC framed the story as Lilly vs Novo.
If amylin drugs carry a tolerability cost as a class, it falls hardest on the company that needs amylin to catch up.
None of my valuation math assumes EloraTZP works.
Foundayo: agreed, there's no number yet. On cannibalization, Lilly owns both the injection and the pill. A cheaper-to-make Lilly pill taking Lilly patients beats Novo's pill taking them. It also reaches people who won't inject.
Jaypirca: agreed, it isn't the thesis. It's upside in the largest BTK segment, and the valuation doesn't need it.

7. The chart, and a tighter plan¶

The technical desk you quoted favors buying, just at better prices. It calls buying the floor its "base case; best reward-to-risk" and says to "prefer buying dips to shorting breakdowns." It labels your short "against the weekly trend; half size."
Your signals don't fit this market. ADX has been below 25 on 38 of 43 sessions, and the desk says "trend signals are unreliable." Your MACD cross, daily SuperTrend and lower highs are all trend signals.
Why pay mid-range? Because the catalysts may arrive before the floor does.
Every likely earnings session in the data closed up 3.8–10.3%.
One of them (2/4) reversed the next day.
The 4/30 jump started a 37% run, and the 8/5 jump added another 10% in two weeks.
Your checklist only clears on a blowout quarter. Gross margin of at least 83% and costs of at most 48% have been met together in one of the last six quarters (Q2'25). A quarter that passes your list is the kind that gaps the stock up. "Buy alongside you at a higher price" could mean paying 4–10% more.
You're right that a 4.6% stop won't survive an earnings gap, so position size has to control that risk. The desk is also right that $1,142.85 is a poor spot for a full position. That's why the starter is only a third:
Starter: one-third now. On the desk's example of a $100k account risking 1%, that's about 7 shares. A 10% earnings gap would cost about $800, inside the $1,000 risk budget.
Second third at $1,107–1,118, with the desk's setup A confirmations: a close back above about $1,115 and RSI holding above 35.5.
Final third after Q3, if revenue is at least $24.2B and costs below gross profit are back to about 51% of revenue or less. Otherwise, add it on a daily close above $1,217.65.
Risk lines. A close below the 200-day average (about $1,071–1,075) means no further adds and a cut back to the starter. A break of the weekly SuperTrend at $979.50 means selling out.

Bottom line¶

You asked me to accept that the business can compound while the stock goes nowhere. In 2026 it already has: trailing EPS is up 30%, the stock is up 7%, and the multiple now sits in the middle of its range. That compression is the opportunity, not the warning.

From here the arithmetic works in my favor: - Q3'25's $6.21 drops out of trailing EPS, and even your worst-case stack beats it. - Your −14% needs April's panic multiple applied to earnings that are about to rise. - Lilly's weakest non-Q1 quarter in the data would meet the revenue line in your buy trigger.

My call on LLY: buy in thirds, starting smaller than I first proposed. If the floor comes first, I add there. If Q3 comes first, I'm already in.

My question back: your deceleration case needs Q3 revenue under $24.2B, which means a sequential gain below $1.25B. No non-Q1 quarter in the data has added less than $1.69B. What's the evidence it happens now, with Foundayo on the market? Bull Analyst: # Bull Rebuttal: LLY. Here's what would make me sell, and why your own math supports the price

You've conceded most of the earnings case. H1 EPS is up 73% like-for-like, Q3 revenue clears $24.2B, trailing EPS rises, the balance sheet is sound, and your short is only a range trade. What's left is the multiple and the calendar. I'll answer your question first, fix the parts of my plan you caught, and then show that the model you built to argue deceleration supports today's price.

What I concede¶

I misquoted the technical desk. It said "a poor spot for a new trade," not "for a full position."
Your risk-budget math is right. Seven shares with a $979.50 exit breaks a $1,000 budget.
Operating cash flow can't settle the Q2 charge. Rising liabilities could have lifted it. The 10-Q will decide, so it's now in my sell rules.
My post-Q3 add was too loose. A daily-trend trigger is also unreliable while ADX sits under 25. I've dropped both.
The trailing multiple did slip on all three report days. Your numbers check out.
CPI is a real near-term risk. Over months, real yields do set the multiple.

1. Your question: what Q3 would make me sell¶

Any one of four things:

Q3 result	Test	Action
Confirmed (all three)	Revenue ≥ $24.6B (≈ +40% YoY); gross margin ≥ 83%; costs below gross profit ≤ 50% of revenue	Add the final third
Broken (any one)	Revenue < $23.5B; gross margin < 81%; costs ≥ 54% again and the 10-Q shows Q2's jump was recurring spending; a cut to full-year revenue guidance	Sell everything
In between	Anything else	Hold; no adds

Each line tests one of my opening's three pillars: the dollar engine, the trade of price for volume, and operating leverage (costs growing slower than revenue).

$23.5B is a stall test. It implies a sequential gain of about $0.5B. In six quarters of data, gains that small have only come in first quarters.
It's also where your pull-forward worry would show up. If Q2's $6.2B build in receivables and inventory borrowed sales from Q3, Q3 revenue is where it surfaces.
An 81% gross margin would sit below every quarter in the data (81.9–85.8%) and below FY24's 81.3%. It would erase two years of gains and mean price cuts are outrunning scale.
A second quarter at 54% or more that the 10-Q can't pin on acquired R&D would mean Q2 reset the cost base. That breaks my claim that profitability is improving structurally.
My "confirmed" row now uses your revenue and gross-margin lines.
The only gap left between our checklists is the cost line: 50% versus your 48%.
That gap is the routine-versus-one-time question, and you answered "routine" (section 5).

2. Your deceleration table answers your five-year table¶

You built the deceleration table by adding my $1.85B a quarter. Run it for five years instead of two:

Your 2031 requirement (your 35% net margin)	Revenue needed	When your model gets there (derived)
25x exit	~$180B	Q4 2029
20x exit	~$225B	Q2 2031

Nothing accelerates in this model. Growth keeps falling, to about 14% a year by 2031. At that rate, the 20–25x multiples you chose are ordinary.
For your table to fail, the dollar engine has to shrink.
Reaching $180B by mid-2031 takes an average gain of about $1.2B a quarter, two-thirds of today's pace.
Reaching $225B takes about $1.8B a quarter, roughly today's pace.
So for the 25x case to fail, average dollar gains have to fall by a third and stay there for five years.
A sustained one-third cut in dollar gains is a stall.
In your first rebuttal you called your case "not a stall, a deceleration."
This round you modeled that deceleration as steady dollar gains.
At that pace, the stock clears your 9% hurdle.
The $100B "record" is a quarter or two away, not a ceiling. Q2 annualizes to $91.9B. Your own Q3 floor of $24.2B annualizes to $96.8B.

None of this is my forecast. It's your model, run longer.

3. Valuation: put the comparisons on the same basis and the price looks different¶

Forward, on your model: - Next-twelve-month revenue comes to about $110.4B. - The trailing net margin of 33.5% already includes Q2's charge, so it matches your "routine" pick. At that margin, EPS is about $41.40, or about 28x forward earnings. - That assumes no further margin expansion. The gap between EPS growth and revenue growth that you say is closing is already zero in my math. - For the stock to be flat by the time that becomes trailing EPS (around next August's report), the trailing multiple has to fall to about 27.6x. That's more than five turns below your April anchor. - Floor case: suppose revenue never rises past Q2's $23.0B and every quarter carries Q2's charge-hit 30.9% margin. Forward EPS is still about $31.80, or 36x, which is below today's trailing 38x.

Your PEG starts the clock a year late: - The next eight quarters in your own table average about 33% growth. Trailing revenue compounds at 32.6% a year over that span. - That gives a PEG (P/E divided by growth) of about 1.1–1.2 (35.3–38.4x ÷ 32.6). - Your 28% only appears if you skip the next twelve months and look at 2027–28 alone.

Your April anchor was the only trailing base this year with no charge in it: - On 4/30, trailing EPS of $28.15 covered Q2'25 through Q1'26. None of the four charge quarters you counted fell inside that window. Today's $29.80 includes Q2'26. - If charges are routine, compare earnings bases that carry the same charges. - The fundamentals desk restated Q2'26 two ways: at Q1'26's cost ratio and at the prior four-quarter average. - Those restatements give trailing EPS of $31.60–32.45, or 35.2–36.2x today. - On that basis, the multiple has risen 2–3 turns (6–9%) since April, not five turns (16%). Two record quarters came in between. - Your post-Q3 downside of $1,007–1,085 applies that charge-free multiple to trailing EPS that will still contain Q2's charge. Put both on the same basis, and April's 33x on my base case gives about $1,148–1,176, at or above today's price. - I'm not calling 35–36x cheap. I'm saying your anchor isn't comparable as stated.

4. Timing: the steepest leg of the rate shock left LLY flat¶

LLY already got through the worst week.
The 10-year TIPS yield went from about 2.6% before Sept 23 to 2.93% on Sept 30. That's about half its entire climb from 2.32%, to the highest level since 2008.
Over that stretch, LLY went from its $1,144.50 open on Sept 21 to $1,157.08 on Sept 30.
It's at $1,142.85 now, down $1.65 from that open.
Your 12.9% slide came before that leg. In your words, the stock "absorbed the rate shock by repricing."
Your own evidence argues against waiting.
You used 10/1–10/2 to show that LLY doesn't track rates day to day.
Add Sept 28: the 2-year yield hit its high, oil rose $14.14, and LLY closed up.
Waiting for CPI only gives you an edge if rate news moves the stock reliably. These two weeks showed a loose link, in both directions.
CPI won't surprise on the headline.
The hot headline is the most predictable print of the year. WTI averaged about $97 in September, against about $84 in August.
The macro desk says a hot headline will probably be looked past if core inflation is soft. August core was 0.29%, right on the line.
My starter isn't a bet that core comes in soft. It's a bet that core won't push LLY below $1,090. LLY hasn't traded below about $1,107 since at least early August, through the first rate hike since 2023 and the TIPS peak.
The bond market isn't pricing stagflation.
Breakeven inflation (the bond market's expected inflation rate) is 2.36%, against 2.32% in late August.
The yield curve steepened because the 2-year yield fell: 4.92% on Sept 28, 4.78% on Oct 1, and lower after payrolls. That means fewer rate hikes are being priced in.
Long real yields haven't followed yet. That is the risk, and my stop covers it. It also covers high-yield credit spreads breaking above 3.5%.
Your table shows the price rising on report days.
You wrote that the multiple falls "instead of the price rising." On all three report days, both happened: the price rose 4.9–10.3% while the multiple slipped.
The stock got cheaper as it went up.
The reversals came from macro events, not from Lilly.
February's jump gave way to April's oil spike ($114.58) and a 0.87% one-month CPI print.
August's gave way to the real-yield climb and the first hike since 2023.
Anyone who bought before each 2026 report is ahead today: +14.4% from ⅔, +34.7% from 4/29, and +2.6% from 8/4.
The February buyer sat through a 15% drawdown first. That's why I'm sizing small and using a stop.
The two possible mistakes don't cost the same. On five shares:
If the floor comes first, buying now costs about $155 more than waiting would have.
If it doesn't, and Q3 moves the stock like the four report days in the data (+3.8% to +10.3%), waiting costs about $215–590.

5. The Q2 charge: your "routine" assumption is my base case¶

If charges are routine, Q3's expected cost ratio is the average with charges included.
That's 49.9% over the last four quarters and 50.9% over all six. My base case uses 50%.
So my base case isn't hedging the one-time story. It's your assumption.
Your worst-case stack needs something that hasn't happened.
It repeats Q2's 54.9% in Q3. If charges are routine, that means two charge quarters in a row.
None of the four you counted (Q3'23, Q3'24, Q1'25, Q2'26) sits next to another.
If charges are routine, your 48% cost line partly tests deal timing, not the business. Only two of the last six quarters met it.

6. Pipeline: your Novo example shows what a failed next drug looks like¶

Novo's CagriSema day: about −20%, per your background figure. That's the market deciding the next leg had failed.
LLY's EloraTZP day: CNBC's tolerability story ran on 10/2, and LLY fell 0.6%.
The two news days together cost 1.2%.
That is the market's estimate of how much of LLY's value rides on EloraTZP.
Yes, I reframed it. The readout was mixed, and I said so. But the market barely moved.
Lilly has more than one next leg. Foundayo has launched, retatrutide is coming, and amylin is one option among several.
A class-wide amylin problem hits hardest where the alternatives are fewest.
This week, that was the company spending about $4B on deals to restock its pipeline.
Foundayo: protecting market share is the point. The pill reaches people who won't inject.
Whether trading price for volume works shows up in dollars. Q2 gross profit rose $6.6B (+50%) in the year Lilly cut prices.

7. The plan, fixed¶

Full size is about 15 shares (the desk's 2×-ATR sizing on its $100k example), bought in three tranches of five.
Starter: 5 shares now (~$5.7k).
Next 5 shares at $1,107–1,118, only if the desk's setup-A confirmations hold:
a close back above about $1,115;
RSI above 35.5;
OBV above 337.85M.
One stop for both tranches before the report: a daily close below $1,090. This is the desk's own setup-A stop.
If it's hit, the loss is about $265 on the starter and $85–140 on the floor tranche.
The starter's reward-to-risk is about 1.4:1 to $1,217.65 and 2.6–2.8:1 to the old highs.
At most 10 shares (~$11.3k) into the report.
A 10% gap would cost about $1,130.
A repeat of February's −7.8% day would cost about $880.
The last 5 shares only after a "confirmed" Q3.
After Q3, the stop moves to just below the report-day low, and the sell table decides each quarter.

You said paying up to 10% more for confirmation beats risking 14.3% without it. Agreed, so I'm not risking 14.3%. I'm risking 4.6% on a third of the position.

Bottom line¶

You've conceded the earnings. Your remaining case is that the multiple falls before the report. Put the comparisons on the same basis, and the multiple is: - about 28x forward earnings on your own model; - about 36x even with no growth and a charge every quarter; - 2–3 turns above April, not five.

The steepest leg of the real-yield climb left LLY flat. My plan risks about $265 on the starter before the report, sells on a broken quarter, and adds only on a confirmed one.

My call on LLY: buy in thirds of five shares. - Start with 5 now. - Add 5 at the floor if the confirmations hold. - Add the last 5 only after a confirmed Q3. - Sell everything if any "broken" line trips.

My question back: Your two tables can't both be the bear case. Your deceleration table assumes Lilly keeps adding about $1.85B a quarter. At that pace, and your 35% margin, your own five-year table clears 9% a year even at a 20x exit. For it to fail at 25x, Lilly's average gains have to shrink by about a third for five years. That's a stall, which you said you weren't arguing. So which one goes: your deceleration case or your five-year table? Bull Analyst: # Bull Rebuttal: LLY. My cell is Lilly's two-year average, and your own entries buy the same grid

You asked me to pick a cell, so I will: the $1.50B row at 20–25x. That row isn't Lilly's record pace. It's what Lilly has averaged over the past two years.

Then I'll show two things your grid and your coin flip leave out: - Your own buy points sit on the same grid, and two of them are at higher prices. - Your no-drift model, run to the end, gives waiting no edge.

What I concede¶

Your grid's arithmetic checks out. I re-ran it: the $1.85B row gives about $89.60 of 2031 EPS and 9.4% a year at 20x.
LLY isn't cheap over five years against a 9% hurdle. My round-1 "margin of safety" meant limited downside, not beating 9%. I'll defend that meaning below, but I won't call this a bargain.
My 36x "floor case" isn't a price floor. A Lilly that stopped growing wouldn't keep 36x.
Report days cut both ways. Your two background misses (10/30/2024 and January 2025) are real, and four up days is a sample of four.
February's give-back began on ⅖, before the oil spike. Also, two of my three "ahead today" entries were bought at the floor.
The 10/1–10/2 moves mixed three stories, so they aren't a clean read on EloraTZP.
Gap risk runs from the pre-report close, not from my cost. I'm adopting your fix (section 4).
The long end prices LLY. The 10-year TIPS yield is 5bp off its high.

1. My cell: the $1.50B row at 20–25x¶

The row is Lilly's two-year average, not its record. - Q2'24 revenue was about $11.3B (derived from Q2'25's +37.6%), and Q2'26 was $23.0B. That's an average gain of $1.46B a quarter over eight quarters. - Those two years include two soft Q1s, the GLP-1 price cuts and tirzepatide supply shortages that lasted into late 2024 (background). - $1.50B a quarter is about $24B of new revenue a year. Trailing-twelve-month revenue is already $26.4B higher than a year ago.

Your evidence question has a direct answer: Lilly is adding a 2022-sized Lilly a year right now. - H1'26 revenue was $14.5B above H1'25. Annualized, that's $29.0B, against $28.5B for all of Lilly in 2022. - It happened in the year Lilly traded price for volume. Q2 gross profit still rose $6.6B (+50%), and gross margin rose. - So the open question is how long this lasts, not whether Lilly can do it. - My cell doesn't need today's pace to last. It needs Lilly to repeat its two-year average, about 84% of a 2022 Lilly each year.

The column: 20–25x for a company your model still has growing about 13% in 2031. - Every row of your grid has Lilly growing 10–15% in 2031 (derived). - Your 7–10x precedents were companies with little growth and a cliff two to four years away. In your model, 2031 Lilly is about five years from tirzepatide's cliff, and Foundayo is five years into its launch. - A cliff multiple is the market betting that the replacements fail. - AbbVie re-rated once Skyrizi and Rinvoq proved they could replace Humira (background). They launched about four years before Humira's cliff. - Foundayo launched about ten years before tirzepatide's cliff. - Lilly's own 2014–19 plateau, your example, followed a cliff that arrived before its replacements had scaled (background).

What your grid leaves out: shareholder yield. - Your hurdle is a total return: a Treasury pays its 5.24% in coupons. Your grid is price-only, with a flat share count. - Diluted shares fell 0.7% last year, and the dividend yields roughly 0.5–0.6% (background). Together, that's about 1.2 points a year. - I've kept your 35% net margin. It assumes margin rises just 1.5 points while revenue more than doubles. Comparing first halves, it rose 4.1 points in the last year alone.

$1.50B row	Your method (price only)	With ~1.2 pts shareholder yield
20x	6.8%	~8.0%
22.5x	9.4%	~10.6%
25x	11.7%	~12.9%

The midpoint is about 10.5% a year against your 9% hurdle.
At your 33.5% margin, take off about 0.9 points. The midpoint is still about 9.6%.
At the bottom of my range, it's about 8%. That's a point short of your hurdle and nearly three above a Treasury.
That's a fair price with a modest cushion. If today's pace holds, or margin keeps rising, that's upside.
Your "six trail a Treasury" depends mostly on one column. Add shareholder yield and five cells trail. Four of those five are in the 15x column, the multiple you said you aren't forecasting.

Margin of safety, in the sense I used it: - Ten of your twelve cells end above today's price, before dividends. - The worst cell is half today's pace at 15x, on a company still growing 10%. It loses about 19% over five years, or about 13% after dividends and buybacks. - The best cell gains 96%. - Bad outcomes cost a little, and good ones pay a lot. That was my round-1 claim, and your grid confirms it over five years.

2. Your entries buy the same grid¶

Entry	Price	Cells clearing 9% (of 12)	Today's pace, 20x
Your buy zone	~1,112	4	10.0%
My starter	1,142.85	4	9.4%
Your breakout trigger	1,217.65	2	8.0%

Your buy zone improves every cell by about half a point a year. The same four cells clear your hurdle.
Your breakout trigger buys where your grid looks worse than today. Only two cells clear 9%. A chart breakout doesn't tell you which row Lilly lands in.
Your confirmed-Q3 entry probably buys after a gap up too. In fairness, a strong quarter does shift the odds toward the upper rows.
So the grid isn't what separates us. If LLY is "fully priced" at $1,142.85, it's fully priced at $1,112 too, and even more so at $1,217.65, where you'd buy. What's left is $30 and three weeks.

3. The three weeks: your no-drift model, run to the end¶

I accept your 70–80% odds of a dip into 1,107–1,118. My plan is built for it: the starter is a third, and the second tranche waits at the floor.
Your table left out what happens in the other 20–30% of paths. A stock that never gives up 2% in 19 sessions has usually rallied.
On your own no-drift inputs, those paths finish about $58–99 a share higher by the eve of the report. That's derived: the $24.85 gap to $1,118, times 70–80%, divided by 20–30%.
On five shares, that's about $290–500 before any earnings move.

Your inputs	Dip odds 70%	Dip odds 80%
What waiting saves in dip paths ($155 × odds)	$109	$124
Starter's pre-report gain in no-dip paths (probability-weighted, derived)	$87	$99
Net before the report	≈ −$22	≈ −$25
Add your "every no-dip path pops" grant (~$400)	+$120	+$80
Net	≈ +$98	≈ +$55

That's not luck. When a stock has no drift, how you time your entry doesn't change the expected result.
What waiting saves in the dip paths, it gives up in the others.
The $20–25 left over is the gap between your $1,118 trigger and the $1,112 fill.
Volatility arithmetic can tell you a dip is likely. It can't tell you waiting pays. Only a downward drift would, and you've said your case for waiting doesn't rest on CPI moving the stock.
Support doesn't change it either. After a touch, we both own the same twice-tested floor, so the difference between us stays $155.
Your floor-break line (−$265) assumes your confirmations keep you out. If they fire first and the floor then breaks, you're stopped at $1,090 too. The gap between us is still about $155.
What remains is the report-day move in the no-dip paths, where I'm long and you're flat.
On your own grant, that leaves me $55–100 ahead.
If you expect Q3's report day to fall, waiting is right. But that's a call on the quarter, not on volatility, and our Q3 checklists now match.
The starter's downside is the stop: $265, about a quarter of a percent of the desk's $100k example account.

4. Gap risk: your fix, adopted¶

New rule: the day before the report, unhedged shares are capped so that open loss plus a 10% gap from that close stays within $1,000. Shares above the cap get a put spread through the print or are sold.
No dip: only the 5 starter shares are held. A 10% gap from around today's price costs about $570.
Floor tranche filled, pre-report close at $1,112:
The starter plus 2 shares stay unhedged.
The $154 open loss plus a 10% gap on 7 shares ($778) totals $932.
The other 3 shares are hedged or sold.
One addition, from the macro desk's bear trigger: no new tranche while the 10-year TIPS yield closes above 3.0%.

5. The multiple guard is the price stop¶

Agreed: fundamental lines fire late. That's why the price stop exists: a close below $1,090 before the report, and below the report-day low after it. You called that fine for a holder.
Your $24.0B example lands in "hold, no adds" on purpose. That's +36% growth and a $1.0B sequential gain. A falling multiple would show up in the stop first.
Your price-for-volume "tax" scales with the base, and so does volume.
The only test we have is the price-cut year: H1 revenue rose 51% and gross margin rose.
If the tax starts winning, my "broken" line (gross margin below 81%) fires.
The same line catches the ex-U.S. semaglutide expiries, which put price pressure first on Novo's drug.

Bottom line¶

My cell: Lilly repeats its two-year average and exits at 20–25x.
Including the shareholder yield your grid leaves out, that's about 8–13% a year, and about 10.5% at the midpoint.
That's a fair price, with upside if today's pace holds.
Your grid runs from −19% to +96% over five years. That's the asymmetry I called a margin of safety.
Your buy points sit on the same grid, and your breakout buys at a worse price on it.
Your no-drift model gives waiting no edge. What's left is a small, sized bet on Q3.

My call on LLY: buy in thirds, with gap-capped exposure into the report. 1. Now: 5 shares. 2. At the floor: 5 shares at $1,107–1,118, with the desk's confirmations: a close back above about $1,115, RSI above 35.5 and OBV above 337.85M. No adds while the 10-year TIPS yield is above 3.0%. 3. Stop before the report: a daily close below $1,090. 4. Into the report: cap unhedged shares so that open loss plus a 10% gap fits the $1,000 budget. 5. After a confirmed Q3, add the last 5 shares. Confirmed means all three of these, which now match your checklist: - revenue of at least $24.6B; - gross margin of at least 83%; - costs below gross profit at or under 50% of revenue. 6. Sell everything on any "broken" line: - revenue below $23.5B; - gross margin below 81%; - costs at 54% or more again, with a 10-Q showing Q2's jump was recurring; - a cut to full-year revenue guidance.

My question back¶

You called LLY "fully priced" on your grid. Then you offered to buy it at $1,217.65, where your grid looks worse. There, only two of twelve cells clear your hurdle, and today's pace at 20x drops to 8.0%. A breakout doesn't change which row Lilly lands in.

So which is the bear case? - If the grid rules LLY out, why buy the breakout? - If it doesn't, our whole disagreement is three weeks, and your own model gives waiting no edge. Where does the edge come from? Bull Analyst: # Bull Rebuttal: LLY. Trend first, range second. And your harsh table freezes Lilly while it doubles

You dropped the breakout, counted the dividend and agreed my row is a fair center if the next five years look like the last two. You also corrected two of my inputs: the buyback and the margin. Your case now rests on those two corrections, because even with both, your center still clears your own 9% hurdle. So this round I'll: - answer your question, with a number for each model; - run your two corrections through your own row, where they turn out to be the worst corner of Lilly's own data; - show that your new "+50%" row is a stall from today's run-rate, not a normal slowdown.

What I concede¶

Q3'24 breaks my round-2 claim. "No non-Q1 quarter added less than $1.69B" held for the six quarters in our data, not for the two-year window I chose. One non-Q1 quarter in six stalled, so the tail is in my own sample.
Report days are close to a coin toss. Across eight reports, the average move is near zero, with double-digit moves both ways (your background). I won't count a pop.
H1'26's payouts were partly debt-funded, because Q2's investing outflow exceeded operating cash.
Under your range model, the floor beats my starter. Your $75–135 gap on five shares is about right if the range holds.
Ending above today's price isn't the bar. The Treasury is.

1. Your question: trend first, range second, in the desk's order¶

The desk ranks its timeframes. Its SuperTrend note says: "when timeframes conflict, the weekly carries the most weight, then monthly, then daily." - Weekly: up, 16.7% above its stop. - Monthly: up. - Daily: down and ranging.

So my plan uses the weekly to decide whether to own and the daily to decide where to add: - the starter is the weekly's tranche (drift); - the floor tranche is the daily's (range); - the last tranche is Q3's (information).

What the starter earns before the report (5 shares at $1,142.85, against your plan):

Model	Starter vs. waiting	Source
Random walk, no drift	−$22 to −$25	Your fill-gap edge
Drift at your own grid's center (~9% a year, ≈ $7 a share by the report)	About even	Derived
Range holds to the middle	−$75 to −$135	Your figures, accepted
Floor breaks	Up to −$265, against ~$0 for you	My stop; your confirmations keep you out

I'm not claiming a timing edge. The starter ties under the model the desk ranks first and trails under the others.
"Waiting is never worse" requires zero or negative drift.
Your own grid implies positive drift.
A negative tilt would be a call on CPI and the Fed, and you said your case for waiting doesn't rest on CPI moving the stock.
Your plan is a full bet on the daily range plus a confirmed Q3. Two-thirds of mine already waits for both. The starter puts the last third on the timeframe the desk ranks first.

What the starter buys is exposure in paths your plan can't enter. - With the breakout gone, the 20–30% of paths where the floor never comes (your volatility math) leave you one entry: a confirmed Q3, bought after the market has priced it. - If Q3 lands between our lines, near your own $24.2B floor case, you have no entry until the next floor test or the next confirmed quarter. You sit out a stock you call fair and hurdle-clearing. - In those paths, waiting doesn't buy information. It leaves you with no position.

How much is still at stake between us: - In expectation, the starter costs nothing under the desk's primary model and up to about $135 under your range model. That's 0.14% of the desk's $100k example account. - On a five-year holding, it's about 0.03–0.16 points a year on the full position. - The cushion question, your 0.2 points against my 1–2, is roughly ten times bigger. So let's settle that.

2. The buyback: your own row pays for it¶

H1's deficit comes from one quarter.
Q2's $15.4B investing outflow was about five times the average of the prior five quarters (~$3.0B).
Before it, trailing operating plus investing cash flow was +$8.9B.
FY25 was +$5.8B, with net financing of −$2.2B.
Run your $1.50B row through Lilly's own ranges (derived; 33.5% margin, flat share count):
Five-year revenue: ~$774B. Net income: ~$260B.
Operating cash flow at 0.82–1.05× net income (FY23–25 range against TTM): ~$213–272B.
Investing at 17–21% of revenue (the 2023–25 range): ~$132–163B.
A dividend growing about 15% a year (Lilly's recent raises, background) from a ~0.55% yield: ~$40B.
Left over: ~$10–100B, about $55B at the midpoints.
That midpoint buys back about 0.9% of shares a year, at prices rising with your center case, with no new debt. Add the dividend, and shareholder yield is about 1.5 points.
Your 0.75 needs the worst corner of both ranges, every year for five years. That means the lowest cash conversion and the highest investment intensity in the data, together. My 1.2 sits below the midpoint.
"Routine" deals are already in the cash, as you asked. The 2023–25 investing ratios include three of your four charge quarters (Q3'23, Q3'24 and Q1'25). Only Q2'26's deal sits outside them.

3. The margin: 33.5% freezes Lilly's cost structure while revenue doubles¶

Holding 33.5% to 2031 means one of two things. Either costs below gross profit stay at 49.9% of revenue while revenue goes from $80B to $203B, or price eats every point of operating leverage.
History points the other way on both.
Those costs fell 14 points (63.9% to 49.9%) while revenue rose 2.3×.
In the price-cut year, gross margin rose: 83.0% in FY25, 84.0% in H1'26.
35% needs very little.
At today's gross margin, costs must fall to 48.4% of revenue. That's 1.5 points over a revenue doubling, about a tenth of the leverage Lilly delivered on its last doubling.
The four quarters before Q2 averaged 47.9% (your figure).
If price takes a point of gross margin, costs need to fall 2.5 points instead.
Fixed-size deals get lighter.
Q2's charge was about $1.6–2.4B after tax (the desk's two restatements).
At one charge quarter in three, that's about 3–4% of today's revenue but only about 1–1.6% of your row's 2031 revenue, unless deal sizes double too.

Your $1.50B row at 22.5x, total return per year (derived):

Net margin	Your 0.75 yield	My 1.2	Midpoint ~1.5
33.5%	9.2%	9.6%	9.9%
35%	10.1%	10.6%	10.9%

Your hurdle already includes ~3.8 points of equity premium over the 10-year yield.
Clearing it means you're paid the full premium you asked for.
That's on a business the macro desk expects to hold up better if credit stress spreads.
On inputs consistent with your own row, the center is about 10–11%, roughly a 1–2 point cushion. That's "a fair price with a modest cushion," as I said.

4. Your "+50%" row is a stall from today's run-rate¶

Start from where Lilly already is. TTM revenue is $79.7B, but Q2 annualizes to $91.9B and your own Q3 floor to $96.8B.
+50% by mid-2031 ($119.5B TTM) means average gains of about $0.37B a quarter, starting now (derived).
That's below my ~$0.5B stall line.
It's only about 5–6% a year from today's run-rate.
That's about half the pace you cite for Novo's slowdown.
Here is Novo's pace applied from Lilly's current run-rate (Novo's ~10% is your background figure):
TTM revenue reaches about $143B by mid-2031.
EPS at 33.5% is about $53.50.
At your 20–25x, that's $1,071–1,339, or −6% to +17% before dividends.
That trails a Treasury, so it's a bad outcome. But at 20x it's −6%, not −22%.
Your row also trips my sell rule at the first print.
A $0.37B gain puts Q3 at about $23.35B, under my $23.5B line.
My plan doesn't hold to 2031; it exits, gap-capped.
Paths that front-load growth and then fade are what the price stop is for.
On proof:
AbbVie re-rated about two to three years after Skyrizi and Rinvoq launched (background). Foundayo launched in 2026, five years before your exit.
The obesity readout that cost 14% in August 2025 is behind it. The drug launched anyway, and this week it added late-stage diabetes data.
Jaypirca's first-line approval is diversification arriving now, and retatrutide is coming behind it.
EloraTZP is optional. None of my numbers need it.

5. The plan: one change. The starter now waits for something¶

You said the starter is the only tranche that waits for nothing. Fair. Now it waits for two things: a close that holds Friday's low, and a price no higher than the middle of the range. - Starter: 5 shares on the first close between $1,136.66 and the ~$1,151 midline. - $1,136.66 is the 10/2 low, which the desk lists as first support. - Monday is the first chance, and the first full session to price the Jaypirca approval. - If LLY closes below $1,136.66 first, I skip the starter, and the floor tranche becomes the first buy. - The desk's next levels are then $1,130–1,134, followed by $1,107–1,115, so your floor test becomes the likely path. - That takes the starter out of the paths where your range edge is biggest. - If it closes above the midline, I won't chase a Jaypirca bounce toward your trim zone. The starter waits for a close back at or below $1,151. - Stop risk on the starter is at most about $305 to the $1,090 stop.

Everything else stands: 1. Floor tranche: 5 shares at $1,107–1,118, with the desk's confirmations: - a close back above about $1,115; - RSI above 35.5; - OBV above 337.85M.

No adds while the 10-year TIPS yield closes above 3.0%. 2. Stop before the report: a daily close below $1,090. 3. Into the report: unhedged shares are capped so that open loss plus a 10% gap stays within $1,000. Shares above the cap are hedged or sold. 4. Final 5 shares after a confirmed Q3: revenue of at least $24.6B, gross margin of at least 83%, and costs at or below 50% of revenue. 5. Sell everything on any broken line: - revenue below $23.5B; - gross margin below 81%; - costs at 54% or more again, with a 10-Q showing Q2's jump was recurring; - a cut to full-year revenue guidance.

From Q4 on, the revenue line becomes any non-Q1 quarter adding less than $0.5B.

A Q3'24-style destocking stall would trigger that rule after the gap, as you say. On five to seven gap-capped shares, a 6% gap costs about $340–470, inside the budget.

Bottom line¶

We've both moved.
You went from "fully priced" to a center that clears your hurdle on your harshest inputs.
I went from "margin of safety" to "a fair price with a modest cushion."
On inputs that fit your own row, that cushion is about 1–2 points a year, for a franchise adding a 2022-sized Lilly every year.
The starter costs nothing in expectation under the desk's primary timeframe, and up to ~$135 under your range model. I pay that to hold the paths your plan can't enter, and it now skips the paths where your edge is biggest.

My call on LLY: buy in thirds. - The starter on the first close between $1,136.66 and $1,151. - The floor tranche on confirmations. - The final third on a confirmed Q3. - Gap-capped into the report; sell on any broken line.

My question back¶

Two parts, one answer each: 1. Your harsh table needs two things to hold at once for five years. - Lilly's cost ratio stays frozen at 49.9% while revenue more than doubles. - Cash conversion and investment intensity sit at their worst levels in the data.

Which of those do you actually expect? If neither, isn't the center back to 10–11%? 2. With your breakout gone, what's your entry if the floor never comes and Q3 lands between our lines, say at $24.3B? If the answer is "none until next quarter," how is that waiting free?

Bear Researcher¶

Bear Analyst: # Bear Rebuttal: LLY. A great business at the wrong price and the wrong moment

Lilly is the strongest growth franchise in large-cap pharma, and nothing below says the business is breaking. My case is narrower and harder to dodge. Your growth figures are flattered, the valuation hasn't absorbed the rate shock, and this week the market told us the good news is already owned.

Your challenge is a false choice¶

You say I must argue either a stall or a big further de-rating. Your own first paragraph describes a third outcome: EPS up about 95%, stock up about 7%. That is what "the business compounds while the multiple shrinks" looks like, and nothing in the data says it's finished. Since you asked, here are milder versions of both options:

Not a stall, a deceleration. If Q3 revenue is flat versus Q2, it grows +30.5% year over year against the year's toughest comparison. Your own base case is +41%, down from +47.7%. The margin expansion that nearly doubled EPS is also fading (section 2).
Not a collapse, a round trip. After its Q1 report in late April, LLY traded at about 33x trailing EPS (derived in section 3). At that multiple on today's $29.80, the stock is worth about $986, roughly −14%. The market paid that multiple five months ago.

1. "It's just rates" failed its own test this week¶

You read one session, 9/30, as rate-driven because the 10-year yield peaked that day. Apply the same logic to the next two sessions:

10/1: The 10-year yield eased to 5.24% and the 10-year TIPS yield to 2.88%. LLY fell 0.6%.
10/2: Payrolls came in at +29K, yields fell, and stocks rallied, per the macro desk. The Jaypirca approval hit the wires with 45 minutes left in the session. LLY fell another 0.6%, posted an outside day, and closed in the bottom quarter of its range.
The week: LLY got an FDA label expansion, two sets of positive trial headlines and no downgrades. It still fell 3.4%, erasing all of the prior week's gain. That is the crowding signal that matters, not the StockTwits tag ratio.

You built your case on one session; I'm using two. Two sessions is a small sample, but it is the only clean test of your thesis, and it failed. LLY fell when real yields rose and kept falling when they eased. That matters because the next macro events lean the wrong way:

Oil: September WTI averaged about $97, against about $84 in August.
Inflation: August core CPI rose 0.29% (about 3.5% annualized), and core PCE is 3.0%.
Calendar: September CPI lands around Oct 14–15. The Fed, which just hiked for the first time since 2023, meets Oct 27–28.
Credit: High-yield spreads have widened 64bp since late August. A flight to quality helps LLY relative to junk bonds, not in absolute terms. The macro desk says LLY "could still fall."

On 2022: tirzepatide was then a brand-new, unpriced blockbuster at a company a fraction of today's size. The macro desk says it directly: at about $1T, with most investors already bullish, each new result moves the stock less and rates matter more.

2. The growth you lead with is flattered, and the engine behind it is slowing¶

You count the charges only when they help. The +95% TTM figure is GAAP. Its prior-year base ($15.30) includes Q3'24 (net income of just $970M) and Q1'25 ($3.06 EPS), both depressed by acquired-R&D charges (one-time expenses for buying drugs in development). You keep that benefit, then strip the same kind of charge out of Q2'26 to argue earnings power is even higher. On a plain GAAP basis, the latest quarter's EPS grew 26% (net income +25.3%).
"Routine" and "one-time" can't both be true. Your own list (Q3'23, Q3'24, Q1'25, Q2'26) is four of the last twelve quarters. A charge that shows up a third of the time is a recurring cost for a company that buys its pipeline.
The balance sheet doesn't clearly support your explanation.
Q2's $15.4B investing outflow reappears almost dollar-for-dollar as $15.9B of new long-term assets.
Money recorded as an asset doesn't hit earnings up front. Expensed acquired R&D doesn't create an asset.
So the $3.8B jump in operating costs may not come from that deal. The fundamentals desk names launch spending (Foundayo just launched) and higher R&D as other candidates, and both recur.
Your $9.70–10.60 "adjusted EPS" is, in that desk's own word, illustrative.

The margin engine is stalling.

	2023	2024	2025	TTM	Q2'26
Costs below gross profit, % of revenue	63.9%	57.8%	51.4%	49.9%	54.9%
Net margin	15.4%	23.5%	31.7%	33.5%	30.9%

Costs fell about 6 points of revenue a year in 2024 and 2025, then only 1.5 points in the six months since, and Q2 went backwards.
Net margin gained about 8 points a year, then 1.8.
That expansion is how 45–50% revenue growth became about 95% EPS growth. As it fades, EPS growth converges toward revenue growth.

Revenue growth now faces its toughest comparison.

Your +41% assumes Q3 adds $1.85B over Q2, the average of the last four quarters. That average includes Q2's record $3.2B and Q1's $0.5B.
Anything under about $24.2B would be the slowest year-over-year growth in the six quarters of data.
Receivables and inventory also rose $6.2B in Q2, about twice the revenue increase. Check the 10-Q before extrapolating that quarter.

3. The valuation hasn't absorbed anything; your start date is doing the work¶

Date	Price	Trailing EPS	Trailing P/E
Late Dec '25 (your start)	$1,037–1,075	$22.95	45–47x
4/29/26 (before likely Q1 report)	$848.53	$22.95	~37x
4/30/26 (likely Q1 report; price derived)	~$932	$28.15	~33x
8/19/26 (closing high)	$1,280.34	$29.80	~43x
Today	$1,142.85	$29.80	~38x

Measured from April, the multiple expanded about 16%.
From late April to the August high, the price rose about 37% while trailing EPS rose about 6%. The summer rally was mostly a re-rating.
Today's 38x is above where LLY traded during April's oil-driven inflation scare, and real yields have since hit their highest level since 2008.
You're paying a negative risk premium on today's earnings.
LLY's earnings yield is 2.6%, against 2.88% on 10-year TIPS and 5.24% on the nominal 10-year.
On your FY26 floor, it's 2.8%, roughly level with TIPS. All the value above that rests on growth.

Your stress test keeps a premium multiple as its floor. Thirty times earnings for 15% growth is a PEG ratio (P/E divided by growth rate) of 2. Here it is re-run at 25x:

FY27 EPS (your numbers)	25x	30x (your "worst")
+15% → $37.26	~$932 (−18%)	~$1,118 (−2%)
+25% → $40.50	~$1,013 (−11%)	~$1,215 (+6%)

If those are trailing multiples, they are prices about 15 months out. A 10-year Treasury pays 5.2% a year over that time with no equity risk. Even your worst cell trails Treasuries by 8–9 points.

Obesity leadership has been de-rated before. This is background, not this week's data. Novo Nordisk, the undisputed obesity leader of 2023–24, lost more than half its value from its 2024 peak during 2025 as growth slowed and competition arrived. You call Novo's roughly $4B of deals "catching up." Not long ago, LLY was the one catching up.

4. Margins and cash are thinner than presented¶

The record gross margin is one odd quarter.
Five of the last six quarters sit between 81.9% and 84.3%. H1'26 combined is 84.0%, against 83.0% for FY25.
In Q2, cost of revenue fell 8.6% while revenue rose 16%, which suggests something non-repeating. The fundamentals desk says the Q2 level "may not repeat."
Gross margin doesn't test the price cuts.
It compares price to manufacturing cost, and unit costs fall as volume scales.
Revenue per patient is the real test of trading price for volume, and Q3 is the first hard look. Medical-care CPI is +1.6% year over year and fell in August.
A pill that's cheaper to make will likely be priced lower too, which risks pulling some patients off higher-priced injectables.
Count the investment you're praising.
The $28.1B of operating cash flow is real. So is $25.1B of TTM investing outflow (31.5% of revenue).
After both, LLY produced +$3.0B TTM, about 0.3% of its $1.02T market cap, and −$3.3B in H1'26.
Leverage just turned up.
In Q2, cash flow after investing was −$4.7B. Financing raised $8.4B, liabilities rose $23B, and about $4.4B went to shareholders.
Your leverage comparison starts at end-2023. Measured from March, liabilities-to-equity rose from 2.74x to 3.20x in one quarter, and the current ratio fell from 1.50 to 1.35.

5. The pipeline week was messier than the headlines¶

EloraTZP:
Up to 27% of patients quit for side effects, against 2.9% on tirzepatide. That is roughly four to nine times the dropout rate of the drug it's meant to upgrade.
You note the comparator is Lilly's own drug. That is the problem: so far, the next-generation product is much harder to tolerate than the current one.
Phase 2b is where that risk lives; it isn't proof the risk is solved.
The number came from CNBC's report on the trial, not from the VKTX promoter. It doesn't get weaker because a promoter repeats it.
Foundayo: The "surprise" has no number attached. The drug is launching into a head-to-head race with Novo's Wegovy pill, and we have no prescription data yet.
Jaypirca: It is a good drug entering a crowded BTK market (Brukinsa, Calquence, Imbruvica) under a "certain patients" label. It diversifies at the margin. The valuation still rides on incretins (GLP-1-type drugs), a concentration the fundamentals desk can't even size from the filings.
Demand and currency: Self-pay patients face high fuel costs and depressed consumer sentiment (51.7 in August, after a record low of 44.8 in May). The dollar rose 2.1% in September, a currency headwind for Q3 and Q4.

6. The chart shows selling, and your trade plan argues against itself¶

The structure: Highs fell from 1,292.65 to 1,215.00 while the floor held near 1,107–1,114. The September bounce was weaker than August's.
9/30 was a failed breakout, not a near-miss.
It was an outside reversal on 3.41M shares (about 1.5x average). It cleared the 9/24 high, then closed in the bottom 3% of its range.
"2.65 points short" means sellers defended that exact level. Quarter-end rebalancing doesn't explain 10/1 and 10/2.
Volume and momentum confirm it:
OBV (on-balance volume) didn't confirm the August high and made a lower low on the September retest.
Volume ran heavier on the decline (about 2.44M shares a day) than on the rally (about 2.04M, excluding options expiration).
RSI made a lower low at the second floor test, so there is no bullish divergence.
MACD failed to hold above zero and likely crosses bearish if Monday closes below about 1,150.
Price is below its 10-, 20- and 50-day averages.
The August floor rally had a catalyst. Q2 earnings landed the next day. This time, CPI and the FOMC arrive before any earnings print.
Earnings pops don't stick. You cite four up earnings days. The 2/4 pop (+10.3%) gave back 7.8% the next day, and by late April LLY was about 23% below its 2/4 close (derived).
The technical desk calls $1,142.85 "a poor spot for a new trade" with a "poor reward-to-risk ratio."
Your plan buys now and adds at 1,107–1,118 "if the floor is retested." If a retest is likely enough to plan for, why pay mid-range for the first tranche?
Your 2.6:1 reward-to-risk needs a lot to go right.
It needs a clean run through four layers of resistance (1,151–1,160, 1,176, 1,185–1,198, 1,215–1,218).
Your 4.6% stop is meant to be carried through earnings, and one earnings-sized gap jumps it.
Even outside earnings, 7/30 gapped down 3.0%.

Bottom line¶

Level	Price	From $1,142.85
Upside trigger (daily SuperTrend)	1,217.65	+6.5%
Range floor	1,107–1,115	−2% to −3%
200-day average	~1,071–1,075	~−6%
April's ~33x on TTM EPS / weekly SuperTrend	~986 / 979.50	~−14%

My call on LLY: don't initiate at $1,142.85. Holders should trim or hedge into 1,165–1,195 before CPI, the FOMC and Q3 earnings. Short-term traders can use the technical desk's setup: sell rallies into 1,165–1,195 with a stop above 1,218, at half size.

What would change my mind:

A daily close above 1,217.65 on above-average volume.
A Q3 print that shows:
revenue of at least $24.6B;
costs below gross profit back to 48% of revenue or less;
gross margin of 83% or more;
a 10-Q confirming Q2's cost jump was one-time.
The 10-year TIPS yield back toward 2.6%.

If those happen, I'll buy alongside you, at a higher price but with far less risk.

You asked which argument I'm making. It's the one in your own first paragraph: the business can compound while the stock goes nowhere. Right now it's going nowhere, with the risk skewed down. Bear Analyst: # Bear Rebuttal: LLY. The quarter is yours, but the multiple decides the trade, and rates move it first

You've won the arithmetic you picked. H1 EPS is up 73% like-for-like, Q3 revenue will probably clear $24.2B, and trailing EPS rises when Q3'25 rolls off. I'll concede all three. None of it is news to the market.

Lilly's likely Q2 report had record revenue, a record sequential gain, a record gross margin and record operating cash flow. LLY jumped 4.9% on 8/5. On 9/11 it closed at $1,115.70, just $1.62 above its pre-report close. My case was never that Lilly misses. My case is that: - good quarters aren't moving the stock; - the multiple matters more than the quarter; - the two events most likely to move the multiple come before Lilly reports.

What I concede¶

H1 against H1 is the fair test. EPS is up 73%, with one heavy-cost quarter in each half. My Q2-only +26% put the charge on one side. Fair hit.
Q3 revenue: I don't forecast anything under $24.2B. Your weakest-non-Q1 math holds.
Trailing EPS will rise, so I'm updating my downside. April's 33x on post-Q3 EPS gives about $1,007–1,085 (−5% to −12%), not −14%.
The balance sheet is sound year over year. I'm not arguing distress.
My short is a half-size range trade (selling rallies near the top of the range), not the thesis.

1. Your question: my deceleration case doesn't need Q3 below $24.2B¶

Deceleration means any Q3 under about $26.0B, which was Q2's +47.7% pace.
Reaching $26.0B needs a sequential gain of about $3.0B, near the record.
Your base case (+41%) is a deceleration. So is a repeat of your weakest non-Q1 quarter (+40%).
Lilly adds a steady number of dollars, not a steady percentage.
Sequential gains totaled $3.73B in H2'25 and $3.68B in H1'26.
Q2's record $3.2B followed Q1's $0.5B, and the two average $1.84B.
Adding $1.85B a quarter to a growing base means the growth rate falls every quarter:

At your $1.85B/quarter run-rate (derived)	YoY revenue growth
Q3'26	~+41%
Q2'27	~+32%
Q2'28	~+24%

The margin gains that doubled EPS growth are fading. The gap between EPS growth and revenue growth was 70 points in FY24, 51 in FY25 and 22 in H1'26. You've already conceded that margin expansion has halved.
Your PEG ratio uses the wrong growth rate.
Dividing 38x by one quarter's +41% gives 0.9.
At your own run-rate, revenue growth averages about 28% over the next two years. That puts the PEG at about 1.25–1.35.
That is a full price, not a cheap one, even before accounting for the highest real yields since 2008.

2. The market already knows earnings will rise¶

Q3'25's $6.21 dropping out is the most predictable event on Lilly's calendar. When growth investors already paid for actually shows up, the trailing multiple falls instead of the price rising. That explains a large part of how 30% EPS growth this year became an 18% de-rating and a 7% gain.
Your table holds 38x through the report; this year's reports didn't. At all three, the trailing multiple slipped on the day (derived):
February: about 49x to 48x.
April: 37x to 33x.
August: 39.6x to 39.2x.
Earnings-day jumps have been sold:

Likely earnings day	Day's move	What followed
2/4/26	+10.3%	−7.8% the next day; about −23% by late April, below the pre-report close
4/30/26	+9.8%	+37% run, starting near the year's low
8/5/26	+4.9%	Back to the pre-report close by 9/11; today below the 8/5 close

Of the three jumps where we know what followed, two fully reversed. The one that held started near the year's low, which is the kind of entry I'm telling you to wait for.

Your own Q3 table says the multiple decides this trade.
At 38x, moving from my worst case to your base case adds about 7%.
In your base case, moving from 38x to 33x costs about 13%.
The multiple swing is nearly twice the earnings swing.
Rate news hits the multiple twice before Lilly reports: CPI (~Oct 14–15) and the Fed meeting (Oct 27–28). Earnings come after (~Oct 30, unconfirmed).

3. Valuation: 33x wasn't panic, and your own stress multiple is my thesis¶

33x was set on 4/30, a +9.8% day. That was the market pricing Q1's new earnings, not fleeing. The panic day was 4/29, at 37x on the old earnings.
Rates are worse now than in April.
The Fed has since hiked for the first time since 2023.
The 10-year TIPS yield has hit its highest level since 2008.
Yet LLY's multiple rose from 33x to 38x. Why should it carry a higher multiple now than in April?
Your "go nowhere" multiple is your own worst case. You say a flat year needs about 29.5x. Your round-1 stress table used 30x as its worst multiple. So the bad outcome in your own tables is a year of nothing while Treasuries pay 5.24%. That isn't a tail risk; it's my thesis.
You called this a margin of safety. Here is what the price requires. This is scenario arithmetic, not a forecast. It assumes a 9% annual return for five years (the 10-year yield plus about 4 points), ignoring the small dividend:

Exit P/E in 2031	EPS needed	EPS growth per year from $29.80	Annual revenue at a 35% net margin
25x	~$70	~19%	~$180B
20x	~$88	~24%	~$225B

Context (background, not this week's data): the largest annual revenue any drugmaker has booked is roughly $100B (Pfizer in 2022, helped by COVID products). The price needs Lilly to reach about twice that and still trade at 20–25x.
It might. But that is a fully priced franchise, not a margin of safety.
TIPS can't grow, as you say. Held to maturity, they also can't de-rate or gap 10% on an earnings report.

4. Rates: your relief is at the wrong end of the curve¶

The relief you cite is in the 2-year yield. LLY's distant profits are valued off long-term yields, which have barely moved.
The 10-year TIPS yield was 2.88% on Oct 1, 5bp below its 2008-high peak.
The gap between 10-year and 2-year yields widened from 0.20% to 0.45%. Long yields are holding while short yields fall.
This mix is close to stagflation. Payrolls rose just 29K, the Fed just hiked and oil is $96. In that mix, long real yields don't have to fall even as growth slows.
Core inflation is firming.
August core CPI rose 0.29%, and core PCE is 3.0%.
The macro desk says this partly supports the view that the Iran war's inflation is "not just because of oil."
Buying your starter now is a bet that September core inflation comes in soft. CPI is about eight trading days away, so waiting costs little.
Credit markets are nearing the alarm. High-yield spreads are at 3.24%, 26bp below the macro desk's 3.5% alarm, after a 51bp move in six sessions. The VIX (16.4) hasn't caught up.
September "held" only after a 12.9% slide from the 8/19 close to 9/11, as yields began climbing. The stock absorbed the rate shock by repricing. If TIPS yields break 3%, the next repricing starts from here.

5. Pipeline: your framing changed¶

You downgraded EloraTZP yourself. In round 1 it was one of three fronts where "the moat widened." Now it's "a mixed Phase 2b readout," and you blame 10/2's drop on its tolerability story. So the market marked the week's pipeline news down, not up.
"None of my valuation math assumes EloraTZP works." Your math doesn't have to; a 38x multiple does. That multiple assumes years of dominance after tirzepatide.
At Novo, the de-rating came before the guidance cuts (background):
Novo's slide began in December 2024. Its own amylin-plus-GLP-1 combination, CagriSema, disappointed, and the stock fell roughly 20% in a day.
Its 2025 guidance cuts came months later.
"No guidance cut this week" isn't protection.
The amylin risk hits both companies.
Both chose amylin as their next leg.
EloraTZP's dropout rate ran 4–9 times tirzepatide's. If that turns out to be a class-wide problem, the market will ask what follows tirzepatide.
That is a bigger question for the company priced at 38x on tirzepatide.
ObesityWeek in early November is the next read.
Foundayo protects market share, not revenue per patient. If it's priced below Zepbound, a pill that takes Zepbound patients can keep gross margin intact while slowing revenue. Its launch spending is also a recurring cost. You can't count only the upside.

6. The Q2 charge: operating cash flow can't settle it¶

Your cash test can't separate the things in question.
The $6.2B build in receivables and inventory is still a drag inside Q2's $10.7B of operating cash flow.
Something larger offset it, plausibly the roughly $10B of non-debt liability growth you found. Current liabilities alone rose $11.1B.
Cash flow lifted by rising liabilities can't vouch for revenue quality. Nor can it show whether the $3.8B cost jump was paid in cash.
I'll pick "routine" in your table, because four charge quarters in twelve is a pattern.
That gives you +73% EPS growth for H1.
But then reported (GAAP) EPS is the right earnings base, and 38x is the real multiple.
The "adjusted" $9.70–10.60 Q2 EPS that made the stock look cheaper in round 1 is off the table.
Your Q3 base case already hedges the one-time story. It assumes costs below gross profit at 50% of revenue. That is above Q1'26's 44.6% and above the 47.9% average of the four quarters before Q2.

7. Your plan: below even money, over budget, and a trigger that can't say no¶

Reward-to-risk is under 1:1.
You fixed the gap problem by moving the starter's exit to $979.50, 14.3% below today.
The old highs are 12–13% above today.
That is about 0.85–0.9 to 1. Round 1's 2.6:1 depended on the roughly $1,090 stop you've now replaced.
The starter alone breaks your risk budget.
Seven shares losing about $163 each on the way to your exit is about $1,140, over the $1,000 budget before tranche two.
If the floor tranche fills before earnings, as your plan anticipates, you carry about 14 shares (about $15.8k) into the report.
A 10% gap then costs about $1,750.
That's not what the technical desk said. It didn't call $1,142.85 "a poor spot for a full position." It said "a poor spot for a new trade" and "poor reward-to-risk for new trades." A third-sized new trade is still a new trade.
A weak trend signal (low ADX) cuts both ways.
If trend signals are unreliable, so are your $1,217.65 add and your $979.50 weekly SuperTrend exit.
The desk's rule for a range is "buy near lower band, fade near upper band." Price sits 40% of the way up the band, so that rule says wait.
My short sits at the upper band; your starter sits in the middle.
OBV and volume aren't trend signals, and you've conceded OBV's lower low.
Your post-Q3 add triggers on a slowdown.
$24.2B matches the slowest YoY growth in six quarters.
A 51% cost ratio is above the pre-Q2 average.
The fundamentals desk says 45–48% is what would confirm Q2 was one-time. Your trigger passes even if your one-time thesis is half wrong.
My checklist is your thesis.
$24.6B of revenue is below your base case.
83% gross margin is below your base case.
Costs at 48% of revenue are what your one-time story predicts.
If hitting all three counts as a "blowout," that tells you how much the price needs. Paying up to 10% more for confirmation beats risking 14.3% without it.

Bottom line¶

Level	Price	From $1,142.85
Upside trigger (daily SuperTrend)	1,217.65	+6.5%
Prior highs	1,280–1,293	+12% to +13%
Range floor	1,107–1,118	−2% to −3%
200-day average (mid-Oct est.)	~1,075	~−6%
April's 33x on post-Q3 EPS (your base / my worst case)	~1,085 / ~1,007	−5% / −12%
Your full exit (weekly SuperTrend)	979.50	−14.3%

My call on LLY: don't initiate at $1,142.85.

Holders: trim or hedge into 1,165–1,195 ahead of CPI, the Fed meeting and Q3. That includes any Jaypirca bounce in Monday's first full session.
Traders: the half-size short at 1,165–1,195, with a stop above 1,218, is the range playbook, not a trend call.
A better entry: CPI and the Fed meeting may push LLY to 1,107–1,118. If the desk's confirmations then hold, the risk is priced in and I'd respect the trade. Those confirmations are:
a close back above about 1,115;
RSI above 35.5;
OBV above 337.85M.

A break of the floor points to the 200-day average, then April's multiple on post-Q3 earnings. - What would change my mind is unchanged: - a daily close above 1,217.65 on strong volume; - Q3 revenue of $24.6B or more, gross margin of 83% or more, costs at 48% of revenue or less, and a 10-Q confirming Q2 was one-time; - the 10-year TIPS yield back toward 2.6%.

My question back: I've given you my buy conditions twice. What Q3 would make you sell? Your plan buys now, adds lower, and adds again after a quarter that matches the slowest growth in six. Your only full exit is a price 14% below today, and none of your exits is tied to the business. A thesis with no fundamental sell condition isn't a thesis; it's a position. Bear Analyst: # Bear Rebuttal: LLY. Neither table goes. Together they say "fully priced," and your starter is a coin flip

You answered my question with a real sell table, and you caught two errors in my valuation math. I'll take both. Then I'll answer your question: neither table goes, because they make the same claim from opposite ends.

Your extension didn't find a margin of safety. It found that the price clears its hurdle only if two things happen. Lilly has to keep most of its record pace for twenty straight quarters, and it still has to command 20–25x earnings at the end.

What I concede¶

Your sell table is a real answer. Every exit is tied to the business: revenue, margin, costs and guidance.
My April anchor mixed bases. April's $28.15 trailing EPS carried no charge quarter, while today's $29.80 carries Q2's.
On consistent bases, the multiple rose 6–9% since April, not 16%.
April's 33x on post-Q3 earnings also lands near today's price, so I'm dropping it as a downside target.
My PEG started the clock a year late. Averaged from today, your run-rate grows about 33%, for a PEG of about 1.1–1.2.
My worst-case Q3 needed two charge quarters in a row. That hasn't happened in the data, so the 54.9% stack is gone.
My cost line moves to 50%. I picked "routine," and under "routine," 50% is the expected ratio. Our "confirmed" rows are now identical.
Forward, LLY trades at about 28x on your run-rate. It's about 29x if Q3 lands at my $24.2B floor and gains run $1.25B a quarter after that.

That narrows us to two questions. What does the price require after next year? And what do the next three weeks cost a buyer at $1,142.85?

1. Your question: neither goes, because your extension is my thesis¶

What each table was for. My deceleration table borrowed your run-rate; it didn't forecast it. It showed that growth slows in percentage terms even at your pace. The five-year table showed what the price needs. Run together, they say the price needs most of your pace to last until 2031.

Here is your method across a range of outcomes rather than one path. All figures are derived. They show the annual price return over five years from $1,142.85, at a 35% net margin, with a flat share count. As before, the small dividend is excluded.

Avg. quarterly revenue gain, Q3'26–Q2'31	2031 trailing EPS	15x exit	20x exit	25x exit
$1.85B (today's pace)	~$90	3.3%	9.4%	14.4%
$1.50B	~$79	0.8%	6.8%	11.7%
$1.20B (two-thirds of today's)	~$71	−1.5%	4.4%	9.1%
$0.90B (half of today's)	~$62	−4.0%	1.7%	6.3%

Four of twelve cells clear the 9% hurdle. Six trail a 10-year Treasury bought today at 5.24%.
Only two combinations clear the hurdle: a 25x exit with at least two-thirds of today's pace, or a 20x exit with all of it.

A one-third fade isn't a stall by your own definition. - Your sell table treats a ~$0.5B quarter as a stall. A $1.2B average is more than double that. - Gains fading from a record to two-thirds of it over five years is how drug franchises ordinarily mature. - Lilly itself sat at $18–22B of revenue from 2014 through 2019 after patent losses.

You're right that the $100B record is close. The issue is the slope. - Your model adds about $30B of revenue a year, every year, to 2031. That's a whole 2022-sized Lilly ($28.5B) each year. - Trading price for volume is a tax that grows with the base. At a $200B run-rate, each 1% of net price given up costs $2B a year before volume adds anything. - The field is getting crowded: - Novo has done about $4B of deals. - Novo's Wegovy pill competes with Foundayo. - Semaglutide patents lapse in several large markets outside the U.S. during 2026 (background).

Two inputs were mine, and both were generous. - Margin. - 35% is above today's 33.5%, which is the right number if charges are routine. - At 33.5%, your full-pace 20x cell drops to about 8.5%, below the hurdle. - Exit multiple. - Your model has 2031 Lilly growing about 14%. Tirzepatide's main U.S. patent would then be about five years from expiry (mid-2030s, background). - Two precedents (background): AbbVie ahead of Humira's U.S. expiry, and Bristol-Myers ahead of Eliquis and Opdivo, traded around 7–10x earnings. - I'm not forecasting 15x. Next to those precedents, even 15x is generous. - The 2031 multiple will be the market's verdict on what replaces tirzepatide.

So pick a cell. If you believe in today's pace for five years and a 20x-plus exit, the price is fair. That's "fully priced," which was my round-2 claim. It is not the "margin of safety" you claimed in round 1.

2. Your "floor case" is a warning, and 28x forward is year one of the grid¶

36x on flat revenue isn't a floor. It's what you'd hold if growth stopped. No-growth drugmakers don't trade at 36x, so that multiple wouldn't survive the scenario that produces it.
28x forward and a PEG of 1.1–1.2 price the next two years fairly. I agree. The grid covers years three to five, and that's where a 38x trailing multiple gets decided.
The multiple swings more than earnings, even within a quarter.
After August's report, it went from about 39x to 43x by 8/19.
It then fell to 37.4x by 9/11, a 13% drop on unchanged earnings.
The stock got cheaper as it went up, and cheaper again as it came down.

3. The starter: your asymmetry counts two of four paths¶

Path to the report	Buying 5 shares now vs. waiting	Source
Floor comes first and holds	−$155	your figure
Floor breaks (close below $1,090)	−$265	your stop
No dip; report pops +3.8% to +10.3%	+$215 to +$590	your figure
No dip; report disappoints ~6%	about −$345	derived; precedent below

How likely is "no dip"? This is derived arithmetic, not a forecast. - LLY's 2.8% ATR (average daily range) implies a daily standard deviation of roughly 1.75–2.3%. - About 19 sessions remain before a likely Oct 30 report. - Over that window, a stock with no drift at all would trade into 1,107–1,118 about 70–80% of the time. - The buy zone starts less than one ATR below today's price. The dip is the base case, not a long shot.

Now grant that every no-dip path pops. At the midpoint pop of about $400: - The expected gain is 20–30% × $400, or $80–120. - The expected cost of the dip paths is 70–80% × $155, or $110–125. - The net is between about −$45 and +$10. - Count a broken floor or a soft report, and it turns negative.

Four up report days is a sample of four. Two precedents (background) are consistent with figures implied by our own data: - On 10/30/2024, Lilly fell about 6% when Q3 revenue of about $11.4B missed as wholesalers cut inventory. - In January 2025, it fell about 7% when it pre-announced Q4 revenue of about $13.5B. - This Q3 follows a $6.2B build in receivables and inventory. That is exactly the risk your own pull-forward line is meant to catch.

Not every reversal was macro. February's give-back began the next morning: −7.8% on ⅖. That was about a month before oil's spike began in early March, well before the macro shock you cite.

Your best "ahead today" example was the floor entry. The +34.7% from 4/29 was bought near the year's low. That's the wait-for-the-floor entry I'm recommending.

4. Your risk budget assumes the stock enters the report at your cost¶

Your stop fixes the reward-to-risk problem I raised. The remaining hole is the earnings gap.
Your $1,130 for a 10% gap is 10% of your cost. But a gap hits the pre-report price, after CPI and the Fed have had their say.
Suppose the floor tranche fills at about $1,112 and you carry 10 shares into the report:
If LLY sits in the buy zone the day before, your own 10% gap costs about $1,265.
If it sits just above your $1,090 stop, the same gap costs about $1,420.
From there, a repeat of February's −7.8% costs about $1,180.
All three break your $1,000 budget.
A closing stop can't stop a gap. And a floor test before the print is the path my case says is most likely.
The consistent version of your plan carries only the starter into the report, or hedges the second tranche through it.

5. Rates: you told half the steepening story¶

The macro desk records both halves: "Long yields rose faster into month-end; short yields fell more after the jobs miss."
The 10-year TIPS yield is 2.88%, 5bp below its highest level since 2008.
That long end is the part of the curve that prices LLY.
Fair hit on "stagflation": breakevens are flat. But that's worse for LLY, not better.
About 94% of the 10-year's rise from late August to the peak was real yield.
Rising real yields hit LLY directly, by raising the rate its distant profits are discounted at.
I agree the daily link is noise. 9/28's "up close" was $1.32.
That's why my case for waiting rests on the range and the volatility arithmetic, not on CPI moving the stock.
CPI and the Fed only decide which way the drift tilts.
Your starter is a bet that a twice-tested floor holds a third time. It has to hold through CPI, the Fed and the print, after RSI and OBV both made lower lows at the second test.

6. Pipeline and your sell lines: both act after the multiple has moved¶

EloraTZP's −1.2% isn't a clean read. Those two days also carried the Foundayo and Jaypirca headlines. Three stories netted out, and they netted negative.
If a week of pipeline news barely moves the stock, the macro desk's point stands. At $1T, results move it less, and the multiple and the print matter more.
Your sell lines guard the business, not the multiple.
Background: Novo's sales kept growing through 2025, and much of its slide came before its first guidance cut. A rulebook like yours would mostly have fired late.
Your valuation needs roughly $1.2–1.8B of quarterly gains, but your sell line fires near $0.5B.
A Q3 of $24.0B would be +36% YoY, the slowest in the data, and it lands in "hold."
That's fine for a holder with a price stop. It's also why the entry price matters: fundamental lines can't rescue a full-price entry.

Bottom line¶

Level	Price	From $1,142.85
Upside trigger (daily SuperTrend)	1,217.65	+6.5%
Prior highs	1,280–1,293	+12% to +13%
Trim/hedge zone	1,165–1,195	+2% to +5%
Buy zone, with confirmations	1,107–1,118	−2% to −3%
Your pre-report stop (daily close)	1,090	−4.6%
200-day average (mid-Oct est.)	~1,075	~−6%
Weekly SuperTrend	979.50	−14.3%

My call on LLY: don't initiate at $1,142.85. It's a great business priced for one corner of the grid, sitting mid-range ahead of CPI, the Fed and Q3. Your revised plan is a sound way to own LLY once you've decided to. My case is that, at this price, the decision isn't paid for.

Buyers have three entries:
A confirmed Q3. Our checklists now match.
The 1,107–1,118 zone, if the desk's confirmations hold: a close back above ~1,115, RSI above 35.5 and OBV above 337.85M. Size it so a 10% report gap fits the budget.
A daily close above 1,217.65 on above-average volume.
Holders: trim or hedge into 1,165–1,195 before CPI, including any Jaypirca bounce in Monday's first full session. A put spread through the report caps the gap risk.
Traders: the half-size range short at 1,165–1,195, with a stop above 1,218.
What would change my mind:
A Q3 with revenue of at least $24.6B, gross margin of at least 83% and costs at or below 50% of revenue, plus a 10-Q showing Q2's jump was a one-time charge rather than recurring spending.
A daily close above 1,217.65 on strong volume.
The 10-year TIPS yield back toward 2.6%.
For the long view, a next-generation obesity drug that patients tolerate as well as tirzepatide. That's what would justify a 20x-plus multiple in 2031.

My question back: Pick your cell. Which row and column are you underwriting at $1,142.85? If it's today's pace to 2031 with a 20x-plus exit, what's the evidence that Lilly can add a 2022-sized Lilly every year while trading price for volume? And if it can't, where is the margin of safety? Bear Analyst: # Bear Rebuttal: LLY. I'll drop the breakout. Your cushion leaned on a borrowed buyback, and your edge leaned on my grant

You picked a cell and ran my coin flip to the end. Both were fair moves, and both caught something real. My breakout trigger didn't fit my own grid, and my timing table left out half the paths. I concede both.

Follow each through, though, and the bull case narrows to very little: - The cushion disappears. Price the buyback honestly and use the 33.5% margin you agreed matches "routine" charges. Your midpoint then sits on my 9% hurdle. - The timing edge disappears. Withdraw the one grant I made in round 4, and your edge is zero.

What's left is a fairly priced stock, bought in the middle of a range, three weeks before the information that decides it.

What I concede¶

The breakout is out as a buy signal. A close above 1,217.65 doesn't tell me which row Lilly lands in, and it buys at a worse spot on my grid. In my plan it now means one thing: stop fading the range and lift the hedges.
My round-4 timing table was incomplete. Under a pure random walk, what waiting saves in dip paths it gives back in no-dip paths. I counted only the first half.
The dividend belongs in the comparison. My hurdle was a total return, and my grid was price-only.
Your row is a fair center if the next five years look like the last two. Lilly is adding about a 2022-sized Lilly a year right now: H1 revenue rose $14.5B, or $29.0B annualized.
Your gap rule closes the hole I raised. Our risk controls now match, so this isn't a fight about blowing up an account.

1. Your question: the grid rules out "margin of safety," not ownership¶

The grid doesn't rule LLY out. It rules out one claim: that $1,142.85 comes with a margin of safety.
You've moved most of the way to my position. You now say "I won't call this a bargain" and "a fair price with a modest cushion." My round-2 claim was "fully priced." The difference is the word "modest," and it rests on two inputs: the buyback and the margin.
Both my remaining entries fit the grid.
The floor buys every cell about half a point a year cheaper.
A confirmed Q3 buys information about which row we're in.
Neither depends on a chart.

2. The cushion: count the dividend, not a borrowed buyback¶

The dividend counts. It adds about 0.5–0.7 points a year as it grows (derived; the current yield is roughly 0.5–0.6%, background).
The buyback was paid for with borrowing, so it isn't free yield.
In H1'26, operating cash flow minus investing outflows was −$3.3B, and financing brought in a net $5.0B. Net, the half's payouts were funded with debt.
At 38x, a buyback retires earnings yielding 2.6%.
Debt at the Treasury's 5.24%, before any credit spread, costs about 4.1% after a 21% tax deduction. In year one, swapping 4.1% debt for 2.6% earnings lowers EPS.
By 2031 in your row, earnings have grown past the fixed interest cost. So the buyback adds back about 0.1–0.2 points a year (derived), not 0.7.
Even on your 28x forward multiple, it's roughly a wash.
You can't treat acquisitions as routine in the margin and optional in the cash.
Corrected, your cell looks like this (about 0.75 points of shareholder yield, derived):

$1.50B row, total return per year	20x	22.5x	25x
35% net margin (my generous input)	~7.6%	~10.2%	~12.4%
33.5% (today's margin, routine charges included)	~6.6%	~9.2%	~11.5%

At the 33.5% margin, your midpoint clears the 9% hurdle by about 0.2 points. The bottom of your column (20x) misses it by about 2.4. That's "fully priced."
This is why your buy-zone table supports my case. At $1,112, the same midpoint is about 9.8%. When the cushion is 0.2 points, the 0.6 points the floor adds is most of it.

3. My grid's floor is a doubling. That's why the downside looked limited¶

Every row I drew roughly doubles revenue or more. Even half today's pace takes TTM revenue from $79.7B to about $158B by mid-2031. Your "worst cell, −19%" is just the worst way to double. That's my mistake: I drew the grid too generously at the bottom.
Ending above today's price isn't the bar. A Treasury at 5.24% compounds to about +29% over five years. With shareholder yield counted honestly, about half my cells still trail it.
Add the row a margin of safety exists for. This isn't a forecast: revenue up 50% in five years, about 8.4% a year.
That's roughly the pace Novo fell to soon after it was the undisputed leader. Its sales growth went from about 30% in 2023 to about 10% in 2025 (background).
At a 33.5% margin, 2031 EPS is about $45 (derived).
At your 20x, the stock is about 22% lower in 2031. At 25x, it's about 2% lower, before dividends.
That leaves it 30–50 points behind a Treasury, in an outcome most drugmakers would call excellent.
A launch isn't proof. AbbVie traded at cliff-level multiples in 2019, the year Skyrizi and Rinvoq launched. It re-rated only after they proved they could carry the company (background).
Your 20–25x in 2031 assumes Lilly's proof is in by then.
This week's evidence is mixed. EloraTZP's dropout rates ran 4–9 times tirzepatide's.
Foundayo has no launch numbers yet. As a cheaper pill, it protects market share more than revenue per patient.
Lilly's last big oral GLP-1 obesity readout came out with the August 2025 report and cost the stock about 14% in a day (background).

4. Your two-year window contains the quarter my case is about¶

You used the last two years to set your row. Here's what's in them. Revenue for Q2–Q4'24 is derived from the year-over-year rates reported a year later.

Quarter	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26
Sequential gain ($B)	+0.13	+2.10	−0.81	+2.83	+2.04	+1.69	+0.51	+3.18

Your round-2 claim doesn't survive your own window. You said no non-Q1 quarter had added less than $1.69B. That held for six quarters, but your window includes a Q3 that added $0.13B.
That was the destocking quarter. The derived $11.44B matches the background: Q3'24 revenue of about $11.4B missed as wholesalers cut inventory, and the stock fell about 6%.
Your sell rule would have fired on it, after the gap. It sits below your stall line of about $0.5B.
Q2'26 carried a $6.2B build in receivables and inventory, about twice the revenue increase. That is exactly what your pull-forward line exists to catch.
I still don't forecast a Q3 below $24.2B. But the same window that gives you $1.46B a quarter also holds one non-Q1 stall in six, with gains ranging from −$0.81B to +$3.18B. The tail is in your own sample, not just in my argument.

5. Where the edge comes from: a random walk can't defend a mid-range entry¶

Your table needs a breakout. - For the no-dip paths to offset the dip paths, they must average $1,201–1,242 on the eve of the report (derived from your $58–99). - That's at or through 1,215–1,218, the ceiling that rejected the stock on 9/30 on 3.41M shares. - So your table needs the average no-dip path to reach that ceiling or break it. A random walk assumes that. The range we're both trading doesn't.

So which model is your plan built on? - Random walk: no entry in either plan has an edge. - That includes your floor tranche, setup A's confirmations, the RSI and OBV levels, and the desk's "best reward-to-risk" you quoted. - It includes my range short too. A price level is just a number. - Range: ADX has been under 25 on 38 of 43 sessions, the floor has held twice, and the ceiling rejected the stock on heavy volume. - In a range, the edge is the distance below the middle. - Your starter is $8 below the 1,151 midline, about a quarter of one day's average range. - The floor is $33–44 below the midline. Weighted by the 70–80% odds of a floor test that you accepted, that's roughly $23–35 a share, against $8 for the starter (derived, assuming the range holds to the middle). - From here, the upper band (1,194.72) is +52 and your stop is −53. That's 1:1, which the desk called "poor reward-to-risk for new trades." - Your 1.4:1 runs past the desk's last range target (1,195) to the breakout line at 1,217.65. Your 2.6–2.8:1 needs the old highs, and that needs a breakout. - Under either model, the starter is the weakest entry in your own plan. It ties under one model and trails under the other. That's the edge: waiting is never worse. - My plan follows the desk's range rule throughout: buy the lower edge, fade the upper edge, do nothing in the middle. Yours follows the same rule, plus one trade the rule doesn't support.

The report day: I'm withdrawing my grant. - Your +$55–98 comes entirely from my round-4 grant that every no-dip path pops. Without it, your own table nets to about zero (−$22 to −$25, slightly in waiting's favor). - Your two-year window doesn't support the grant. - The four reports in our data closed up 3.8–10.3%. - Three of the four before them fell about 6%, 12% and 14% (background). - The average is near zero, with double-digit moves both ways. - Two of those drops had nothing to do with our checklist. One was a competitor's formulary win (May 2025); the other was Lilly's own oral GLP-1 obesity data (August 2025). Q3 brings Foundayo's first launch numbers. - Pops haven't reliably held. - Most of 2/4's jump was gone the next day, and the stock was below its pre-report close by late April. - 8/5's jump was gone by 9/11. - Waiting for confirmation hasn't reliably meant paying up.

Waiting buys information at no expected cost, by your own math. - It lets me see CPI, the Fed's guidance, Q3 and the 10-Q before deciding. - Your plan already works this way for two of its three tranches. The floor tranche waits for confirmations and a TIPS check, and the last tranche waits for Q3. - The starter is the only tranche that waits for nothing.

Bottom line¶

Level	Price	From $1,142.85	In my plan
Prior highs	1,280–1,293	+12% to +13%	—
9/30 high / daily SuperTrend	1,215–1,218	+6.3% to +6.5%	Close above on volume: stop fading, lift hedges. Not a buy.
Trim/hedge zone	1,165–1,195	+2% to +5%	Holders trim or hedge; half-size range short
Range midline	~1,151	+0.7%	No edge either way
Buy zone, with confirmations	1,107–1,118	−2% to −3%	Buy, sized so a 10% report gap fits the risk budget
Pre-report stop	1,090	−4.6%	Exit
200-day average (mid-Oct est.)	~1,075	~−6%	—
Weekly SuperTrend	979.50	−14.3%	—

My call on LLY: don't initiate at $1,142.85. - We now agree it's a fair price, not a bargain. - At the 33.5% margin, your own midpoint barely clears my hurdle. - Your timing edge disappears once my old grant goes. - Three events in three weeks will tell us which row and which multiple we're in: CPI (~Oct 14–15), the Fed (Oct 27–28) and Q3 (~Oct 30, unconfirmed). The 10-year TIPS yield is 2.88%, and high-yield spreads are at 3.24%.

What I'd do in each seat: - Buyers have two entries. - The 1,107–1,118 zone, if the desk's confirmations hold (a close back above about 1,115, RSI above 35.5, OBV above 337.85M) and the 10-year TIPS yield closes below 3.0%. - A confirmed Q3. - Holders: trim or hedge into 1,165–1,195 before CPI, including any Jaypirca bounce in Monday's first full session. A put spread through the report caps the gap risk. - Traders: the half-size range short at 1,165–1,195, with a stop above 1,218.

What would change my mind: - A Q3 with revenue of at least $24.6B, gross margin of at least 83%, and costs at or below 50% of revenue. It would also need a 10-Q showing Q2's cost jump was one-time. That changes the row and the margin, not just the price. - The 10-year TIPS yield falling back toward 2.6%. - A next-generation obesity drug that patients tolerate as well as tirzepatide. That's what would earn a 20x-plus multiple in 2031.

My question back¶

Random walk or range? - If it's a random walk, your floor tranche, its confirmations and the "best reward-to-risk" you quoted are decoration. You should be indifferent to where you buy. - If it's a range, you're starting at the one spot where the range offers almost nothing: $8 below the midline, with 1:1 reward-to-risk to the band.

Which model is your plan built on, and what does the starter earn under it? Bear Analyst: # Bear Rebuttal: LLY. Neither harsh input. Your center averages a year that misses and a year that clears, and Q3 is the next reading

You asked two direct questions, so here are direct answers. Your corrections also land. My "+50%" row started from trailing revenue, but Lilly's run-rate is already 15% higher. And I shouldn't stack a 33.5% margin on worst-case cash for five straight years.

Here's where that leaves me: - Question 1: neither. On balanced inputs your center is about 10% a year, roughly one point above my 9% hurdle. But that center averages two very different years. If the weaker year repeats, LLY earns 6–7% a year. If the stronger one repeats, it earns about 13%. My break-even sits between them. - Question 2: a $24.3B Q3 lands right on that break-even, below your own center. In that path I shouldn't pay today's price. My entry there is the same one your floor tranche already uses. And in that path you also sit out ten of your fifteen shares.

What I concede¶

My "+50%" row was a stall. Measured from the current run-rate, it's 5–6% a year. In section 5 I replace it with Novo's growth pace applied to your run-rate, using your figures.
I don't expect both harsh inputs together. My center uses a 34–35% net margin and about 1.2 points a year of shareholder yield (dividends plus buybacks).
H1's cash shortfall came from one quarter's deal.
Charges shrink relative to revenue, as long as the expensed part of each deal stays near $1.6–2.4B after tax.
The technical desk does rank the weekly trend first when timeframes conflict.
Waiting isn't free in every path. In the path you describe, I own nothing.

1. Your first question: neither, and here's the center I'd underwrite¶

Margin: 34%, with 35% as your upside case. - The four quarters before Q2 included none of the deal-charge quarters on our list, and they earned a 35.0% net margin. - You sized routine charges at 1–1.6% of 2031 revenue. That brings 35.0% down to 33.4–34.0%. - So 34% doesn't freeze Lilly's costs; it holds today's margin. Getting to 35% needs cost leverage to outrun price cuts. Section 2 explains why I won't assume that.

Cash: I'll use your 1.2. - Your range for cash conversion (operating cash flow divided by net income) has four readings: - three full years at 0.81–0.83; - one trailing-twelve-month reading at 1.05. - Each of those four windows contains exactly one charge quarter. The 1.05 reading leans on Q2's $11.1B jump in current liabilities, which you conceded could have lifted operating cash. - Centering conversion at 0.85–0.9, with investment at its 2023–25 average of 19.5% of revenue, gives about 1.1–1.3 points (derived). I'll use your 1.2. - I won't go higher. If deals of Q2's size are routine, investment over the last six quarters ran at 28% of revenue.

At your 22.5x exit multiple, total return per year (derived; 894M shares; 1.2 points of shareholder yield):

Average quarterly revenue gain to mid-2031	What it repeats	34% margin	35% margin
$1.06B	The year to Q2'25	~6.2%	~6.8%
$1.46B	The two-year average	~9.6%	~10.2%
$1.85B	The year to Q2'26	~12.6%	~13.2%

Break-even against my 9% hurdle: about $1.39B a quarter at a 34% margin and $1.31B at 35%. Revenue for Q3–Q4'24 is derived from growth rates reported a year later. My grid's $1.50B row sits slightly above the actual two-year average of $1.46B.

The center is about 10% (9.6–10.2%), so the cushion is 0.6–1.2 points a year.
That equals about one turn of the 2031 P/E multiple, or about $0.1B a quarter of revenue growth.
The two years you averaged differ by $0.8B a quarter.
A margin of safety should survive the weaker of your two sample years. Yours doesn't.
Repeat the year to Q2'25 and LLY earns 6–7% a year at 22.5x. That's only 1–1.5 points above a risk-free Treasury.
At 20x it earns about 4%, below the Treasury.
Clearing the hurdle at the center means you get paid if the center is right. A margin of safety still pays if it's wrong.
The weaker year includes Q3'24's destocking stall, when wholesalers ran down inventory. That's no reason to drop it. Q2'26 just added $6.2B of receivables and inventory, about twice its revenue gain, and Q3 is next.

Why not assume the stronger year repeats? - Supply. You cited tirzepatide shortages lasting into late 2024. If they held back the weaker year, the stronger year includes the catch-up, which flatters it. - Gross margin was falling until one unusual quarter (section 2). - Competition is widening: - Novo is buying pipeline, with about $4B across two deals. - Novo's Wegovy pill competes head-on with Foundayo. - Semaglutide goes generic in several large markets outside the U.S. during 2026 (background). - EloraTZP's dropout rates ran 4–9 times tirzepatide's. - Scale (background, approximate): - Repeated, the stronger year adds about $148B of annual revenue run-rate by mid-2031. - Most published forecasts size the entire global obesity-drug market around 2030 at roughly $100–150B. - Diabetes and Lilly's other franchises can carry some of that growth. Most of it has to come from obesity.

Q3 is the next reading on which year we're in:

Q3 revenue	Gain over Q2	Reads like
$24.6B or more	$1.63B or more	The stronger year (our shared confirm line)
~$24.3B (your example)	~$1.33B	My break-even
Under $23.5B	Under $0.53B	Your stall line

You said the cushion question is ten times bigger than the timing question. Agreed, and Q3 informs the cushion question. - One quarter can't settle a five-year growth rate. - By your own table, waiting through the report costs roughly nothing in expectation. - If Q3 says anything about which year we're in, waiting is worth something. - For the starter to come out ahead, Q3 has to tell us nothing and the range has to behave like a random walk. Even then, it only ties.

2. "Gross margin rose in the price-cut year" rests on one quarter we both said may not repeat¶

Before Q2, gross margin fell three quarters in a row: 84.3% in Q2'25, then 82.9%, 82.5% and 81.9% in Q1'26.
Q2's 85.8% came when cost of revenue fell 8.6% while revenue rose 16%. You conceded in round 2 that it may not repeat, and the fundamentals desk agrees.
Set Q2 at the prior three quarters' average (82.4%), and H1'26 gross margin is about 82.2%. That is below FY25's 83.0% (derived). On that basis, gross margin fell in the price-cut year.
The pressure on price is growing.
Foundayo, a pill that's cheaper to make, will likely sell for less.
The pricing deal widened coverage at lower prices (macro desk background).
What a 35% net margin needs at an 82% gross margin:
Costs below gross profit at 47% of revenue, routine charges included.
The four quarters before Q2 averaged 47.9%, with no charges at all.
So 35% needs Lilly to beat its cleanest recent stretch by roughly 2–2.5 points every year, with charges included.

3. Your second question: at $24.3B, Q3 lands on my break-even, and my entry is your floor tranche¶

What a $24.3B quarter says:
It's a $1.33B gain over Q2 and +38% year over year, the second-slowest growth rate in the data.
That's below your $1.46B center and inside my $1.31–1.39B break-even.
In that path the evidence says the cushion is thinner. I won't pay the same price for less of it.
My entries in that path:
The first post-report test of the range floor (1,107–1,118) or the rising 200-day average (est. ~1,075–1,085). That requires the desk's confirmations and the 10-year TIPS yield below 3.0%. It's the same entry as your floor tranche.
A confirmed Q4 (est. late January or early February), on our shared checklist.
If neither comes, I own none of a stock I call fairly priced.
What that costs me is the equity premium on money I haven't invested.
At a 9–10% expected return against 4.17% on 3-month T-bills, that's about 1.2–1.5% a quarter, or $70–85 a quarter per five shares (derived).
That isn't a loss. It's the return I give up for not carrying risk through CPI, the Fed meeting and a report day you call a coin toss.
Your plan in the same path: hold five shares, add nothing.
You sit out ten shares of a stock you say clears the hurdle; I sit out fifteen.
The gap between us is five shares, worth about $70–85 a quarter.
The pre-report gains are counted twice.
Your random-walk figure already includes the gains in paths where the stock never dips. Those gains offset my savings in the dip paths and leave −$22 to −$25.
You can't count "exposure in paths my plan can't enter" inside that table and again as a separate reason outside it.

4. "Trend first": the desk ranked the weekly first and still said wait¶

The ranking is already built into the desk's verdict.
The desk states that the weekly ranks first. Its verdict still calls $1,142.85 "a poor spot for a new trade," with better entries at 1,107–1,118.
Its action line for the weekly uptrend is "Prefer buying dips to shorting breakdowns."
In the desk's own words, the weekly tranche is the dip-buy.
Use the higher timeframe for direction and the lower one for both entry and exit.
You use the daily range for your exit. A close at $1,090 still leaves the weekly uptrend intact, 11% above its $979.50 stop.
But you use the weekly for your entry.
One ranking has to govern both.
Drift doesn't rescue the starter.
Cash earns 4.17%. Net of that, your center's expected drift is roughly 5–6 points a year, or about $4–5 a share over 19 sessions (derived).
That's less than the $6 gap between my trigger and my fill. And the starter earns it only in the sessions before I'm in.
Your "about even" row is your random-walk row: a tie at best.
So the accurate version of my line: waiting is never meaningfully worse, and under the range model it's $75–135 better.
My case only needs the range to describe the next 19 sessions at least as well as a random walk does.
Three things say it does:
- the ADX trend-strength reading stayed below 25 on 38 of 43 sessions;
- the floor has held twice;
- the ceiling rejected the stock on heavy volume.
The timeframe you rank first just printed a bearish bar. The week opened at 1,180.30, spiked to 1,215, and closed below the prior week's open, erasing that week's gain (desk).
Your new starter band already contains Friday's close.
The 1,136.66–1,151 band runs from −0.54% to +0.71% around $1,142.85. The starter fills at about today's price unless LLY first falls half a percent.
Once it fills, the 70–80% chance of a floor test is still ahead.
Nearly the whole band sits below ~1,150, where the desk estimates a Monday close turns MACD momentum bearish. So the "something" the starter waits for is a close on the wrong side of the desk's pivot.

5. Novo's growth pace should come with Novo's multiple¶

Your numbers:
Novo's ~10% growth applied to Lilly's run-rate gives about $143B of trailing revenue by mid-2031 and EPS of about $53.50.
At 20–25x, that's −6% to +17% before dividends.
You've already ruled on this kind of pairing. When your floor case paired "no growth" with 36x, you conceded that a Lilly that stopped growing wouldn't keep that multiple. A Lilly growing at Novo's pace doesn't obviously keep 20–25x either.
Novo didn't keep it. It went from roughly 45–50x earnings at its 2024 peak to the low-to-mid teens by late 2025, while sales were still growing (background, approximate).
At 15x, your Novo-pace EPS is worth about $800, roughly −30% before dividends (derived). A five-year Treasury returns +29% over the same stretch. That bad outcome, not my old "+50%" row, is what a margin of safety protects against.
Proof comes from sales, not launches.
AbbVie re-rated only after Skyrizi and Rinvoq posted enough sales to replace Humira.
Q3 brings Foundayo's first launch numbers and the first read on revenue per patient against the Wegovy pill.

Bottom line¶

Level	Price	From $1,142.85	In my plan
9/30 high / daily SuperTrend	1,215–1,218	+6.3% to +6.5%	Close above on volume: stop fading rallies, lift hedges
Trim/hedge zone	1,165–1,195	+2% to +5%	Holders trim or hedge; half-size range short
Range midline / MACD pivot	~1,150–1,151	+0.6% to +0.7%	No edge; a Monday close below likely turns MACD bearish (desk est.)
Buy zone, with confirmations	1,107–1,118	−2% to −3%	Buy, sized for a 10% earnings gap, with TIPS below 3.0%
Pre-report stop	1,090	−4.6%	Exit
200-day average	~1,075–1,085 (est.)	~−5% to −6%	Post-report entry, with confirmations
Weekly SuperTrend	979.50	−14.3%	—

Where we stand: - Value: we agree LLY is fairly priced, with about a point a year of cushion. The cushion holds if the two-year average repeats and disappears if the weaker year does. - Risk controls: same Q3 checklist, same cap on gap risk, and a report day we both call a coin toss. - Timing: your own table gives the starter a tie at best. The next reading on which year we're in arrives in about four weeks, after CPI (~Oct 14–15) and the Fed meeting (Oct 27–28). - Macro: - The 10-year TIPS yield is 2.88%, 12bp below your no-add line. - High-yield credit spreads are 3.24%, 26bp below the macro desk's alarm level. - The tape hasn't changed: - Price is below its 10-, 20- and 50-day averages. - On-balance volume and RSI both made lower lows at the last floor test. - The 9/30 breakout attempt failed on 1.5 times average volume.

My call on LLY: don't initiate at $1,142.85. - Buyers have three entries: - The 1,107–1,118 zone, with TIPS below 3.0% and the desk's confirmations: - a close back above ~1,115; - RSI above 35.5; - on-balance volume above 337.85M. - A confirmed Q3. - After an in-between Q3, the first post-report test of the floor or the 200-day average. - Holders: trim or hedge into 1,165–1,195, including any Jaypirca bounce on Monday. A put spread through the report caps the gap risk. - Traders: the half-size range short at 1,165–1,195, with a stop above 1,218.

What would change my mind: - A Q3 that meets all four of these, pointing to the stronger year and a gross margin that isn't eroding: - revenue of at least $24.6B; - gross margin of at least 83%; - costs below gross profit at or below 50% of revenue; - a 10-Q showing Q2's cost jump was one-time. - The 10-year TIPS yield falling back toward 2.6%. - A next-generation obesity drug that patients tolerate as well as tirzepatide.

My question back¶

You asked which of my harsh inputs I expect, and the answer is neither. Now it's your turn. Your center averages a year that misses my hurdle ($1.06B a quarter) and one that clears it ($1.85B). Which year do you expect to repeat? - If the stronger one: what in this week's data supports that? Gross margin was falling until one quarter you've said may not repeat, and the supply catch-up you cited flatters that year. - If the average: you're underwriting a cushion of about one turn of multiple, and it disappears if the weaker year returns. - That's a fair price, which has been my position since round 2. - Q3 is the next reading on which year we're in. Why buy the starter before it?

Research Manager¶

Recommendation: Overweight

Rationale: Short version: the bull won the argument about the business, the bear won the argument about the entry, and by the end neither side was arguing that we shouldn't own LLY. On fundamentals the bear conceded nearly everything. Q2 revenue was $22.97B, up 47.7%. H1'26 EPS is up 73% like-for-like, with one charge quarter in each half. TTM operating cash flow is $28.1B, and leverage is down year over year. Both sides expect Q3 to clear $24.2B. Q3'25's $6.21 also drops out of trailing EPS, so trailing EPS rises even in the bear's old worst case. The bull also took apart the bear's valuation anchors. April's 33x sat on a charge-free base, and on consistent bases the multiple is up only 6-9% since April, not 16%. PEG is about 1.1-1.2 measured from today, and LLY trades at about 28x forward on the current run-rate. The bear won two points that drive sizing. First, 'margin of safety' was oversold. On balanced inputs (34-35% net margin, about 1.2 points of shareholder yield, a 22.5x exit), Lilly's two-year-average pace returns about 10% a year against a 9% hurdle. Repeat the weaker year of that sample and the return falls to 6-7%. Novo-pace growth with a Novo-style multiple is roughly -30%. Beyond the valuation math, gross margin outside Q2's unusual quarter fell from 84.3% to 81.9% over three quarters, and margin expansion has roughly halved. Q2's $6.2B build in receivables and inventory, plus the Q3'24 destocking stall in our own sample, keep a real tail on the print. At about 38x trailing, that's a fair price with roughly a point a year of cushion, not a bargain. Second, timing. LLY sits just below its range midline, and the technical desk calls $1,142.85 'a poor spot for a new trade.' OBV and RSI made lower lows at the last floor test, and the 9/30 breakout failed on 1.5x average volume. CPI (~Oct 14-15) and the FOMC (Oct 27-28) both land before earnings, with 10-year TIPS at 2.88%, 5bp below their highest level since 2008. The bull accepted 70-80% odds of a floor test before the report. He also accepted that a starter only ties under a random walk and trails under a range. Why not Hold? Because the bear's case was 'buy lower or buy on confirmation,' not 'avoid.' The bear's own plan has three buy entries, and both sides now share the same Q3 checklist, gap-risk cap and broken-thesis exits. When the best remaining bear argument is that the center clears the hurdle by only a point and the entry should be about $30 lower, the direction is constructive and the disagreement is about execution. Why not Buy? Because the valuation is fair rather than cheap, and the next three weeks are heavy with macro and earnings risk. So the decisive arguments were the bull's earnings and forward-valuation case for direction, and the bear's thin-cushion and mid-range-entry case for pacing. The result is Overweight, built gradually, with most of the money going in at the floor (the desk's best reward-to-risk) or after a confirmed Q3, which is the data point that tells us which growth year we're in. I'm allowing a smaller starter than the bull asked for. Its expected cost versus waiting is tens of dollars per five shares under every model debated, and it keeps us from owning nothing in the 20-30% of paths where the floor never comes.

Strategic Actions: Sizing: build LLY toward 1.0x a standard allocation over the next 4-6 weeks in three tranches. Running modestly overweight (up to ~1.25x) is allowed only after a confirmed Q3 plus a 10-Q showing Q2's $3.8B cost jump was one-time. 1) Starter, 0.25x: buy on the first daily close between $1,136.66 (the 10/2 low, first support) and ~$1,151 (the range midline and MACD pivot). Monday is the first full session to price the Jaypirca approval. If LLY bounces above $1,151, don't chase; wait for a close back at or below it. If LLY closes below $1,136.66 before the starter fills, skip it and add that slice to tranche 2. 2) Floor tranche, 0.35x: buy in $1,107-1,118 only with the technical desk's confirmations: a daily close back above ~$1,115, RSI holding above 35.5, and OBV above 337.85M. Buy only while the 10-year TIPS yield closes below 3.0% (now 2.88%) and high-yield spreads stay below the macro desk's 3.5% alarm (now 3.24%). Re-check both gates after CPI (~Oct 14-15) and after the FOMC (Oct 27-28). 3) Pre-report risk: a daily close below $1,090 exits tranches 1 and 2. Re-enter only on a reclaim of ~$1,115 with the same confirmations, or on a confirmed Q3. A close below the rising 200-day average (~$1,071-1,085) means no adds. A break of the weekly SuperTrend at $979.50 means a full exit and thesis review. 4) Gap cap into Q3 (~Oct 30, unconfirmed; verify the date): the day before the print, limit unhedged shares so that open loss plus a 10% gap from that close fits the position's risk budget (~1% of portfolio in the desk's example). In practice that is about half the target. Put-spread or sell any excess through the print, and rebuy after if the quarter confirms. 5) Confirmed Q3 means all three: revenue >= $24.6B, gross margin >= 83%, and costs below gross profit <= 50% of revenue. On a confirmed Q3, add the final 0.40x plus any unfilled floor slice. 2026's report-day pops faded: 2/4 gave back 7.8% the next day, and the 8/5 gain was gone by 9/11. So buy half after the first post-report session closes. Buy the other half on the first pullback within two weeks, or at the end of that window if price holds above the report-day low. After the report, the stop moves to just below the report-day low. 6) In-between Q3 (neither confirmed nor broken, e.g. ~$24.3B, near the ~$1.31-1.39B-a-quarter break-even): hold what's owned and add nothing. The next entries are the first post-report test of $1,107-1,118 or the 200-day with confirmations, or a confirmed Q4. 7) Broken Q3: exit everything if any one of these hits: revenue < $23.5B; gross margin < 81%; costs >= 54% of revenue again with the 10-Q showing Q2's jump was recurring spending; or a cut to full-year revenue guidance. From Q4 on, any non-Q1 quarter adding less than $0.5B sequentially also triggers a full exit. 8) Existing holders: keep the core up to 1.0x and don't add mid-range. If a Jaypirca bounce reaches $1,165-1,195, holders above target should trim back to target or buy a put spread through the report to meet the gap cap. Don't run the bear's half-size range short; it fights the weekly uptrend and this rating. 9) Rating triggers. Move toward Buy on a confirmed Q3 backed by the 10-Q, a daily close above $1,217.65 on above-average volume (also the signal to lift hedges), or 10-year TIPS falling back toward 2.6%. Move toward Hold or Underweight on any broken line, a close below the 200-day while TIPS are above 3.0% or HY spreads above 3.5%, or ObesityWeek or Foundayo data pointing to falling revenue per patient or poor tolerability for next-generation drugs. Data gaps: the Q3 date is unconfirmed, and the 10-Q explaining Q2's cost jump isn't out yet. There are no Foundayo prescription or launch figures, and no consensus estimates or company guidance numbers in the materials. Jaypirca's label breadth is unclear. The dividend and buyback figures used in the valuation debate are background rather than tool data.

III. Trading Team Plan¶

Trader¶

Action: Buy

Reasoning: The research plan's Overweight maps to Buy. The bull won on the business: Q2 revenue was $22.97B (+47.7%), H1'26 EPS rose 73% like-for-like, TTM operating cash flow is $28.1B, and the stock trades near 28x forward with a PEG of about 1.1-1.2. The bear argued only for buying lower or on confirmation, but at ~38x trailing LLY clears the ~9% return hurdle by only about a point, so this is a paced build, not a chase. Price structure supports the direction but not full size today: weekly (stop 979.50) and monthly SuperTrends are up and price is 6.7% above a rising 200-day (1071.34), yet the daily SuperTrend is down (1217.65), the 9/30 push to 1215.00 reversed on ~1.5x volume, MACD is near a bearish cross below ~1150, RSI (43) is falling, OBV made a lower low, and 1142.85 sits ~1.1 ATR above the 1107-1118 floor and ~1.6 ATR below the 1194.72 upper band, a spot the desk calls poor for new money. So only a 0.25x starter goes in near current levels; the remaining tranches are reserved for a confirmed floor test (1115 entry vs. 1090 stop gives ~1.4-3.2x reward-to-risk to 1151/1176/1195) and a confirmed Q3, with a gap cap because CPI (~Oct 14-15), the FOMC (Oct 27-28) and earnings (~Oct 30, unverified) all land this month with 10y TIPS at 2.88%.

Entry Price: 1143.0

Stop Loss: 1090.0

Position Sizing: Current holdings were not provided, so apply these as fractions of your standard LLY allocation (desk example: 1.0x = about 20 shares, ~$22.9k on a $100k book risking 1%). Build to 1.0x over 4-6 weeks. (1) Starter 0.25x (~5 sh): buy on the first daily close within 1136.66-1151 from Mon 10/5; entry reference ~1143. If a Jaypirca pop closes above 1151, wait for a close back at or below it. If a close below 1136.66 comes first, skip the starter and add its slice to tranche 2. (2) Floor 0.35x (~7 sh) at 1107-1118 (~1115): buy only after a daily close back above ~1115 with RSI above 35.5 and OBV above 337.85M, and only while 10y TIPS close below 3.0% (now 2.88%) and HY spreads stay below 3.5% (now 3.24%). Re-check both after CPI and the FOMC. Open risk on tranches 1+2 to the 1090 stop is about $265 + $175, or ~0.44% of the book. (3) Final 0.40x, plus any unfilled floor slice, only on a confirmed Q3: revenue >= $24.6B, gross margin >= 83%, and costs below gross profit <= 50% of revenue. Buy half after the first post-report close and half on the first pullback within two weeks; then move the stop to just below the report-day low. Go up to 1.25x only after the 10-Q shows Q2's $3.8B cost jump was one-time. On an in-between Q3, hold and add nothing. Gap cap: the day before the print, limit unhedged shares so open loss plus a 10% gap stays within ~1% of the book (~8-9 sh, roughly half the target); put-spread or sell the excess and rebuy if Q3 confirms. Exits: a daily close below 1090 exits tranches 1-2 (re-enter only on a reclaim of ~1115 with the confirmations, or on a confirmed Q3). No adds below the 200-day (~1071-1085). A break of the weekly SuperTrend at 979.50 means a full exit and thesis review. A broken Q3 means a full exit: revenue < $23.5B, gross margin < 81%, costs >= 54% of revenue that the 10-Q shows are recurring, or a full-year guidance cut. Existing holders: keep the core up to 1.0x and add nothing mid-range; trim or put-spread any above-target excess into a 1165-1195 bounce; do not run a range short. Upgrade toward a full Buy on a daily close above 1217.65 on above-average volume or a confirmed Q3. Missing from the materials: the confirmed Q3 date and the 10-Q.

FINAL TRANSACTION PROPOSAL: BUY

IV. Risk Management Team Decision¶

Aggressive Analyst¶

Aggressive Analyst: Neither of my colleagues has spoken yet, so let me set the frame before the caution arrives. I think the real risk in this LLY trade is owning too little of it over the next six weeks, not too much.

Start with what the stock has actually done. LLY's last three monthly closes were 1147, 1157 and 1157. Over that stretch the business reported: a record $22.97 billion quarter, up 47.7%, a record 85.8% gross margin, and a record $10.7 billion of operating cash flow in one quarter.

Trailing EPS is $29.80. That is up about 95% year over year and about 30% since the full-year 2025 figure of $22.95. The stock is up roughly 7% this year. When earnings grow like that and the price goes sideways, the valuation multiple is being compressed, and we know why. At the August 19 closing high of 1280.34, LLY traded around 43 times trailing earnings. Today it's about 38. Over the same weeks the 10-year TIPS yield climbed from 2.32% to a 2.93% peak, the highest real yield since 2008.

The timing of the failed breakout matters. The spike to 1215 reversed on 1.5 times normal volume on September 30. That was the same session the 10-year hit 5.29% and real yields peaked. A long-duration quality stock got hit on the worst rates day of the cycle. That is not evidence that holders are dumping a broken thesis. The macro report tells us to separate a rate-driven drop from a broken story, and this is the former.

The rate picture is already turning. September payrolls were only +29 thousand, unemployment rose to 4.2%, and the 2-year yield fell from 4.92% to 4.78% even before that report. In the 2022 rate shock, LLY rose about 32% while the S&P fell about 19%, because product news outweighed rates. September headline CPI will probably run hot on oil. The macro report expects that and says a soft core reading will likely be looked past. The plan also re-checks the TIPS level after CPI and after the FOMC.

The part I suspect both colleagues will underweight is the Q3 math. The plan's confirmation bar is $24.6 billion of revenue, which needs 7.3% growth over Q2. Over the last five quarters LLY's quarter-over-quarter growth averaged about 12.7%, and four of the five cleared 7.3%. The one miss was a first quarter, and first quarters were soft in both years of this data. Last year's Q3 grew 13.1% over Q2.

Take the plan's minimum confirmed thresholds literally: $24.6 billion revenue, 83% gross margin, and costs below gross profit at 50% of revenue. That gives about $8.1 billion of net income, roughly $9.08 a share. Drop last year's $6.21 Q3 out of the trailing sum and trailing EPS becomes about $32.67. At today's 38 times, with no multiple expansion, that's about 1,253. That is above the 1217.65 daily SuperTrend and nearly 10% above here. Put the other way, if Q3 merely clears the minimum bar, the multiple has to fall another 9%, to about 35 times, for the stock to stay flat.

If Q3 repeats last year's 13.1% sequential growth with costs back at 48%, even at an 83% margin, EPS is about $10.17. At a constant multiple that's about 1,295, roughly the old 1292.65 high. That's my arithmetic on the fundamentals report's numbers, not a forecast. It shows how little has to go right.

That's why I want to put a price on waiting for confirmation. The highest-volume sessions in the technical report, which it reads as earnings days, were up 3.8%, 10.3%, 9.8% and 4.9%. That averages about 7.2%, roughly 82 points or 2.6 ATRs (average true range, LLY's typical daily move of about 32 points). A move like that lands near 1225. That is through the daily SuperTrend in one session, which is the plan's own upgrade trigger. The February and April reports each moved the stock about 10%, at market caps of $750 billion and up, so the stock is not too big to move.

Tranche three is about 8 shares bought after the report. If this report looks like the last four, waiting costs about $650 on that tranche alone. That is about one and a half times the $440 of open risk the plan budgets for tranches one and two combined. Gaps cut both ways. February's jump gave back 7.8% the next day, and July 30 gapped down 3%. But the only downside gap the report cites is 3%, and the plan's gap cap already assumes a 10% drop. Confirmation isn't free. You pay for it with the gap.

On technicals, I expect the conservative case to be a list: daily SuperTrend down, MACD about to cross, RSI at 43 and falling, OBV making a lower low. Taking them one at a time:

The daily SuperTrend line is 1217.65 and the 9/30 high was 1215.00. Three sessions ago LLY came within about a quarter of a percent of flipping all three timeframes up. That's a hair trigger, not a lasting downtrend.

The weekly and monthly SuperTrends are up. Price is nearly 17% above the weekly stop and 6.7% above a 200-day average that keeps rising toward 1075.

ADX, which measures trend strength, is 23.9 and has been under 25 on 38 of 43 sessions. That means this is a range. In a range, daily MACD crosses and RSI dips are the least reliable signals available.

The OBV lower low is 337.85 million against 342.54 million. That's about 4.7 million shares, roughly two days of normal volume.

Meanwhile ATR is down a quarter from August and the Bollinger Bands are only 7.6% wide. Volatility tightening after a 51% run, inside an uptrend, just before a cluster of catalysts, is a setup, not a warning. Anyone tempted to short rallies into 1165 to 1195 would be shorting a weekly uptrend into a report whose last four comparable sessions rose an average of 7%. That is the genuinely reckless trade here, and the plan is right to rule it out.

On fundamentals, the bear points will be the $3.8 billion jump in Q2 costs, the $23 billion rise in liabilities, and negative operating-plus-investing cash flow in the first half. The cost jump fits LLY's own history of one-time charges for acquired research projects: the Q3 2023 loss, the $970 million Q3 2024, the soft Q1 2025. It also lines up with a $15.4 billion investing outflow in Q2. Strip it out and Q2 EPS is roughly $9.70 to $10.60. Annualized, that puts the stock at about 27 to 29.5 times earnings at 1143. That matches the 28 times forward and the PEG of 1.1 to 1.2 the trader cites. So the claim that LLY clears the 9% return hurdle by only a point uses trailing earnings that include that charge. The real cushion is wider.

On leverage, liabilities are 3.2 times equity, down from 4.5 at the end of 2024. Equity is up 85% in a year, and the company generated $10.7 billion of operating cash in a single quarter. LLY's Q2 investing outflow alone was nearly four times the roughly $4 billion Novo spent on two deals to catch up. On pricing, the deal that cut GLP-1 prices in exchange for wider coverage was struck in November 2025. Q2 still posted a record gross margin and 47.7% growth. Volume is outweighing lower prices.

On news and sentiment, this week brought: Jaypirca's approval for previously untreated CLL/SLL, late-stage Foundayo diabetes data, positive obesity trial results, and no LLY-specific negative at all: no downgrade, no safety signal, no guidance cut.

The Jaypirca news circulated around 3:15 Eastern on Friday, in the last hour of trading. Monday is the first full session to price a growth source outside the obesity and diabetes drugs.

The EloraTZP discontinuation rates, 10.8% to 27% versus 2.9% on tirzepatide, are a fair criticism of a Phase 2b dose-finding combination. But the revenue engine is tirzepatide at 2.9%, and the combination is extra upside on top. Nobody should call this a crowded trade based on the 93% bullish tag ratio. The sentiment report shows that ratio is inflated by posts tagged with other tickers. The actual content splits about evenly, and retail posters are asking why the stock dropped this week. That's an investor base still doubting the story, not euphoria.

I expect the neutral view to say 1143 is a poor entry because it's 1.1 ATR above the floor and 1.6 ATR below the upper band. That's a range trader's measure applied to building a position. The upper band isn't our target. From 1143 to the 1280 to 1292 highs is 137 to 150 points of upside, against 53 points of risk to the 1090 stop. That's about 2.6 to 2.8 to 1. And the floor test isn't guaranteed. If Monday's Jaypirca reaction holds 1136 and the stock grinds into the report without revisiting 1107 to 1118, the patient trader carries a quarter-size position into the biggest event of the quarter and then chases.

So I'm firmly with the Buy. Where I'd push is execution, not direction:

Double the starter to 0.5x, about 10 shares. Risk to 1090 goes from $265 to $530. Adding the floor tranche's $175 brings total open risk to about $705, or 0.7% of the book, still inside the desk's 1% standard.
Don't let a Jaypirca jump above 1151 knock you out of the starter. The technical report says a close above roughly 1150 prevents the bearish MACD cross. So take at least the original 0.25x there, up to the 10/2 high near 1165. That costs about two-thirds of an ATR, against an 82-point average earnings move.
Loosen the conditions for the floor tranche. OBV has only about 8 million shares of room above 337.85 million, roughly three and a half average down days, so the drop to 1115 could trip it automatically. A close back above 1115 with RSI holding above 35.5 would be a real bullish divergence. Keep that condition and the TIPS limit. Treat OBV and high-yield spreads as information rather than vetoes, since the macro report expects quality stocks to hold up relatively well if credit stress spreads.
Meet the gap cap by buying the put spread rather than selling shares, so we keep the upside if the stock gaps higher.
If the desk won't carry more stock into the report, buy part of tranche three as a defined-risk call spread after CPI. That way we own the gap instead of paying for it.

The downside here is stopped out at 1090 with well under 1% of the book at risk, and the weekly trend line sits down near 980. The upside on a merely adequate Q3, at today's multiple, is around 1,250. On a repeat of last year's Q3, it's the old high. My conservative colleague can explain why we should pay 80 points more for the same shares after the report. My neutral colleague can explain what a quarter-size position earns if the floor never comes. Until then, LLY is a Buy, and this plan should lean in, not hang back. Aggressive Analyst: Let me start by conceding what my colleagues have earned, because it sharpens the rest. The gap cap is arithmetic, and I accept it as the ceiling into the print. My neutral colleague is right about contract size. One listed option covers 100 shares, about $114,000 of stock, so at desk-example scale my put-spread and call-spread ideas don't fit, and you meet the cap by selling. My conservative colleague is right that the report says a close above 1150 delays the MACD cross rather than prevents it, and the 9/30 close was a rejection. The neutral is also right that "minimum" was the wrong word for a margin-and-cost combination LLY has hit once in six quarters. So I'm withdrawing the 10-share starter and the option structures at this scale.

Now look at what the neutral's homework actually proved. I think it's the most important finding in this debate, and it supports my side, not the middle. He ran the plan's Q3 test against our own history. None of the four quarters behind those 3.8, 10.3, 9.8 and 4.9 percent rallies would have passed it. So the rule that releases the plan's biggest tranche would never have opened, on four quarters the market rewarded every time. That isn't a filter. It's a locked door, and my conservative colleague wants to add locks.

Here's what that costs. After the April report the stock went from about 932 to 1280. Q1's 81.9% gross margin fails our test, so tranche three and the unfilled floor slice sit out a 37% run. That's up to three-quarters of the position. Eight shares bought at that report-day close would still be up about $1,700 today, even after the whole derating. We've spent two rounds arguing over roughly $200 of pre-print risk. The post-print rule is where the money is.

So fix the test, using the plan's own logic. The $24.6 billion revenue bar is the plan's own 40% growth line, which measures the engine. All four of those quarters cleared 40% year over year: 53.9, 42.5, 55.5 and 47.7 percent. Make revenue the confirmation variable. Move margin and costs to the broken side of the ledger, using the plan's existing triggers: margin under 81%, recurring costs at 54% or more, or a guidance cut.

And measure costs both with and without the acquired-research charge the 10-Q identifies. My conservative colleague made that argument for me. If charges in four of twelve quarters are "how Lilly buys its pipeline," then a GAAP cost bar fails about one quarter in three for a reason he calls normal business. A deal charge says little about whether the obesity franchise is working, and that's what tranche three is supposed to confirm. As for whether those deals pay off, Jaypirca came out of Lilly's 2019 Loxo acquisition. The payoff he says we can't see yet arrived Friday afternoon.

Would the revenue test have fired in February too? Yes, and the next session gave back 7.8%. So I'll take three protections against that. One is the neutral's breakout route as written. Another is his five-session rule for the rolled slice. The third is the plan's stop under the report-day low. February is also why I care about being at the cap before the print, rather than leaning on buying after it.

Now the multiple. You both built your price ranges on it, and you both left out a data point. My conservative colleague puts April's 33 times on post-Q3 earnings and gets 1,080. My neutral colleague says the truth is in between.

Look at February, measured at the report-day close the way you measured April and August. Q4 2024 earnings back out to about $4.88 a share from the report's 50.5% growth figure. So the stock went into that report at about 49 times trailing and came out at about 48. Trailing earnings stepped up 12%, and the multiple gave up less than 2%. In August, a 6% step-up cost about 1%.

April's step-up was 23%. Its compression of about 10% came during the spring oil shock, when WTI went through $114 and headline CPI printed 0.87% in a single month. This quarter's step-up is about 10%. The two quarters that look like it compressed 1 to 2 percent. Thirty-three times is a stress multiple from a stress spring.

So put real numbers on the neutral's "in-between" quarter: $24 billion of revenue, an 82.5% margin, and costs at half of revenue. That fails our test on two counts, and it works out to about $8.72 a share. Apply February's compression to today's 38.35 times and you get about 1,217, right on the daily SuperTrend line. Apply August's and it's about 1,227. That's my arithmetic, not a forecast. An April-style rate shock would break it, which is what the TIPS veto and the 1090 stop are for. But with ordinary multiple behavior, an ordinary LLY quarter lands at the plan's own upgrade trigger. The breakout route isn't a long shot; it's the typical outcome.

On the forward frame, my conservative colleague says 28 times forward implies about $10.20 a quarter, so $9.08 is below expectations. But 28 times forward is an average across a rising stream of earnings. Start at $9.08, grow about 8% a quarter, and you get $40.80 for the year. That quarter isn't short of the forward path; it's the first step on it. He's right that real upside needs a real beat. Four report-day rallies in a row are what beats look like, from a business whose trailing earnings are still up 95%.

Now his test of my rate thesis. He says we tested it Thursday and Friday and the stock fell anyway. Two paragraphs later he says TIPS is only five basis points off its peak, and the long end got the least relief. Those can't both be true. If the yield that discounts Lilly's 2030 cash flows barely moved, the rate thesis wasn't tested.

Look at the tape. September 30^th alone went from an 1186 open to a 1157 close, on the day TIPS peaked at 2.93%. The two sessions after it cost 14 points combined, under half an ATR. Friday's StockTwits posts turned skeptical as CNBC's EloraTZP tolerability story circulated, and weekend posts turned constructive. Jaypirca got 45 minutes of trading. That isn't a verdict. CPI is the test.

That gives me a principle that squares my position with the cap. Waiting for information is cheap when the event moves the stock a little, and expensive when it moves it a lot.

Here's a rough exchange rate, and my conservative colleague needs it as much as I do. His whole case for caution around CPI assumes this stock trades on real yields. The multiple fell from 43 times to 38 times while TIPS rose from 2.32% to 2.88%. That's roughly 2% of multiple per 10 basis points. By that yardstick, a hot core print that adds 10 basis points is worth about 2% on LLY. The report has averaged 7.2%. So I'll wait for CPI, but I won't wait for the report.

The same yardstick exposes a problem with the floor tranche. TIPS at 3% is 12 basis points away. That's worth about 2.3% on the stock, which puts LLY near 1,117, inside the floor zone. The likeliest road to the floor runs through rising real yields, and that's exactly when the TIPS veto blocks the floor buy. The trigger and the veto cancel each other. Stack the OBV line, the freezes and the date check on top, and the realistic pre-print position is five shares. My neutral colleague called that a Hold waiting for permission, and I agree.

It gets worse in the scenario we should want most. Suppose Monday's Jaypirca reaction closes above 1151 and keeps going. The plan says to wait for a close back at or below 1151. If that never comes, there's no starter. The floor is too far below. The neutral's post-CPI route requires LLY under the 50-day, about 1171. So in the path where the bull case works fastest, we go into the print owning nothing, unless the stock first runs all the way through 1217.65.

So here's what I'm asking for, all inside risk the plan already set.

First, if Monday closes above 1151, buy a smaller starter sized to the same $265 of risk to 1090. That's about four shares at 1160, or three and a half at 1165. My conservative colleague says 1165 is where Friday's rally got sold. If Monday closes there, it wasn't sold, and that passes the "good news still lifts the stock" test he said we failed. The dollar risk is identical to the plan's starter, and I'll take his 1065 intraday backstop under either version.

Second, adopt the neutral's post-CPI checkpoint, but drop the 50-day ceiling. Sizing to the $440 budget already does that job: at 1180, what's left after a full starter buys under two shares. The ceiling only bites when a soft core CPI and a rising stock arrive together, which is exactly when we should own it. If core is 0.3% or more, or TIPS is at 3%, nothing goes in, as he wrote it.

Third, replace the OBV line with the neutral's volume test. One expiration session moved that line four and a half million shares. My conservative colleague described the danger as a third test of the floor on heavier selling, and that's exactly what the neutral's test measures.

Fourth, read the Q2 10-Q on Monday, as my conservative colleague says. If the $3.8 billion is acquired research, the plan's 1.25x ceiling opens for after the print, and the cost bar is measured excluding that line. Reading a filing is free upside.

Then fill toward the $440 through whichever route fires first, and trim to the cap before the print by selling. Existing holders above the cap should trim into a bounce to 1165–1195, as he says. Then they should rebuy on the fixed test, or they'll never rebuy.

A few quick answers on pricing, the balance sheet, the pipeline and valuation.

On pricing, Q1 was the first full quarter after the November deal. Its margin was 0.6 points below Q1 2025, while revenue grew 55.5%, the fastest in the series. Volume outweighed price immediately, and the next quarter set a margin record. The dollar's 2.1% rise came in the last three weeks of the quarter. The tough year-ago comparison is why the plan judges Q3 on sequential dollars, where LLY has averaged 12.7% a quarter over the last five.

On the balance sheet, the $8.4 billion financing inflow is less than one quarter of operating cash, which hit a record $10.7 billion in Q2. Liabilities are 3.2 times equity, against 4.5 a year earlier. The current ratio is 1.35, against 1.28 a year earlier. The $15.4 billion investing outflow matches a $15.9 billion jump in long-term assets, so they bought something.

On EloraTZP, a Phase 2b dose-finding study exists to find the doses that are too high. Lilly says later studies will target tolerability, and the revenue engine is tirzepatide, at 2.9% discontinuation.

On valuation, I'll take the neutral's normalized 33 times, which already includes the charges. Comparing the earnings yield to TIPS treats LLY like a bond. A bond's yield is its return. A 3.6% forward yield on earnings growing 30% a year becomes about 4.6% on today's price in a year, and 6% in two.

On crowding, my conservative colleague says the sentiment data can't support a crowding warning. I agree. Then the "bullish crowd" caveat he used to argue that rates matter more than in 2022 falls with it.

On reward to risk, my neutral colleague says I paired a range trader's stop with a trend follower's target. But buying a higher low inside a weekly uptrend, with the stop under the swing low and the target at the prior high, is the standard trend-following trade. His pure-trend version puts the stop 163 points away, about five ATRs, and nobody sizes a pullback entry off that. The range tells you where to add; the weekly trend and the catalyst tell you how much to own. I grant it's a better trade at 1115, which is why I want the floor tranche to be able to fill.

As for the resistance levels at 1160, 1176, the 1190s and 1218, those matter for slow climbs. The average report-day move is 82 points, nearly the width of the entire Bollinger band. From here, that clears all four in one session.

Last, my conservative colleague says missing a gain is only money we didn't make, while a gap is money we lost and takes a bigger gain to earn back. At the 1% loss the cap allows, that extra gain is about one-hundredth of a percentage point. The asymmetry he describes barely exists at this size. Here's what does exist. LLY is a Buy-rated stock that has rallied on four straight reports. Our confirmation test would have missed all four. And the plan's likeliest pre-print outcome is a quarter-size position, or nothing.

He says the firm can always buy LLY next month. It can, at next month's price, through a door that wouldn't have opened in any of the last four quarters. So my answer is Buy. Accept the cap, wait for CPI, and don't wait for the report. Fill the budget the plan already set through more than one route, and fix the test so the biggest tranche can actually go in. That isn't more risk than this desk agreed to. It just makes sure we actually own the stock we say we like. Aggressive Analyst: Let me be exact about where I've moved. What's left to argue is narrower than either summary suggests, and almost all of it sits in one rule.

I'm dropping the Monday chase. My neutral colleague says it breaks my own rule about waiting for CPI. Strictly it doesn't, because the plan's own starter at 1143 doesn't wait for CPI either. A close at 1160 is the same pre-CPI $265 at a worse price. But his route is better than mine. It puts that $265 to work after the cheap event, on any close below 1217.65, and fixed dollar risk shrinks the share count as the price rises. I'll take it.

I also withdraw my claim that the floor trigger and the TIPS veto cancel out. At 2.99% the floor fills, and past 3% we'd be averaging into the macro report's own bear case.

I accept the next-close rule. I accept the flush cap with the October 16 expiration excluded, and the five-session wait for the rolled slice. I accept the catch that the pullback half needs the report-day low intact, and a 1% budget to the new stop after the print.

On revenue alone, my conservative colleague's $8.12 quarter wins the point. Revenue up 7% with earnings up 2% isn't confirmation. One correction for the record: buying the first post-report close was in the plan before I said a word. I'm glad to see it go.

What I won't accept is a confirmation door that skips the winner and at best buys the loser. My neutral colleague showed the plan's original test went zero for six. My conservative colleague's repaired version keeps revenue at the 40% line and an 83% gross margin, and measures costs with and without the charge. Run it over the three entries he priced.

February's quarter had an 82.5% gross margin, so it fails. Fine, that's the one that gave back 7.8%. April's had 81.9%, so it fails too. That's the entry that's up 23% today and was up 37% at the August high. August's had 85.8%, and with the charge stripped out its costs pass. So his door opens there, at 1168.19, the entry he told us is underwater. Read his cost bar strictly and it opens for none of the four report days we have. Either way, it refuses the year's best trade.

That isn't bad luck, and I think it's the most useful finding on the table. Line the four report days up against the quarters they reported:

The two highest gross margins, 85.8 and 82.9 percent, got the two smallest moves, 4.9 and 3.8 percent. The two lowest, 82.5 and 81.9, got the two biggest, 10.3 and 9.8. Net margin runs the other way. The 37.4% and 34.4% quarters got the 10% days, and the 31.7% and 30.9% quarters got the small ones. Earnings per share is cleanest of all. Where EPS rose from the prior quarter, by 19% and 12%, the stock jumped about 10%. Where it slipped, by 1% and 4%, the stock rose about 4 to 5%.

Four data points prove nothing on their own. But they're the only evidence we have about this bar, and they say the market paid for earnings and ignored gross margin. Q1 had the lowest gross margin of our six quarters and the highest net margin. An 83% gate would have called the franchise into doubt in the most profitable quarter in our data.

My conservative colleague's real worry is pricing, and the plan already has a line for that. Gross margin under 81% is a broken quarter and a full exit. Gross margin swung almost four points in one quarter, from 81.9 to 85.8. That's the noisiest line in the income statement to hang a second, tighter gate on. On the buy side, it only blocks quarters like Q1, where a lower margin came with 55% growth.

So my neutral colleague is right to put the bar on the bottom line. But a ratio still punishes the trade he described himself, growth against margin. Take the fundamentals report's own 45% growth line, $25.5 billion, at a 32% net margin. That's about $8.16 billion of net income, or $9.13 a share. It earns more than the $24.6 billion, 33% quarter his bar passes, yet his bar fails it.

So write the bar in dollars: revenue of at least $24.6 billion and net income of at least about $8.1 billion, or $9.08 a share. Exclude acquired in-process R&D if the company itemizes it. Translate it back the way he translated his ratio, as 33% of each quarter's own 40%-growth revenue line. It opens for all four rallied quarters, Q2 only once the charge comes out. That includes last October, which his ratio shuts: 54% growth more than paid for a 31.7% margin. My conservative colleague's $8.12 quarter still fails it.

And $9.08 is the number I've defended since the first round, so I'm not moving the goalposts. I'm fixing them in place. Put the next-close rule on top and February still gets sidestepped. On the three entries we can price, that's April's 23%, a small loss on August, and February avoided. That's a door that both opens and shuts.

On the overweight, my neutral colleague says it needs a real beat, and we don't have consensus. I agree on the beat. But a door keyed to a number nobody has pulled is a lock. Pull consensus Monday along with the options-implied move. If we can't get it, use his own line: $9.40 a share excluding acquired R&D, the first step of the growth his PEG math implies. Clear that with a clean 10-Q and 1.25x is allowed. Anything less earns the full position and never the overweight, which is what my conservative colleague asked for.

On the post-print budget, a wide report day shrinks what fits, and I accept that. But the technical report says the real upside in a breakout comes from trailing the stop. So as the stop trails up under higher lows, reuse the risk it frees for the rest of the tranche. Never have more than 1% open, and never go past the target. That's also how the overweight comes to fit, once the stop sits within about 40 points. A wide day delays the full position; it doesn't cancel it.

On the multiple, my neutral colleague says we're each picking which February to believe. Fair. I'll stop forecasting the print off trailing multiples. So should my conservative colleague. He told us trailing arithmetic doesn't set this stock's price on report day, in the same breath he used it to put an in-between quarter on the floor. He was right the second time.

As for his "starting point we don't have": today's 38 times includes Q2's charge, and April's trailing earnings carried nothing that size. Strip it out the way the fundamentals report does, and today is 35 to 36 times against April's 33. That's two or three turns, not five. And the stock got there the same way, during a macro shock: oil at $114 then, the highest real yields since 2008 now.

Now rates. We've each been arguing from one week, so let's use two. Two Mondays ago LLY opened at 1144.50, with the 10-year TIPS near 2.6%. Real yields then ran to 2.93%, their highest since 2008, and stood at 2.88% on Thursday. LLY closed Friday at 1142.85, under two points from where it started.

My conservative colleague said that if my yardstick held, 23 basis points would take us to the stop. He showed the yardstick doesn't hold, and he's right, so I'll drop it. But the move we actually got was bigger than 23 basis points, and the stock finished flat. My read is that the six-week derating did its work, and the stock has stopped paying for more of it.

That's also my answer on correlation. He says a hot CPI gaps every long-duration name on the book the same morning. But he showed us himself that LLY reclaimed its 50-day in the week real yields spiked, and in 2022 it rose 32% while the S&P fell 19%. It's a long-duration stock that hasn't traded like a pure rate bet. So per-name sizing is the right budget, unless the rest of the book is all long-duration growth. That's my neutral colleague's rule, and I accept it.

It settles the checkpoint too. The macro report expects September's headline CPI to run hot on oil, with crude averaging about $97 in September against $84 in August. It also says a hot headline with soft core will probably be looked past.

My conservative colleague wants real yields to close lower on that print. That turns "the event passed without damage" into "the event was good news," on a print everyone expects to run hot. An in-line core print with real yields up two basis points on an oil headline fails his rule. He counts five doors, but a door that shuts on that kind of noise isn't really one of them.

My neutral colleague's five-basis-point tolerance blocks the 2.97% case, a nine-basis-point jump, and lets ordinary noise through. His version stands: core under 0.3%, TIPS under 3% and within five basis points of its pre-CPI close, and high-yield spreads under 3.5%. The starter's money can go in up to 1217.65, and the floor money stays under the 50-day.

Now my neutral colleague's best new idea: set the gap cap off the options market. Yes, but write it so it can move both ways. He said a 6% implied move makes a 10% stress a sensible tail. That's about one and two-thirds times the implied move, so make that the rule.

At a 9% implied move the stress is 15%, and the cap drops under six shares. At 5% the stress is about 8.3%, and the cap is about ten and a half.

If we're setting the cap off the market, we can't listen only when the market says get smaller. That matters all the more because the only downside gap our technical report cites was 3%. And the standing sell order into 1176 to 1195 should sell down to that cap, not to a fixed eight shares.

Three quick ones.

First, my conservative colleague says Q2's spending was debt-funded with real yields near their highest since 2008. But Q2 ended June 30. On August 25, after the quarter closed, the 10-year TIPS was 2.32%; the peak he means came September 30. Whatever Lilly borrowed, it didn't borrow at the peak. And the $8.4 billion financing inflow was smaller than that quarter's $10.7 billion of operating cash.

Second, on Jaypirca, the news report says this week moved it from later-line use into first-line. It was already an approved product, and this week opened its biggest segment. The same report reads the Foghorn exit as Lilly focusing its spending. Pruning a bet is discipline, not a warning.

Third, on the good-news test, Friday never got to weigh the approval against the tolerability story. For what it's worth, Friday's StockTwits posts skewed skeptical seven to four, and the weekend's skewed constructive four to one. Monday's close decides, and the plan already lets it.

So here's where I land: Buy, at the risk the plan already set.

Before the print, the starter goes in within its band, with no chase. The floor tranche needs a close back above 1115 with RSI above 35.5, TIPS under 3% and high-yield under 3.5%. It also needs the volume test and the flush cap, with expiration day excluded.

The post-CPI checkpoint runs on my neutral colleague's terms, with the freezes as agreed. On Monday we read the 10-Q, confirm the Q3 date, and pull consensus and the implied move. The gap cap is about one and two-thirds times the implied move, in both directions. Any excess sells into 1176 to 1195. Existing holders trim above the cap into the same strength and rebuy through the same doors.

After the print, nothing goes in on the report-day close. Confirmation needs at least $24.6 billion of revenue and about $8.1 billion of net income, $9.08 a share, excluding itemized acquired R&D. Every broken trigger stays as written, including the 81% gross margin line.

The breakout route needs a next close above 1217.65 with the report-day low intact. The pullback half goes in only above that low, and the rolled slice waits five sessions. Open risk stays inside 1%, with freed risk reused as the stop trails up.

The 1.25x overweight needs a beat, against consensus or $9.40 if we can't get it, plus a clean 10-Q and a stop that fits.

Exits are unchanged: the 1090 close, the 1065 backstop and no adds below the 200-day. A close below 979.50 or a broken quarter means a full exit.

Four reports in a row have moved this stock 4 to 10 percent on the day. The only shares that capture that move are the ones we hold at the close before the print. The only way to build the rest afterward is a door that opens on what the market actually pays for.

My conservative colleague says every yes has to be earned. Agreed. But his gross-margin gate would have said no to the most profitable quarter in our data, and yes only to the entry that's underwater. That rule doesn't earn us anything. It makes the plan look careful while it misses the trade. Fix the gate, keep the cap, and let the doors open when the evidence is good. That's how this desk ends up owning the stock it says it likes. Aggressive Analyst: Let me concede what I owe first. Both of you landed clean hits, and I'd rather spend this round on the one rule that decides whether this desk ever owns the full position in a stock it rates a Buy.

My neutral colleague caught me fairly on the gap cap. For three rounds I told you this stock averages a 7.2% move on report day. One and two-thirds times that is 12%. I can't use that average to justify carrying shares into the print and then size them as if the move were 5%. So the stress is the larger of 10% or one and two-thirds times the implied move, measured mark-to-market. That cuts against anyone sitting on a gain, and it's still right, because a gain handed back is a loss to the book. My conservative colleague's point that Q3 will probably show the slowest headline growth in five quarters is a fair reason for the floor. It's also why the fundamentals report says to judge the quarter on sequential dollars.

My neutral colleague also caught me keeping Q2's record margin when I valued the stock. Normalize the same way everywhere and LLY trades at about 31 times run-rate earnings, not 27 to 29.5. I'll take that. Thirty-one times is still fair for earnings compounding at 30% or more, and the plan's 28 times forward never depended on my version.

My conservative colleague is right that my report-day pattern in sequential EPS breaks once Q2 is measured ex-charge. I'll stop using it. Expectations set report-day moves.

On the overweight, I withdraw the $9.40 fallback. It sits below Q2's cost-normalized earnings, and a beat that's a sequential decline isn't a beat. No consensus, no overweight. It needs Q3 above both the top of the band and consensus on the same basis, plus a clean 10-Q, sized inside the 1%. Caution on the slice above a full position is cheap.

I'll also take four smaller rules: - the five-basis-point test read on the CPI close, - the levels rechecked on the day we buy, - the expiration test for October 16^th, - the ObesityWeek wait for the rolled slice.

That last one is my own principle: let the cheap event pass before the money goes in.

That leaves three things: what opens the full position inside the band, how holders get their core back, and one deadline. That's where the money is.

Start with the bar, and use one ruler throughout. My conservative colleague's $9.70 isn't an itemized number. It's Q2 with costs set at their prior four-quarter average, which he said isn't generous because it includes a heavy quarter. Fine. Set Q2's gross margin at its prior four-quarter average too: 84.3, 82.9, 82.5 and 81.9 percent, averaging 82.9. On that basis Q2's underlying earnings come to about $8.98 a share. My neutral colleague's slightly kinder version, using the trailing margin, gets $9.10. Leave everything in and Q2 earned $7.94. Treat both lines the same way and $9.08 is flat or better. The only way to reach $9.70 is to average the bad line and keep the good one.

Once the 10-Q is read, his bar becomes Q2's actual earnings with the itemized charge stripped out, record margin included. That's consistent, I'll grant. But it's a sequential test against a record, on a line that swung almost four points in one quarter, and it can rise. If the 10-Q itemizes the full $2.4 billion the fundamentals report sized off Q1's cost ratio, the bar becomes about $10.60. On $24.6 billion of revenue, that's a 38.5% net margin. The best quarter in our data printed 37.4%. Q2 reaches $10.60 only by pairing the record gross margin with the lowest cost ratio in the series. That's the plan's original test requiring everything at once, the one that passed none of six quarters, coming back in.

It also contradicts what my conservative colleague said in round one. Q1's 81.9% was the lowest margin of six quarters, Q2 jumped to 85.8%, and in his words, "one strong quarter after a soft one isn't a trend yet." Last round he said he wouldn't ask Q3 to match the top of the range for that reason. His bar makes Q3 match the quarter he told us wasn't the trend.

So he faces the choice my neutral colleague put to me. If 85.8% is the run rate, his bar can sit on Q2's record, but then the stock trades at 29.5 times run-rate earnings or less, and his thin-cushion valuation case goes with it. If it isn't the run rate, the stock is at 31 times and the flat line is about $9.10. He can't have both an expensive stock and a record-margin bar. I've taken my half. He should take his.

Now to my neutral colleague, who built the band. I accept its edges. Above the top, it confirms. Below $9.08 it doesn't, and only the breakout route opens. I won't ask for the ten cents between his $9.08 and my $8.98. My quarrel is with what decides the full position inside the band.

Here's what he said in round three about $9.08: "neither a miss nor a beat. That's enough to finish the 1.0x, because there the question is whether the franchise is intact. It isn't enough for the 1.25x. The overweight should need a real beat." That was the right division of labor. His fourth-round correction fixed the ruler, and on the fixed ruler the flat line is still about $9.10. So the franchise test belongs to the full position and the beat test to the overweight. Putting consensus inside the band hands the full position to the beat test.

Look at what the band calls in-between. A Q3 at $9.10 ex-charge is up 46% on last year's reported $6.21. It's still up about a third if you also strip a charge out of last October, as my neutral colleague suspects you should. And it follows the biggest dollar jump in revenue in our data. That's a franchise that grew earnings by a third to a half while the Street perhaps expected a few cents more.

Consensus also isn't the clean five-minute number it sounds like. If I recall Lilly's practice correctly, since 2024 its adjusted EPS has included acquired research charges rather than stripping them out. If so, the Street's number may carry exactly the charges our test removes, and making it like-for-like means rebuilding it ourselves, the guesswork the band was supposed to escape. For the overweight that's fine, because it can wait a quarter. It's a poor thing to hang the full position on.

We already have a live expectations test in every post-print buy, on whatever basis the market actually uses: the next-close rule with the report-day low intact. So here's my one change, and it adds a route rather than removing one. Inside the band, the full position confirms if either: - Q3 is at or above like-for-like consensus, or - the report-day close is at or above the prior close, and the next close holds the report-day low.

If the Street was disappointed in a way that matters, that's where it shows up. The stock closes down, or the low gives way the next day, and the door stays shut. February would almost certainly have failed it, at the same point the next-close rule did. If the market shrugs off a few cents against a number it may have built on another basis, we finish the position the plan already sized. Every broken trigger stays, including the 81% gross-margin line.

My route never opens below $9.08, the line below which, in my neutral colleague's words, the quarter stepped back on any reading. Inside the band, the only open question is whether Q2's record margin was the run rate, and my conservative colleague has told us twice that he doubts it.

Why lean toward yes there? My neutral colleague is right that no bar built on four up days can prove it filters anything, mine or my conservative colleague's. His opens on all three entries we can price, just as mine does. So the choice has to come from the cost of each mistake. My neutral colleague named that too: a good trend entry has small capped losses and one big gain.

A false yes costs the distance to the report-day low on eight to fifteen shares, inside the 1%. A false no costs a leg of the trend. Eight shares bought around April's report-day close were worth about $2,800 more at the August high. They're still up about $1,700 after six weeks of multiple compression.

Then think about where the band sends a below-consensus quarter. My neutral colleague's own central case for an in-between quarter is more of this range, around 1,170. The macro report's base case is a range into Q3. The sentiment report reads the market as wanting proof before it re-rates this stock, and Q3 is that proof. In the likeliest tape, the breakout route doesn't fire for weeks, and new money sits under half a position while the re-rating happens without us. In round two my neutral colleague called that a Hold waiting for permission. As written, the band builds one in its most probable case.

Now the holders, where my neutral colleague found the most valuable thing said this round. The trader gave holders two tools for the print. A put spread keeps the core through any quarter that doesn't break the thesis. A sale comes with a rebuy only if Q3 confirms. We dropped the put spread at desk scale for contract size, correctly, but kept the rebuy rule that came with selling. That quietly turned a 20-share core into about nine on any in-between quarter, with no date for getting back. Nobody argued for that.

His restore rule fixes it. On the first close after the report, if the low holds and nothing broke, the trimmed shares come back up to the pre-trim count, never above 1.0x. I'll defend that against anyone who calls it tranche three without confirmation. It isn't new money. It's the core the trader told holders to keep, sold only because a closing stop can't protect anyone through an overnight gap.

I'd extend it on the same logic. If the cap forces floor shares out at market before the print, they come back on the same test. They were bought at the plan's best price under every veto we wrote. Selling them for the event and not buying them back treats insurance as a verdict on the thesis, the mistake he just caught. If the standing order took them out at 1176 to 1195, that's a range trade that worked, and that money goes back through the normal entry rules like any new money.

That brings me to the deadline. Both of you want the excess gone before the FOMC decision. I'd keep the standing sells working through the Fed and sell any remainder on the close before the print, as the trader wrote. The gap cap exists because a closing stop can't protect you through an overnight gap. Lilly reports before the open: February 4^th opened at 1069.95 against a 998.64 close.

The Fed doesn't gap us. It announces at 2 p.m. with the session open, the 1065 backstop live and the 1090 close behind it. Forcing a market sale before the decision is what my conservative colleague warned against in round one: selling on the eve of an event at whatever price is there. It just moves the eve two days earlier. If the Fed reads the payroll report the way the bond market did, those are the sessions when the standing orders could fill. Keep the buy freeze, but selling into strength should never be frozen.

On freed risk, I'll drop my version for my neutral colleague's. Freed risk can be reused only when: - the stops on what we own sit at or above cost, - on a closing trail no tighter than one and a half ATRs, - after a close above 1217.65, - and only to complete the full position.

But the ADX gate should go. ADX has been above 25 on five sessions since early August: the cluster right after the 8/19 top, and 9/30, the failed breakout. The technical report says the 9/30 reading counted a bearish reversal as upward pressure. It also lists the missing directional lines as a data gap. A confirmation whose direction we can't read isn't a confirmation. A close above 1217.65 is the report's own signal that all three timeframes have turned up, and that's the confirmation.

At desk scale the budget rarely binds here anyway. Finishing the position after an ordinary report day means eleven to fifteen shares on a 60-point stop, about $660 to $900, inside the 1%. So I'm happy to leave the rule tight. It mostly governs the overweight and unusually wide days.

On rates, I'll take my neutral colleague's verdict: the two weeks are a draw, and the checkpoint settles it. On correlation, 1% per name is a ceiling, not a target. We agree.

So here's where I land: Buy, at the risk the plan already set.

Before the print: - The starter fills in its band with no chase. - The floor tranche carries every veto, the volume test and the flush cap, and waits for the print if the 10-Q shows Q2's jump was recurring cost. - The post-CPI checkpoint reads the five basis points on the CPI close and rechecks the levels on the day we buy. The starter's money can go in up to 1217.65; the rest stays under the 50-day. - The freezes stand. - On Monday we pull the 10-Q, the Q3 and ObesityWeek dates, like-for-like consensus and the implied move. - The gap cap is the larger of 10% or one and two-thirds times the implied move, marked to market. - Excess, for new money and holders alike, sits on standing sells into the top of the range through the Fed. Any remainder goes on the close before the print.

After the print: - Nothing goes in on the report-day close. - Above the top of the band, the full position confirms. - Inside the band, it confirms at or above like-for-like consensus, or on a report-day close at or above the prior close whose low holds the next session. - Below $9.08, only the breakout route opens. - The pullback half and the rolled slice keep their rules. - Freed risk completes the position on my neutral colleague's terms, without ADX. - The overweight needs a real beat against real consensus, above the top of the band, with a clean 10-Q. - Anything the cap forced out at market comes back on the holder's test.

Exits are unchanged: the 1090 close, the 1065 backstop, no adds below the 200-day, and a full exit on a close below 979.50 or a broken quarter.

My colleagues have built a plan that can't be hurt much when it's wrong. My job is to make sure it still gets paid when it's right. A quarter that grows earnings by a third or more, holds its ground with both lines treated the same way, and isn't sold by the market is not one to sit out. Keep the cap, restore the core, and let the market break the tie inside the band. That's how this desk ends up owning the stock it likes, on evidence, inside the risk it already agreed to take. Aggressive Analyst: Let me start with what I'm giving up, because both of you earned it. Then I'll spend the rest of my time on the two rules that still decide how much of this stock the desk actually owns.

The green-day door is gone. My conservative colleague put it exactly: it isn't built on the four up days, it is the four up days. A sign test that every report day in our data passed can't tell a quarter the market likes from one it hasn't made up its mind about. He's also right that April passes every bar still on the table. So the missed gain I kept pricing came from rules nobody is defending anymore.

He also caught me forgetting the shares we already hold. Twenty shares sixty points above a report-day stop is $1,200 at risk, which is more than the 1%. On my own example the position goes to sixteen shares, and the last four wait for a higher low. And my neutral colleague is right that my $8.98-to-$9.10 range averaged in last October's 51.2% cost ratio, so it wasn't one ruler either.

The rest I'll take as written. Floor shares the cap forces out at market come back through the normal doors. My version gave the range trade that missed its target a faster way back than the one that hit it, which is backwards. The restore needs a close back above 1090, because the plan can't sell new money below 1090 on report day and buy holders back at 1065 the next session.

The date settles the deadline. October 30^th is a Friday, and all four report days in our data fell on a Wednesday or a Thursday. So the standing sell works through the morning of decision day, and anything left goes before the 2 p.m. statement, or before the print if that comes first. Volume goes back on the breakout route; I dropped it along with both of you.

And on the rules we've written, the overweight needs ATR under about 26.7. That's lower than any reading in our technical report. It's off this quarter, and I won't spend this round arguing for the slice above a full Buy.

Now the door into the full position, which governs more money than everything I just conceded put together.

My neutral colleague owned the mistake of letting consensus decide the full position. My conservative colleague should own it too, because the case against it is his. In round three he told us the quarter-size above a full position is a bet that the quarter beat what the market expected. If we don't know what the market expected, he said, we can't know it beat. That's the overweight's question, and his version now asks it of the full position.

Look at how that plays out. He told us acquired research sits on its own line of Lilly's income statement. Good. Then my neutral colleague's test runs entirely off the release and the 10-Q we're reading Monday, with nothing borrowed from anyone.

Consensus works the other way. As my neutral colleague and I both read Lilly's practice, its adjusted earnings have kept acquired research in since 2024. So the Street's number may already carry a known charge. And his own fallback says that if we can't line it up cleanly, the quarter is in-between and only 1217.65 opens. Under his version, the full position depends on whether someone else's number can be made comparable to ours. That isn't a filter on the business. It's a filter on data hygiene.

He says a position at the gap cap, with a door at 1217.65, is the right size for a range. But the cap's size never came from the range. It came from a 10% overnight stress, and that overnight event is over the morning the print comes out. Holding the cap's size after a quarter that held its ground is the insurance outliving the event. That's the same mistake my neutral colleague caught on the restore.

The trader sized 1.0x for a Buy inside this very range, with the stop under its floor. A quarter that held its ground like-for-like leaves that Buy exactly where we put it. Asking it to beat the Street before we own a Buy-sized position is sizing a Buy as a Hold. He priced the cost of waiting at $500 to $700, but that was against a green-day door firing at 1170, which I've withdrawn. The real comparison now is a full Buy against a quarter to half of one, after a quarter that held its ground on our own numbers.

His objection that an in-range door buys the upper half of the range with a stop in its middle applies just as much to his consensus door, as my neutral colleague pointed out. We handle where a door fires by sizing to the actual stop, which we've now agreed. And his line that I can't have both a range and a re-rating we're missing was aimed at the door I've withdrawn. The test I'm backing doesn't forecast either one. It asks whether the business held its ground and sizes the Buy accordingly.

So I'll take my neutral colleague's test. Excluding acquired research, Q3 has to clear $9.08. It also has to earn at least what Q2 would have earned at Q3's own gross margin. That's my conservative colleague's principle, no like-for-like step back, on one ruler. And it asks the question tranche three exists to ask: did the extra revenue pay for the extra spending? If the 10-Q shows the full $2.4 billion was acquired research, that test asks more than the $9.08 I defended for four rounds. I'll take it anyway, because it's the right question.

I have one amendment, and it comes from my neutral colleague's own best line: each of us kept Q2's best feature in whichever number helped our side.

His test fixes the gross-margin record by letting Q3's margin restate Q2. It doesn't fix the cost line, and the 10-Q decides how flattering Q2's cost line looks. Q2's costs jumped $3.8 billion. The $2.4 billion in his worked example is the fundamentals report's illustration, built on Q1's cost ratio. It isn't a number from any filing. A quarter with a $15.4 billion investing outflow leaves plenty of room for a bigger one.

Suppose the 10-Q itemizes $3 billion. Then Q2's remaining costs ran 41.8% of revenue, lower than any quarter in our data. Run his test at an 83% margin on $24.6 billion, and the bar becomes about $10.58. That's a 38.4% net margin, above the best quarter we have at 37.4%. It's the same $10.60 bar I objected to last round, arriving by a different road.

The fundamentals report tells us what normal looks like. It says costs returning to about 45 to 48% of revenue would confirm Q2's jump was one-time. With an uncapped test and a $3 billion line, a $24.6 billion quarter fails anywhere in that range.

Here's the case that should bother both of you. Last round my neutral colleague used my ordinary quarter as the example that passes. That's last year's 13.1% sequential growth, an 83% margin and costs at 48%, which earns $10.17. With a $3 billion line, it fails. Nothing about the business differs between those two verdicts. The only difference is the size of an acquisition charge in the quarter before.

So give the bar a ceiling to match its floor. My neutral colleague wrote that the bar can never drop below $9.08, so the 10-Q can't make it easier than the plan's own number. I'm asking for the mirror image. For the bar, Q2's underlying costs can't count as less than 44.6% of its revenue, the lowest ratio in our six quarters. Past that point, the bar stops rising. At an 83% margin, that caps it at $9.87, his own number.

It changes the verdict on none of our historical quarters, because none of them ran below 44.6%. It only stops a filing from turning Q2's cost line into a record that Q3 then has to repeat.

I'm not asking to neutralize the cost line. That's the question the test exists to ask. Neutralizing it would take us back to the revenue-only door my conservative colleague shut with his $8.12 quarter, and that quarter still fails either way. And I won't use the same filing to flatter the valuation. A $3 billion line would put Q2's run rate near $11.30 a share and the stock around 25 times earnings. I'll keep saying 31.

Now the risk ruler and the restore. My neutral colleague has both right, and I want to add one thing.

My conservative colleague was right that "stops at or above cost" measured what we paid, not the book. So mark-to-market risk to the stop we actually hold limits every add. But it limits adds; it doesn't force sales. Applied continuously, the way he wrote it, the desk's entry rule becomes an exit signal keyed to ATR. And ATR jumps around every print, including the ones that go our way. The session after August's 4.9% report day, it hit 42.72. Under his rule, a full position gets trimmed the morning after a report that worked. The stops, the gap cap and the broken triggers handle exits. That's their job.

On the restore, he calls the trimmed shares an add. Then measure them his way. A holder who kept nine shares already has about $995 at risk to 979.50 at 1090. Not one share comes back, ever. That's the permanent halving he told us last round nobody argued for.

And look at what the add label does. The trader offered holders two kinds of insurance: buy a put spread on the excess, or sell it. A holder who bought the put spread still owns twenty shares the morning after the print. Nobody calls them an add or measures them to 979.50. A holder who sold the same shares, for the same reason, ahead of the same event, would need a fresh budget to get them back.

That's the same stock and the same core under two risk budgets, depending on which kind of insurance fit the account. At desk scale the options didn't fit, and that's the only reason he sold. The restore is the put spread he couldn't buy.

It isn't free insurance, either. On an up report day, and that's four for four in our data, the holder pays the move to get his shares back. That's his premium. On a gap down, he skipped the loss and waits for 1090. That's a put spread's payoff, paid in a different currency.

So the restore stays a restore. The trimmed shares come back on the first close after report day if three things hold: the report-day low is intact, the close is above 1090, and nothing broke. They come back up to the pre-trim count, never above 1.0x. The 10-Q wait applies only in the narrow case where costs reach 54% of revenue and the jump isn't on the acquired-research line.

The 200-day condition is redundant, since that average should still sit below 1090 through late October. In the case our data says is likeliest, a report day that closes green, that holder is back to his full core by the second close.

Two definitions on the breakout route, so it does what we think it does. First, above-average volume should mean above the pre-print 20-day average. That's about 2.3 million shares, the threshold the technical report gives for this setup. Otherwise the report day's six to eight million shares lift the average for a month and raise the bar against the stock's own follow-through. Second, the route stays open on any later close above the line with the report-day low intact, not just the second session. A re-rating that takes a week to clear 1217.65 is still a re-rating.

So here's where I land: Buy, at the risk the plan already set.

Before the print, everything we agreed stands. The starter fills in its band with no chase. The floor tranche carries every veto, the volume test and the flush cap. It also waits for the print if the 10-Q shows Q2's jump was recurring cost. The post-CPI checkpoint and the freezes run as written.

On Monday we read the 10-Q, confirm the Q3 and ObesityWeek dates, and pull consensus and the options-implied move. The gap cap is the larger of a 10% move or one and two-thirds times the implied move, marked to market. The excess sits on standing sells into 1176 to 1195 through the morning of decision day. Anything left goes before the 2 p.m. statement, or before the print if that comes first.

After the print, nothing goes in on the report-day close. The full position confirms on $24.6 billion of revenue plus earnings, excluding acquired research, that clear two bars. One is $9.08. The other is Q2's earnings restated at Q3's gross margin, with Q2's costs counted at no less than 44.6% of its revenue. Otherwise the breakout route decides: any close above the line, on volume above the pre-print average, with the report-day low intact.

The pullback half needs that low intact, and the rolled slice waits five sessions and until after ObesityWeek. Every add fits inside 1%, marked to market against the stop we actually hold, and nothing gets sold because that number grew. Holders restore on the conditions I just gave, and floor shares come back through the normal doors. The overweight waits for a same-basis beat, a clean 10-Q and a stop that fits.

Exits are unchanged: the 1090 close, the 1065 backstop and no adds below the 200-day. A close below 979.50 or a broken quarter means a full exit.

Remember what we're sizing. This business grew revenue 48% to $23 billion in a single quarter. It generated a record $10.7 billion of operating cash in three months. On Friday afternoon it won FDA approval for Jaypirca in previously untreated patients, the biggest segment of that blood-cancer drug market. And it trades at about 31 times run-rate earnings. The desk rated it a Buy. The rules should let us own a Buy when the business holds its ground.

My conservative colleague named three gaps last round. They were a door that opens on any green day, a budget that forgets the shares we already own, and a restore that buys below the line where the stop just sold. I've closed all three.

What's left on his side is a full position keyed to the Street's number. There's a sizing rule that, applied continuously, trims when ATR rises. And there's a restore that, on his own ruler, can't return a single share. Those don't make the plan safer. They make it smaller than its rating, by rules that disagree with each other.

The plan now loses only amounts we've agreed to. With my neutral colleague's structure and my two amendments, the bar ceiling and the breakout definitions, it also gets paid when it's right. That isn't more risk than this desk signed up for. It's the risk the desk signed up for, actually put to work.

Conservative Analyst¶

Conservative Analyst: Let me start where my aggressive colleague and I agree, because it shapes everything after. The weekly and monthly trends are up, the business is exceptional, the thesis isn't broken, and nobody on this desk should short LLY. I'm not arguing against the Buy. I'm arguing about how much of the firm's capital goes at risk before three events in about two weeks tell us whether this is a pause or something longer. He says the real risk is owning too little. For the firm, those two mistakes aren't the same size. Missing part of a gain on eight shares is money we didn't make, and the plan already has a defined way back in. A gap through an oversized position is money we lost, and it takes a bigger gain to earn it back.

Start with rates, because his whole case leans on them. The claim is that the six-week derating was driven by real yields and that rates are now turning. We got to test that on Thursday and Friday.

On October 1 the 10-year eased from its 5.29% peak to 5.24%, and LLY closed lower at 1149.85. On Friday payrolls came in at plus 29 thousand, yields eased again, the broad market rallied, and the Jaypirca approval hit the tape in the last hour. LLY traded up to 1164.92, got sold, and closed at 1142.85, in the bottom 22% of the day's range.

So across the week the stock had an FDA approval, positive data headlines and two days of falling yields. It still lost 3.4% and erased the entire prior week's gain. The macro report told us to watch whether good news still lifts this stock, and this week it didn't. That's not a broken thesis. It's a market that isn't paying for good news at this price, and that's when you hold size steady rather than double it. The same macro section he quoted about separating a rate-driven drop from a broken story says the distinction matters for when to enter and how much. The very next takeaway recommends buying in stages rather than full size before CPI.

The rate relief is also thinner than it sounds:

The 10-year TIPS yield, the exact series he blames, is 2.88%. That's only five basis points off its peak.

The curve steepened to 45 basis points on Friday because short yields fell more than long ones. The long end, which is what discounts Lilly's 2030 obesity cash flows, got less of the relief.

The Fed hiked less than three weeks ago, its first hike since 2023. Core CPI ran 0.29% in August, core PCE is 3%, and oil fell $10.65 and then jumped $14.14 within a few sessions.

The plan's 3% TIPS veto is 12 basis points away. High-yield spreads are 26 basis points from the 3.5% alarm after widening 51 in six days. Those two thresholds together are the macro report's own definition of the bear case, and CPI is about ten days out. On the 2022 comparison, the same report warns that at a trillion-dollar valuation with a bullish crowd, rates matter more now than they did then.

Now the Q3 arithmetic. He presents it as his strongest point, and I think it's his weakest. I won't argue Q3 can't clear $24.6 billion; four of the last five quarters would have. My point is that clearing it is already in the price.

He holds today's 38 times trailing multiple fixed and adds a $9.08 Q3 to the trailing sum to get 1,253. But in the same speech he says the stock really trades at 27 to 29.5 times adjusted earnings, because the market already looks through to $9.70 to $10.60 a quarter. He can't use both frames. Twenty-eight times forward at 1143 implies about $40.80 a year, or roughly $10.20 a quarter. His own minimum confirmed Q3 of $9.08 is below that.

Holding the trailing multiple fixed while trailing earnings catch up to what investors already expect creates upside that isn't there. Hold the forward multiple fixed instead, and an in-line quarter leaves the stock roughly where it is. Upside needs a real beat or falling real yields, and we control neither.

He also says the multiple would have to fall another 9% for the stock to stay flat, as if that were a stretch. It fell almost 11% in the last six weeks, from 43 times to 38, with no change in earnings at all.

Go back to the April report day. By my arithmetic on the reports' prices and quarterly EPS, the stock closed around 930 on trailing earnings of $28.15, roughly 33 times. Put 33 times on his post-Q3 trailing figure of $32.67 and you get about 1,080, below our 1090 stop. So a confirmed Q3 doesn't land us at 1,253. It lands us anywhere from under our stop to the old highs, and real yields decide where. That's exactly why the plan won't carry full size into the report.

On the one-time charge, the fundamentals report calls that explanation an inference that needs checking in the 10-Q, not a fact. And look at his own evidence: charges in Q3 2023, Q3 2024, Q1 2025 and Q2 2026. That's four in twelve quarters. A cost that shows up every third quarter isn't one-time; it's how Lilly buys its pipeline. Annualizing an adjusted Q2 takes the record-margin quarter, assumes no more charges, and calls it the run rate. That's the most generous number available, not a cushion.

The cash flow shows what that pipeline costs:

Operating plus investing cash flow was negative $4.7 billion in Q2 and negative $3.3 billion for the half.

Liabilities rose $23 billion in one quarter alongside an $8.4 billion financing inflow, which the fundamentals report reads as likely new debt.

Liabilities to equity went back up from 2.74 to 3.2 times, and the current ratio slipped from 1.50 to 1.35.

Outspending Novo nearly four to one is a bet whose payoff we can't see yet. And the valuation cushion is thin however you cut it. The trailing earnings yield is about 2.6%, below the 2.88% on an inflation-protected Treasury. Even at 28 times forward it's about 3.6%, roughly 70 basis points over a risk-free real bond. That thin gap is why this stock trades on rates.

On pricing, Q1 was the first full quarter after the November deal. It had an 81.9% gross margin, the lowest of the last six quarters, before Q2 jumped to 85.8%. One strong quarter after a soft one isn't a trend yet, and the fundamentals report itself says Q2's margin may not repeat. Add a dollar that rose 2.1% in September, medical prices that fell in August, and the hardest year-ago comparison of the year.

On EloraTZP, I agree tirzepatide is today's engine. But a stock priced on 2030 cash flows is partly priced on the next generation of drugs. Discontinuation rates of 10.8% to 27% against 2.9% are exactly the detail competitors are already using. On sentiment, the report rates its own confidence low, with Reddit switched off and a StockTwits sample covering only 32 hours. It can't support a contrarian buy signal any more than a crowding warning.

Now the cost of waiting. The four earnings-day gains averaging 7.2% are a sample of four, all up days, from a year in which earnings nearly doubled. And two of the four handed most of the move back to anyone who waited.

February's 10.3% jump gave back 7.8% the next day, so a buyer who waited a day paid about 1.7% over the pre-report close, not 10%. August's report day closed at 1168.19, and the stock is below that today. The plan's third tranche buys half after the first post-report close and half on the first pullback within two weeks, which is built for exactly that pattern.

His $650 of missed gain on tranche three is an upside case. The $440 is what we've agreed to lose if we're wrong. Comparing them compares two different things. And the plan isn't sitting out the print. It carries up to the gap cap, eight or nine shares, about half the target, because that's the most the 1% rule allows once you price in a 10% gap.

That gap is what the aggressive sizing skips. His 0.7% of the book is the distance to a closing stop, and a closing stop doesn't protect you through an earnings gap. Seventeen shares into a 10% gap is about $1,900, close to 2% of the book. So the gap cap forces roughly eight of those shares out, or into a hedge, before the print anyway.

Unless we pay for puts nobody has priced, the doubled starter doesn't buy more of the earnings gap he wants. It mostly buys more exposure to CPI and the FOMC, the two events where the evidence is against us. His point that the only downside gap on record is 3% comes from that same strong year, so it says little about how this stock trades on a real disappointment. August's 136-point drop from the month's high to its close shows how fast it can give back 10%. And because 1090 is a daily-close stop, a day like 9/30, with a 60-point range, can leave the exit well below 1090.

On technicals, my case isn't a list of indicators. It's what the closes say.

The 9/30 high came within 2.65 points of the daily SuperTrend line. Then it closed 60 points below it, in the bottom 3% of a range 1.8 times ATR, on 1.5 times normal volume. Intraday proximity doesn't count. The close is the vote, and the vote was rejection.

On ADX, he can't use "it's a range" to dismiss MACD and RSI, then call range math the wrong tool for the entry. If it's a range, 1143 is the lower middle and the top is 1195.

His 1,280 target has to clear 1160, 1176, the high 1190s, 1218 and 1247. Meanwhile the highs have already stepped down from 1292.65 to 1215. A 2.7-to-1 payoff is only worth the odds of reaching it. The technical report's own breakout setup gets just 1.3 to 1.5 times risk to those highs.

One correction: the report says a close above 1150 would delay the MACD cross, not prevent it.

On the Bollinger squeeze, a squeeze tells you a move is coming, not which way. With the daily trend down and selling volume heavier, the near-term evidence leans the wrong way.

On OBV, direction matters more than size. It didn't confirm the August high, and it made a lower low in September. The September bounce was padded by 4.54 million shares of likely options-expiration volume on a 49-cent gain. Take that one day out and OBV is about 341.3 million, already below the August low of 342.54. The late-August-to-September decline averaged 2.44 million shares a day. The September rally averaged 2.04 million, excluding expiration day.

His point that a slide to 1115 could trip the OBV filter automatically is the reason to keep it. If the third test of the floor comes on heavier selling than the second, the floor is weakening. You don't unplug a smoke detector because it's likely to go off.

That matters more because the floor stop is only 25 points, 0.78 ATR, below a 1115 entry. The technical report already said a stop that tight calls for smaller size. And the weekly line at 980 isn't reassurance. It's 14% below here.

So, on his five proposals.

Doubling the starter: no. It adds CPI and FOMC exposure at the price the technical report calls poor for new money, and the gap cap unwinds it before the print anyway. The trader's quarter-size starter will likely fill on the same close that triggers the bearish MACD cross. That argues for keeping it small, not doubling it.

Chasing up to 1165: no. That's exactly where Friday's rally was sold. From 1165 the risk to 1090 is 75 points, 2.35 ATR, against about 30 points to the upper band. That's 0.4 to 1, and only about 1.5 to 1 even to 1,280. The Jaypirca label says "certain patients," nothing in our materials says how many, and the plan already buys a Monday close up to 1151.

Loosening the floor-tranche conditions: no, for the reasons above.

The put spread instead of selling: only with a live quote, the premium counted against the risk budget, and strikes that actually cover a 10% gap, because a put spread stops paying below its lower strike. None of our reports contains a single option price. Without one, sell the excess.

The call spread after CPI: no. It's tranche three bought before the confirmation that defines tranche three. It pays the premium options carry ahead of earnings, plus two weeks of time decay through the FOMC. On an in-between quarter, where the plan says hold and add nothing, that premium just bleeds away. Defined risk isn't low risk when the whole premium can go to zero.

The changes I'd make go the other way, and they're small:

Keep the Buy and the 0.25x starter exactly as written, with no chasing above 1151.

The Q2 10-Q is already on file, so read it before tranche two rather than after. If the $3.8 billion turns out to be recurring operating cost rather than acquired research, the 50% cost bar for Q3 is in doubt, and the floor tranche waits for the report.

Confirm the Q3 date before any floor buy. Until it's confirmed, treat a floor fill as if it were inside the gap-cap window.

Don't fill the floor tranche in the two sessions before CPI. If the floor confirms then, wait for the CPI close and re-check TIPS. Apply the same freeze from the FOMC decision through the print.

Keep RSI, OBV, TIPS and high-yield spreads as hard vetoes.

Add a hard intraday backstop just under the 200-day, around 1065, the level the technical report itself suggests. That way a slide that keeps going after the open can't run the loss far past budget while we wait for the close.

Existing holders above the gap cap should get under it on any bounce to 1165–1195, not on the eve of the print, when you sell at whatever price is there and hedges cost the most. Rebuy on a confirmed Q3.

Now his two questions. Why pay 80 points more for the same shares after the report? Because they aren't the same shares. After the report they come with known revenue, margins, costs, guidance and an explanation for the $3.8 billion. And in two of the last four reports, most of that premium came back within days or weeks.

What does a quarter-size position earn if the floor never comes? It earns participation, and the unfilled slice rolls into tranche three. A missed floor costs us an opportunity. A broken floor bought without confirmation costs us capital.

If our neutral colleague is tempted to split the difference, the gap cap is arithmetic, not a negotiating position. The firm can always buy LLY next month. It can't undo a gap. So my answer is Buy, as the trader structured it, with these tightenings: not bigger, and not sooner. Conservative Analyst: Let me start with what's settled, because it's more than it was last round. My aggressive colleague has withdrawn the doubled starter and the option structures at this scale. Everyone at this table now accepts the gap cap, the 1090 closing stop and the 1065 intraday backstop, and at desk scale we meet the cap by selling. My neutral colleague is right that the pre-print disagreement is three or four shares, and right that the size lives in the post-print rules. So that's where I'll spend most of my time.

That's also where the aggressive package adds risk while calling itself "inside the budget." The $440 is a pre-print budget. Three of his changes sit outside it: confirming on revenue alone, opening the 1.25x ceiling on a revenue number and a 10-Q footnote, and buying a report-day spike on its close. That's post-print exposure with no budget attached. It lands in the exact window where February took 7.8% off the stock in a single session.

Start with the locked door. He says the plan's test would have kept tranche three out of four rallies, and that April alone cost about $1,700 on eight shares. So run his revenue-only door against the three post-report entries we can actually price. All three quarters cleared 40% revenue growth, so his door opens every time.

In February it opens at the report-day close near 1101. The next session takes 7.8% off that, and by April 29^th the stock is 23% below the entry. In April it opens near 932 and makes his $1,700. In August it opens at 1168.19, and that entry is underwater today. The plan's door kept us out of all three: it cost us April and spared us February and August.

And the one winner started at about 33 times trailing earnings, after the stock had already fallen 23% from its February report-day close. A post-print entry this quarter, on a typical pop, starts near 38 times. That isn't a door hiding money. It's one big win from a starting point we don't have, set against two entries that lost.

Revenue is also the wrong thing to confirm, because it's the one thing nobody doubts. Take a quarter his rewritten test would confirm: $24.6 billion of revenue, an 81.5% gross margin, and costs below gross profit at 52% of revenue. That trips none of his broken-thesis triggers. It also works out to about $8.12 a share, below Q1's $8.26 and 11% below the $9.08 he called the first step on the forward path.

That's revenue up 7% sequentially and earnings up 2%, in a stock priced at 28 times forward. That's a miss, and his test would put up to three-quarters of the position to work on it. The open questions this quarter are whether the November pricing deal is costing margin, and whether Q2's $3.8 billion cost jump repeats. Q2's record margin came with cost of revenue falling 8.6% while revenue rose 16%, and the fundamentals report says that level may not repeat. Margin and costs are the questions. Revenue is the answer everybody already has.

Here's what I'll grant him. If the 10-Q itemizes Q2's jump as acquired research, measure the Q3 cost bar both with and without that line. The plan's own exit trigger already counts only costs the 10-Q shows are recurring, so treating confirmation the same way is consistent. But the margin bar stays. The answer to a test that's too tight isn't a test that can't fail. It's the second door my neutral colleague already built, the breakout route, where the market itself has to confirm. I'll support it, with one change that comes straight out of my aggressive colleague's multiple argument.

He says an in-between quarter, with February- or August-style multiple compression, lands around 1,217 to 1,227, right on the trigger. So the breakout is the typical outcome. He accused both of us of leaving out February. He left out two things.

First, February one session later, which is when a post-print buyer learns whether the move held. By that close the multiple was about 44 times, down roughly 9.5% from where it went into the report, close to April's 10.5%. Apply either compression to his in-between quarter and it lands around 1,110 to 1,125. That's the floor, not the trigger. My neutral colleague was right that my 1,080 was the stress end, but the middle isn't 1,217 either.

Second, last October. Trailing EPS jumped by about a third as the $970 million charge quarter rolled off. Hold the multiple, as his method does, and you'd forecast a 30%-plus day. The stock did 3.8%. He'll say the market had already looked through that charge. Exactly. That's the forward frame I gave him last round.

Line up all four reports. Trailing EPS stepped up roughly 34, 12, 23 and 6 percent. The report-day moves were 3.8, 10.3, 9.8 and 4.9. The biggest step-up got the smallest move. Trailing arithmetic doesn't set this stock's price on report day. A 4-to-10 percent pop has been typical. Whether it sticks hasn't been. Of the three we can follow, one kept going, one gave back 7.8% the next session, and one sits below its report-day close today.

So he's persuaded me the breakout route could fire on the report day itself, since a 7% pop from here clears 1217.65. That's exactly February's setup. Here's my rule for every post-print buy, through either door. Nothing goes in on the close of the first session that trades the report. The earliest buy is the next close, and only if the report-day low has held. For the breakout route, that next close also has to be above 1217.65. It costs one session, and it's the session that bit us in February.

Now rates. He says I contradicted myself: I said the thesis was tested Thursday and Friday, then said TIPS barely moved. But the test I invoked was the macro report's own: whether good news still lifts the stock. That test doesn't need yields to move. The stock got a first-line FDA approval and three positive data headlines, and it lost 3.4% on the week. His explanation for Friday makes my point. If the selling was CNBC's EloraTZP tolerability story, the market weighed one detail from a dose-finding study over an FDA approval. At this price it's grading the pipeline harder, not easier.

Then his exchange rate, about 2% of multiple per 10 basis points of real yield. That's a six-week average, and it breaks down on the sessions around the peak. In the week TIPS climbed from about 2.6% to 2.93%, LLY didn't lose the six or seven percent his rate implies. It reclaimed its 50-day average and held it for four sessions. Then TIPS eased, and the stock fell anyway. September 30^th fits his story; the days on either side don't.

So either the yardstick holds or it doesn't. If it holds, a 23-basis-point rise in real yields takes LLY to 1090. That's smaller than the rise we got in that single week. A CPI print that moves real yields that much isn't a 2% event; it's a stop-out. If the yardstick doesn't hold, he has no basis for pricing CPI at 2% at all. Either way, anything we own before CPI has to be sized as if CPI can take the stop.

The same yardstick answers his complaint that the floor trigger and the TIPS veto cancel out. By his numbers, TIPS at 3% puts LLY near 1117. Every 10 basis points past that is another 22 or 23 points: about 1094, then the 200-day in the low 1070s. When the road to the floor runs through real yields above 3%, the floor isn't a floor. It's the first step of the macro report's bear case, and the veto exists so we don't average down into it. When the stock reaches the floor for any other reason, say a sector rotation or a headline shakeout, the veto doesn't bind and the tranche fills. That's not the rules cancelling. That's the veto telling the two cases apart.

On the Monday starter above 1151, no. It carries the same $265 of risk in a worse trade. From 1165 it's 75 points to the stop for about 30 to the upper band, 0.4 to 1. That's in the zone the technical report says to fade, where intraday rallies were sold into the close on two of the last three sessions. He's already granted the trade is better at 1115. It's worse at 1165.

He says a close there would pass the good-news test. One close inside a range doesn't pass anything. LLY closed above its 50-day four sessions running in late September, and one outside day put it back below. The close that passes is 1217.65, and the breakout route buys it. My neutral colleague had it right: don't convict on one hour, and don't chase on one day. In the fastest bull path, the cost of waiting is about 52 points on three and a half shares, roughly $180. And for anyone who already holds LLY, owning nothing was never the outcome, because the core stays.

I'll accept my neutral colleague's post-CPI checkpoint, with two changes.

First, keep his 50-day ceiling, which my aggressive colleague wants gone. Above roughly 1171 you're buying into the 1176-to-1197 cluster where every rally since late August has stalled or reversed. If the stock is strong enough to be there, the breakout route is 40 points away, with real confirmation.

Second, replace "TIPS under 3%" with "TIPS closes below its pre-print level." As written, a 0.29% core print that pushes real yields from 2.88% to 2.97% passes the gate. That's a hawkish print releasing a buy. My aggressive colleague says CPI is the test, so let the bond market grade it. If real yields fall on the print, his rate thesis has finally shown up in the series he blames. Then I'm glad to add, inside the $440 and under the cap.

On OBV, I'll take the substitution, but the replacement has the same hole as the line it replaces. The slide we're in now, four down closes since 9/28, averages about 2.32 million shares a day. That passes the 2.44 million bar, yet it includes 3.41 million shares on 9/30, the heaviest non-expiration session since August 19^th. Now put his own bearish flush, one 4-million-share day, into a four-day slide with three ordinary 1.8-million days. The average is 2.35 million, and that passes too.

So add one line: no down day in the slide heavier than the 9/30 rejection, about 3.4 million shares or one and a half times average volume. If there is one, the floor buy waits for a second close back above 1115. That doesn't block the floor; it makes a flush prove it was capitulation. And I agree that RSI, TIPS and high-yield spreads are conditions for adding, not reasons to sell what we hold. The selling rules are the 1090 close, the 1065 backstop, the weekly line and a broken quarter.

Now my neutral colleague's charge that my version is a Hold waiting for permission. Count the doors after this round: the starter band, the floor, the post-CPI checkpoint, the breakout route and a confirmed quarter. That's five ways in, each tied to a reason.

Suppose CPI runs hot, the floor only comes with real yields above 3%, the quarter is in-between, and the stock can't hold a close above 1217. Then we carry a quarter position into November. That isn't the plan failing; it's the plan reading the evidence. He's right that my rolled-over floor slice would have gone in during the riskiest window. His five-session rule fixes that, and I accept it. My next-close rule applies the same February lesson to the rest of tranche three.

On the 10-Q, read it Monday. But it's free information, not free upside. If it shows the $3.8 billion is recurring operating cost, the floor tranche waits for the print. If it shows acquired research, the cost bar can exclude it, but valuation and leverage can't. Q2's $15.4 billion investing outflow was partly debt-funded, with real yields near their highest since 2008.

He says Jaypirca proves those deals pay off. It came from a 2019 deal and won its first-line label this week. That's seven years from check to payoff. The same week, Lilly ended its Foghorn collaboration. Pipeline buying is a portfolio of long-dated bets, and the cash and the debt are today. So 1.25x stays where the plan put it, behind a fully confirmed quarter and a clean 10-Q. An in-between quarter plus a breakout earns the full position, never the overweight.

Three concessions, because they were earned.

First, he's right that recovering a 1% loss takes only 1.01%, so I'll drop the compounding point. The asymmetry that's real is correlation. A missed LLY gain belongs to LLY alone. A hot CPI gaps every long-duration name on the book the same morning, so a 1% budget per name stops being 1% for the firm. That's why every share added before CPI and the FOMC deserves more scrutiny than its own stop distance suggests.

Second, he's right that thirty-two hours of StockTwits can't show crowding. But the macro report's warning was that at a trillion dollars, each new result moves the stock less. You don't need posts to see that; you need this week's tape.

Third, both colleagues are right that an earnings yield isn't a bond yield. My narrower point stands: when most of the value rests on growth that hasn't happened yet, the discount rate does most of the work. That's how a stock with earnings up 95% lost 11% of its multiple in six weeks.

So here's where I land: Buy, as the trader structured it, with these rules before the print.

The 0.25x starter goes in within the 1136.66-to-1151 band, with no chase above it.

The floor tranche needs a close back above 1115, RSI above 35.5, TIPS under 3% and high-yield spreads under 3.5%. It also needs the volume test with a cap on any single flush day.

The post-CPI checkpoint opens only if three things hold: core comes in under 0.3%, real yields close lower than before the print, and LLY sits between the floor and the 50-day. Size it inside the $440.

No floor fills in the two sessions before CPI, or from the FOMC decision through the print.

Read the 10-Q Monday and confirm the Q3 date.

Into the print, unhedged shares stay under the gap cap. At desk scale that means selling. Books large enough to trade listed options can hedge instead, with a live quote and the premium counted inside the 1%.

After the print, the confirmation test keeps margin and costs. Costs get measured both ways if the 10-Q itemizes acquired research. The breakout route covers an in-between quarter.

Nothing goes in on the first post-report close. The earliest buy is the next close, with the report-day low intact, and the rolled slice waits five sessions. The 1.25x overweight comes only on full confirmation.

Existing holders trim anything above the cap into a 1165-to-1195 bounce and rebuy through either door.

Exits stay as written: the 1090 close, the 1065 backstop, and no adds below the 200-day. A close below the weekly line at 979.50 means a full exit, and so does a broken quarter.

My aggressive colleague wants the firm to have more ways to say yes. After this round it has five. What it needs is for every yes to be earned, at a price the evidence supports, inside a loss we've already agreed to take. Conservative Analyst: Let me start by giving ground where it's been earned. What's left is narrow, and it's where the money is.

My aggressive colleague is right about the gross-margin gate. It would have refused April, the year's best entry, and opened only on August, which is underwater. I'm dropping the 83% bar from the buy side, though not for his reason. Of the four quarters behind those report days, the two with the highest gross margins also had the heaviest costs below gross profit, 54.9% and 51.2% of revenue. Four data points can't separate gross margin from spending. I'm dropping it because the 81% broken trigger already polices pricing, and earnings capture the rest.

My neutral colleague is right that I oversold February. The stop under the report-day low would have taken that entry out on day two at about an 8% loss. It would not have sat 23% underwater by April. My aggressive colleague is right that Q2 closed in June, before real yields peaked, so I shouldn't have tied Lilly's borrowing to the peak. He's also right that buying the first post-report close was the trader's rule, not his. And this week did open Jaypirca's biggest segment. I undersold that.

I'll take the five-basis-point tolerance at the post-CPI checkpoint. Asking real yields to fall on a print everyone expects to run hot was asking for good news, not for no damage. One clarification: the TIPS and high-yield conditions get checked on the close of the day we buy, not just on CPI day. The window runs two weeks, and at the pace of the last six sessions, spreads could cover the 26 basis points to the alarm in about three.

I'll also accept the split on the starter money. A fixed $265 buys fewer shares at a worse price, about two and a half at 1190, so the risk doesn't grow.

That leaves four rules where risk is being moved rather than removed: the confirmation bar, the overweight, reusing freed risk, and the gap cap. Between them they govern up to three-quarters of the position and everything above it.

Start with the bar. My aggressive colleague says $9.08 is the number he's defended since the first round. The number hasn't moved, but the ruler has. In round one, $9.08 came from the plan's thresholds as written: an 83% margin and costs below gross profit at 50% of revenue, charges included. That 50% sits right on the trailing ratio of 49.9%, which includes Q2's jump. Now both my colleagues measure Q3 with acquired research stripped out, against a bar built with it left in.

Here's what that does. In the same speech, my aggressive colleague strips Q2's charge out to show the stock trades at 35 to 36 times rather than 38. Fine. On that basis, the fundamentals report's illustration puts Q2's underlying earnings at about $9.70 to $10.60 a share. His $9.08, measured the same way, sits 6 to 14% below the quarter we just had. So under his rule, and under my neutral colleague's 33% version, tranche three can go in on a quarter where like-for-like earnings fell. He can't use the ex-charge Q2 to make the stock look cheaper and then set the Q3 bar below it.

His own best finding shows why the ruler matters. He found that report-day moves tracked sequential EPS. Quarters where it rose 19% and 12% got about 10% days, and quarters where it slipped got 4 or 5%. That's GAAP EPS. Measure it ex-charge, the way he wants to measure Q3, and the pattern breaks. Q2's underlying earnings rose 17 to 28% from Q1, as big a jump as any in the set, and the stock got 4.9%, the second-smallest move.

So either the market didn't look through the charge, in which case we shouldn't strip it from the test, or sequential EPS doesn't explain report-day moves, in which case it can't calibrate anything. The honest answer is my neutral colleague's: expectations set report-day moves, and we don't have them.

And notice what's happened over three rounds. The bar keeps getting redrawn against the same four report days. My aggressive colleague's version now passes all four, Q2 once the charge comes out. But all four were up days. On the basis he wants to use, his bar has never said no to a real quarter. Its only rejection is the $8.12 quarter I made up. That's a fit to the sample, not a filter.

So here's my version. It isn't tuned to report-day moves at all. It asks the question tranche three exists to answer: is the franchise still compounding? It's in dollars, as he asked, and on one ruler.

Revenue has to be at least $24.6 billion. With acquired research left in, EPS has to be at least $9.08, as the plan wrote it. Take acquired research out of Q3 and you take it out of Q2, and then Q3 has to at least match Q2's underlying earnings.

The low end of the fundamentals report's range is $9.70, and that figure isn't generous to Q2. It assumes Q2's costs at their prior four-quarter average, which already includes one heavy quarter. If the 10-Q shows less of the jump was acquired research, the bar comes down with it, never below $9.08. And I won't ask Q3 to match the top of the range, because Q2's record gross margin may not repeat.

On history, that principle behaves like my neutral colleague's ratio. The principle is simply no like-for-like step back from the prior quarter. It opens on the quarters reported in February and April, and on August's once the charge comes out. It shuts on last October's, where EPS slipped. With the next-close rule, it very likely takes April and sidesteps February. So it doesn't lock the April door. It locks the door on a quarter where the business earned less than it did three months earlier.

My aggressive colleague's own ordinary quarter from round one had 13.1% sequential growth, an 83% margin and costs at 48%. That comes to about $10.17, which clears $9.70 comfortably. The gap between us is 62 cents a share. But it's the gap between a quarter that held its ground and one that went backwards. If Q3 lands in between, the breakout route is still there, behind the next-close rule.

To my neutral colleague: you built the right structure. One earnings bar, charges out for the test and in for the valuation. The only flaw is calibration. We set the number with charges in and now measure with them out.

That settles the overweight too. My aggressive colleague's fallback, if we can't get consensus, is $9.40. That's below even the low end of Q2's underlying range, and a beat that's a sequential decline isn't a beat.

Look at why our internal numbers disagree. Twenty-eight times forward implies about $40.80 a year. That's almost exactly Q2's underlying earnings times four, which is $38.80 to $42.40. Read that way, the forward multiple already assumes the run rate holds, and a beat has to clear it. Read my neutral colleague's way, with growth inside the year, the first quarterly step is $9.40. We don't know which basis the 28 times uses. That's exactly why the overweight needs the real consensus number, not our reconstruction of it.

He says a door keyed to a number nobody has pulled is a lock. It's a lock on the one door we never need. The 1.0x is the full position. The quarter-size above it is a bet that the quarter beat what the market expected. If we don't know what the market expected, we can't know it beat. No consensus, no overweight. It waits for the next quarter.

Third, reusing freed risk as the stop trails up. That's pyramiding, and in this tape it's how a capped loss stops being capped. My neutral colleague made the key point last round: small capped losses and one big gain is what a trend entry should look like. The losers in that sample stayed capped because the stop sat under the report-day low and nothing was stacked on top. Trailing a stop protects a gain. Spending that protection on new shares turns it back into risk, so one reversal hands back the gain we'd locked in.

The technical report's line about trailing comes from its breakout setup. It says the real upside comes from trailing the stop if price makes new highs. That's about protecting a trend, not adding inside a range where ADX has been under 25 on 38 of 43 sessions. A 40-point trailing stop is 1.25 ATRs, and the 9/30 outside day had a 60-point range.

A trailing stop is still a closing stop, too. The first week of November brings ObesityWeek, where the EloraTZP tolerability question likely gets a fuller airing, plus Novo's Q3 and the October jobs report.

So freed risk gets reused only after a close above 1217.65 with ADX above 25. And only once the stops on everything we already own sit at or above cost, so the new shares carry the only open risk. It never buys the overweight.

Fourth, the gap cap. Setting it off the implied move is my neutral colleague's best idea, and I accept it, with a floor. My aggressive colleague wants it to move both ways, so a 5% implied move would cut the stress to 8.3% and lift the cap to about ten and a half shares.

Here's the problem. The implied move is the market's estimate of the average move, not the tail. On a bell curve, a drop of one and two-thirds times the average move happens roughly one report in ten. Earnings moves have fatter tails than a bell curve, and our own sample has two report days of about 10% out of four.

The market can tell us the tail is fatter than our sample. It can't tell us our sample didn't happen. That isn't listening only when the market says get smaller. It's letting the market add to what we know without erasing what we've seen.

Two more reasons not to let a low implied move loosen the cap. First, the macro report says stock volatility is lagging credit. The VIX is 16.4 while high-yield spreads widened 51 basis points in six days, so options can be cheap exactly when they shouldn't be.

Second, this quarter brings a headline our four rallies never saw. At the $24.6 billion bar, growth prints about 40% against the year's hardest comparison. That's the slowest since Q2 of last year, and all four rallies came on growth of roughly 42 to 56%.

He's right that the only shares that capture the report-day move are the ones we hold at the prior close. They're also the only ones exposed to the gap. So the stress is the larger of 10% or one and two-thirds times the implied move. It can tighten the cap. It can't loosen it below 10%.

On rates, my aggressive colleague's two-week window runs from 1144.50 on September 21^st to 1142.85 on Friday, with real yields up roughly 28 basis points. True. But in between, the stock went to 1215 and came back. That's a 70-point round trip from the bottom of the range to the bottom of the range.

That shows the range held. It doesn't show the stock has stopped paying for rates. And it says nothing about the one scenario our data has never shown us: the macro report's bear case, with TIPS through 3% and high-yield through 3.5%. My neutral colleague is right that nobody here can price what CPI does to LLY. That's the case for keeping the vetoes and the 10% floor, not for loosening them.

On correlation, I'll take my neutral colleague's rule, but don't size LLY up because the rest of a book is cyclical. In 2022 LLY beat the market because tirzepatide news outran rates, not because it ignored them. The macro report says rates matter more now, at a trillion dollars. In the bear case, cyclicals take the credit stress and long-duration names take the real yields, so there's no hedge in it. Per-name 1% is a ceiling, not a target.

Two small ones. On the flush cap, I'll exclude October 16^th on the same standard I used for 9/18: heavy volume on a close that barely moves. 9/18 moved 49 cents. If the 16^th closes within about a quarter of an ATR, roughly eight points, it's expiration noise and we exclude it. If it's a 30-point drop on four million shares, that's a flush, whatever the calendar says.

On the floor overshoot, I accept the standing sell at 1176 to 1195. If it hasn't filled by the FOMC, sell the excess before the decision, not on the eve of the print. There's no reason to carry shares we've already decided to sell through a Fed decision.

So here's where I land: Buy, as the trader structured it, at the risk the plan already set.

Before the print, the starter goes in within its band with no chase. The floor tranche needs a close back above 1115, RSI above 35.5, TIPS under 3% and high-yield under 3.5%. It also needs the volume test and the flush cap, with expiration excluded only if it trades like expiration.

The post-CPI checkpoint runs on my neutral colleague's terms, checked on the close of the day we buy. The starter's $265 can go in up to 1217.65, and everything else stays under the 50-day. Floor fills freeze in the two sessions before CPI and from the FOMC through the print.

On Monday we read the 10-Q, confirm the date, and pull consensus and the implied move. If the 10-Q shows Q2's jump was recurring cost, the floor tranche waits for the print. The gap cap uses the larger of a 10% stress or one and two-thirds times the implied move. Excess sells into 1176 to 1195, or before the FOMC if that order doesn't fill, and existing holders trim above the cap into the same strength.

After the print, nothing goes in on the report-day close. Confirmation needs $24.6 billion of revenue and EPS on one ruler. That's $9.08 with acquired research in, or Q2's underlying level, $9.70 at the low end, with it out of both quarters. Every broken trigger stays, including the 81% gross-margin line.

The breakout route covers an in-between quarter, on a next close above 1217.65 with the report-day low intact. The pullback half needs that low intact too, and the rolled slice waits five sessions. Open risk stays inside 1% of the book. Freed risk gets reused only above 1217.65 with ADX above 25 and stops at or above cost on what we already own. The overweight needs the consensus beat and a clean 10-Q.

Exits are unchanged: the 1090 close, the 1065 backstop, no adds below the 200-day, and a full exit on a close below 979.50 or a broken quarter. Trimmed holders rebuy through the same doors.

My aggressive colleague says fix the gate and let the doors open when the evidence is good. I've dropped the gate he was right about. All I'm asking is that "good" mean the business earned at least as much as last quarter, measured the same way both times. A bar we cleared by changing the ruler isn't evidence; it's permission. That's how the firm owns the stock it likes without buying three-quarters of the position on a quarter that went backwards. Conservative Analyst: Let me start with what's settled, because that list is now longer than the list of disagreements.

My aggressive colleague accepted the 10% floor on the gap cap, measured mark-to-market. He also withdrew the $9.40 fallback. So the overweight needs a real beat against real consensus, on the same basis, plus a clean 10-Q. All three of us agree on these: - the CPI checkpoint, with the five-basis-point test read on the CPI close and the limits rechecked on the day we buy, - the expiration test for October 16^th, - the ObesityWeek wait.

That's real movement, and I'll match it.

I'll take my half on the bar. My neutral colleague's $9.50 example was exactly right. My test gave a clean quarter and a deal quarter opposite verdicts on the same business. And $9.70 normalized Q2's cost line while keeping its record gross margin. That's two rulers inside one number, the mistake I charged both of them with. On one ruler, Q2's underlying earnings were about $8.98 to $9.10.

So I accept the band as my neutral colleague built it. Above the top, which the 10-Q may move, the quarter confirms. Below $9.08 it doesn't. In between, like-for-like consensus decides.

I'll take the valuation consequence too. On normalized earnings the stock trades in the low thirties, not at 38. I never called it a bubble. My point was that the multiple is what the market has been moving, about 11% in six weeks with trailing earnings unchanged. CPI and the Fed are still ahead of us.

On ADX, you're both right. It's been above 25 on five sessions since early August, all at or just after a top. Without the directional lines, we can't tell which way it points. I drop it.

On the restore, my neutral colleague found the most valuable thing said last round, and the flaw was mine. In the first round I wrote "rebuy on a confirmed Q3." On an in-between quarter, that quietly halves a holder's core. Nobody argued for that. I accept the restore in principle, but as written it has a hole, and I'll come back to it.

That leaves four disputes: my aggressive colleague's second door inside the band, how we measure risk after the print, the restore's conditions, and the deadline.

Start with the door. He wants the full position to confirm inside the band on either like-for-like consensus or a report-day close at or above the prior close, provided the report-day low holds the next session. The next-close rule already applies to every post-print buy. So the only new condition is that the report day closes green.

All four report days in our data closed green: 3.8, 10.3, 9.8 and 4.9 percent. My neutral colleague told us no bar built on four up days can prove it's a filter, and my aggressive colleague agreed this round. This route isn't built on the four up days. It is the four up days. And the threshold is zero. This stock has moved 4 to 10 percent on every report day. Closing a dollar above the prior close isn't the market shrugging off a miss. It's the market undecided.

Then look at where it fires. He told us the likeliest tape for an in-between quarter is more of this range, around 1170, which is my neutral colleague's central case. A green report day in that tape closes near the 50-day, under the late-September highs, in the upper half of a range the technical report says to fade near its top. The stop goes under the report-day low, which in that tape sits inside the range, maybe 1130 to 1140. So his route buys the upper half of the range with a stop in its middle. In a range, that stop gets hit by ordinary range swings. That isn't an occasional, cheap false yes. It's a likely one.

His case for leaning toward yes rests on the cost of a false no: April, $2,800 at the August high and still $1,700 today. But April passes the band. Q1's earnings rose about 12% on Q4's, a step forward on any reading. It passes my principle, which he conceded opened on all three entries we can price. It passed my neutral colleague's net-margin version too. The only rules that missed April were the trader's original three-part test and my gross-margin gate, which I dropped last round. So the false no he's pricing belongs to rules nobody is defending.

The false no that's actually left is a quarter inside the band, below consensus, that the market likes anyway. That quarter still has a door at 1217.65. If his route would have fired around 1170, waiting costs about 48 points on the eleven to fifteen shares he wants to buy. That's roughly $500 to $700, about the size of the false yes, not a leg of the trend.

He also says the market wants proof before it re-rates this stock, and Q3 is that proof. Agreed. A re-rating means the market paying a higher multiple. If it happens, it shows up as a close above 1217.65, and we buy it. If the likeliest tape is a range around 1170, then no re-rating is happening without us. He can't have both a range and a re-rating we're missing.

In that range, a position at the gap cap with a door at 1217.65 isn't a Hold waiting for permission. It's the right size for a range.

On consensus, he says Lilly's adjusted EPS may include acquired research, so lining the Street's number up with our band means rebuilding it. It doesn't. Lilly reports acquired research as its own line on the income statement, so lining Q3 up against the Street is one adjustment. If we can't do it cleanly, my neutral colleague's rule already covers it: the quarter is in-between, and the market decides at 1217.65. That isn't a lock. It's the market grading the quarter we can't grade, at the level where the daily trend turns.

There's one thing all three of us dropped along the way, me included. The trader's upgrade trigger wasn't just a close above 1217.65. It was a close above 1217.65 on above-average volume. My neutral colleague's first draft of the breakout route had it. By last round it was gone from every summary. Put it back.

Apart from expiration, the heaviest volume since August 19^th came on 9/30, and that was the rejection. If the market is going to tell us the range is over, it should say so on a close, with volume. Volume on an up close has a direction built in, which is what we wanted from ADX and couldn't get.

Now risk measurement, where I owe a correction of my own. Last round my neutral colleague settled how the gap cap is measured: mark-to-market, because a gain handed back is still a loss to the book. My aggressive colleague accepted that, and so do I.

But the freed-risk rule runs on the other ruler. It says that once the stops on what we own sit at or above cost, those shares carry no risk and the new shares carry the only open risk. That condition was mine, and it's the two-ruler mistake again. A stop at cost protects what we paid. It doesn't protect the book. Twenty shares on a trail one and a half ATRs below price carry about $960 of mark-to-market risk at today's 31.91 ATR. That's the whole 1%, whatever we paid for them.

Put every budget on that one ruler: the gap cap, the post-print budget, freed risk and the overweight. Three things change.

First, my aggressive colleague says the budget rarely binds, because eleven to fifteen new shares on a 60-point stop is $660 to $900. That's true only if the shares we already hold count for nothing. After tranche three, the plan moves the stop under the report-day low. Twenty shares sixty points above their stop is $1,200, or 1.2% of the book. The budget binds on his own example. And that window isn't quiet: ObesityWeek, Novo's Q3 and the October jobs report all land in the first week of November.

Second, that delays the full position rather than cancelling it, which is exactly what he asked for. Volatility expands after a print. After August's report, ATR hit 42.72 the next day and then decayed. On a stop one and a half ATRs away, twenty shares fit inside $1,000 once ATR is back under about 33. So the full position completes as the stock calms down, without pretending a gain can't be lost. That's simply the desk's original sizing rule applied continuously: the full position is the size whose one-and-a-half-ATR stop risks 1%. The separate freed-risk rule folds into it.

Third, the overweight. My neutral colleague wrote two rules. The trail is never tighter than one and a half ATRs, and the 1.25x fits only on a stop within about 40 points. Together those need ATR under about 26.7. The lowest ATR in our technical report was 29.48, on September 18^th. So on one ruler, the overweight doesn't fit at any volatility in our data. I'm comfortable with that. It's the slice above a full position. It should wait for a calmer stock than one coming off a report day.

Now the restore. As written, it buys back trimmed shares on the first close after report day if the report-day low holds and nothing broke. Run it through a bad in-between quarter: - The stock gaps down 7% and closes at 1060, with nothing on the broken list fired. - By that close, the stop rules have taken new money's tranches out. - The next session closes at 1065, above the report-day low. - The restore buys holders back in, eleven or twelve shares.

So the plan sells new money's shares below 1090 and buys holders' shares below 1090 a day later, in the same stock, on the same quarter. And it buys under the 200-day, where the plan says no add can happen. The technical report calls a close there the first real warning to the long-term trend.

My neutral colleague will say a holder with a put spread would still own twenty shares at 1065. True, and he'd hold them under the core's rules. But the trader wrote "keep the core up to 1.0x." That's a ceiling, not a target. Shares the trim turned into cash are an add when they come back.

Look at the asymmetry. If the holder waits for a close back above 1090, that costs about 25 points if the stock comes straight back, roughly $300 on twelve shares. Restoring at 1065 leaves those shares 85 points above the core's only price exit at 979.50, roughly $1,000 at risk. Waiting is the cheap mistake.

So the restore needs a close above 1090 and above the 200-day, with the report-day low intact and nothing broken. I'd add one more condition. On the first close after report day, we'll have the release, not the 10-Q. If costs run 54% of revenue or more and the jump isn't on the acquired-research line, we can't yet know whether the broken trigger fired. So the restore waits for the 10-Q. That's the trigger the trader wrote, read in the order the information arrives.

My aggressive colleague also wants floor shares that the cap forced out at market to come back on the holder's test. Look at what his own distinction does. If the standing sell took them out at 1176 to 1195, he calls that a range trade that worked, and that money goes back through the normal doors. If the order never filled and we sold at market, lower, those shares get the easier door.

So the range trade that failed gets a faster way back than the one that succeeded. That's backwards. Those shares were bought knowing they'd have to be sold before the print, and my neutral colleague built the standing sell for exactly that reason. They were range money from the start, and range money comes back through the doors, however it left.

Last, the deadline. My aggressive colleague wants the excess carried through the Fed and the remainder sold on the close before the print. He says a market sale before the decision is what I warned against in the first round. What I warned against was leaving the trim to the last session and selling at whatever price was there.

The deadline isn't the plan; it's the backstop. The plan is a standing sell into 1176 to 1195 that works for up to seventeen sessions before the decision. Selling into strength never gets frozen. If the stock hasn't reached the top of the range in seventeen sessions, holding two more isn't selling into strength. It's waiting to see whether the Fed reads the payroll report the way the bond market did, with shares we've already decided not to own. Two extra sessions don't change the price we should expect. They just add the decision and the press conference to the outcome.

He says the Fed doesn't gap us, because it announces at 2 p.m. with the 1065 backstop live and the 1090 close behind it. For new money, a 3% Fed-day slide trips neither, and it can take more than the standing order was reaching for. For a holder, the excess is core, and the core has no 1090 and no 1065. Its line is 979.50.

And between the decision and his deadline sits the GDP release, before the open on the 29^th. He told us the gap cap exists because a closing stop can't protect you through an overnight gap. The GDP release is an overnight event.

Then there's the date, which none of us has confirmed. Every day the technical report reads as an earnings day fell on a Wednesday or a Thursday: last October 30^th, February 4^th, April 30^th and August 5^th. This October 30^th is a Friday. If Lilly keeps its habit, the print moves to the 28^th or 29^th, or into the first week of November.

If it's the 29^th, his "close before the print" is the FOMC close. That means selling at whatever price the Fed leaves, on the very eve he says he wants to avoid. "Before the FOMC or the print, whichever comes first" is the only version that doesn't depend on a date nobody has checked.

So here's where I land: Buy, as the trader structured it, at the risk the plan already set.

Before the print, the starter fills in its band with no chase. The floor tranche carries every veto, the volume test and the flush cap. The post-CPI checkpoint runs on the agreed terms.

On Monday we read the 10-Q, confirm the Q3 and ObesityWeek dates, and pull like-for-like consensus and the implied move. Until the date is confirmed, the FOMC decision is the deadline. The gap cap is the larger of 10% or one and two-thirds times the implied move, marked to market. Excess sits on standing sells into 1176 to 1195. Anything unfilled goes before the FOMC or the print, whichever comes first.

After the print, nothing goes in on the report-day close. Above the top of the band, the quarter confirms. Inside it, the quarter confirms at or above like-for-like consensus. Below $9.08, or inside the band without a usable consensus, the breakout route decides: a next close above 1217.65 on above-average volume, with the report-day low intact.

Open risk is measured mark-to-market everywhere, so the full position completes as volatility allows. The overweight waits for a real beat, a clean 10-Q and a calmer tape.

Holders restore trimmed shares only on a close above 1090 and the 200-day, with the report-day low intact and nothing broken. If costs ran hot, they also wait for the 10-Q. Floor shares the cap forced out come back through the normal doors.

Exits are unchanged: the 1090 close, the 1065 backstop, no adds below the 200-day, and a full exit below 979.50 or on a broken quarter.

My aggressive colleague says his job is to make sure the plan gets paid when it's right. Fair enough. Mine is to make sure that when it's wrong, it's wrong by an amount we agreed to, measured the same way every time. A door that opens on any green day, a budget that forgets the shares we already own, and a restore that buys below the line where the stop just sold don't make the plan bolder. They make it carry risk nobody priced. Close those gaps, and the firm owns the stock it likes without being surprised by how much of it it owns. Conservative Analyst: Let me start by paying what I owe. My aggressive colleague named three of my rules last round, and he was right about all three.

The first is the door into the full position. It shouldn't hang on the Street's number. In round three I said the slice above a full position is the bet that the quarter beat what the market expected. Then last round I put that same bet in front of the full position. If consensus carries acquired research that our test strips out, the full position depends on whether we can rebuild someone else's arithmetic. That filters data hygiene, not the business.

So I'll take my neutral colleague's door. The full position needs $24.6 billion of revenue and earnings, excluding acquired research, that clear two bars: $9.08, and what Q2 would have earned at Q3's own gross margin on the same basis. That's my own principle, no like-for-like step back, measured on one ruler. Consensus goes back on the overweight, and the overweight is off this quarter anyway because the stop math doesn't fit.

The second is the risk ruler. My neutral colleague is right that I wrote it as continuous and everywhere, and both words break it. Continuous trims a position for working, or because ATR jumped after a good print. Everywhere cuts every holder to about six shares. So marked-to-market risk to the stop we actually hold limits every add, and it never forces a sale.

The third is the restore. He caught my arithmetic running backwards: restoring at 1090 leaves more distance to 979.50 than restoring at 1065, not less. The real case for the 1090 condition is information. A close back above the plan's own stop says the market reversed the gap. I'll write that reason down instead of mine. He's also right that the 200-day condition on the restore is redundant, so I'll drop it there and use the 200-day where it does real work, which I'll come to.

I'll take the rest as well. The restore is a restore, not an add. The breakout volume bar is the pre-print 20-day average, and the route stays open past the second session. The deadline runs through the morning of decision day, and anything left goes before the 2 p.m. statement, or before the print if that comes first. And "upper half of the range with a stop in its middle" describes every door below 1217.65, not just the one I was attacking.

That leaves my aggressive colleague's two amendments, the ceiling and the breakout definitions. It also leaves three threats nobody at this table has priced: what the new door can't see, what a holder's core is actually risking, and the first week of November. The second one is bigger than anything we've argued about since the first round.

Start with the ceiling. He wants Q2's underlying costs to count as no less than 44.6% of revenue, "the lowest ratio in our six quarters." His worry is that a $3 billion acquired-research line would put Q2's running costs at 41.8% and push the bar to $10.58. That's a 38.4% net margin, "above the best quarter we have at 37.4%." He says the fundamentals report tells us what normal looks like: 45 to 48%.

Every one of those benchmarks is a reported number with deals inside it. The 44.6% is Q1 with whatever acquired research Q1 carried. The 37.4% best quarter is reported. The 45-to-48% range is the fundamentals report describing reported costs, ordinary deal flow included.

Since the first round, all three of us have treated four charges in twelve quarters as how Lilly does business. If that's true, an ordinary quarter's cost ratio sits lower once its deals are stripped out. So a stripped Q2 coming in under every unstripped quarter isn't a record. It's what a stripped number looks like next to unstripped ones. His cap compares a charge-free quarter with charge-laden history and calls the gap a fluke. That's the mistake I had to own with $9.70, coming back from the other side.

His own test case has the same flaw. His ordinary quarter has 13.1% sequential growth, an 83% margin and costs at 48%. It earns $10.17 and fails a $10.58 bar. But that 48% dates from round one, when every cost figure we had was reported, deals included. Measure it the way the test measures, and Q3's own deals come out too. On $26 billion of revenue, it takes only about $360 million of Q3 acquired research to bring his ordinary quarter up to $10.58, uncapped. That's roughly an eighth of the line he's worried about. The case he said should bother both of us fails only because it treats a reported number as a stripped one.

He also says nothing about the business differs between those two verdicts, only the size of a charge in the quarter before. But Q2's total costs below gross profit are fixed at $12.6 billion. Every dollar the 10-Q puts on the acquired-research line is a dollar the ongoing business didn't spend. A $3 billion line instead of $2.4 billion means Q2's running costs were $600 million lower. That is the business differing. The size of the charge isn't noise on top of the measurement. It is the measurement.

And the test doesn't ask Q3 to repeat a record ratio. It asks Q3 not to earn less. Take his own $3 billion line. At an 83% margin, a $24.6 billion Q3 can spend about $1.35 billion more than Q2's running costs and still pass. That's 14% more spending on 7% more revenue. Its stripped cost ratio can run up to 44.6%, the very number he wants as Q2's floor. The quarters that fail at 45 to 48% are quarters where running costs rose 15 to 23% on 7% revenue growth. Spending outran revenue two and three times over, which is exactly what tranche three exists to catch.

He also offered to keep saying 31 times earnings rather than 25, so a $3 billion line doesn't flatter the valuation. That's generous in a speech and free in a rule. Nothing in our plan triggers on the multiple we quote. Everything triggers on the bar. He's trading a concession in what we say for a change in what we buy.

If his real worry is that Q2's running costs were unusually low for a one-quarter reason, I'll meet it on one ruler. The Q2 10-Q has a six-month column and prior-year comparisons. So it gives us the acquired-research line for the first two quarters of both this year and last. If Q2's stripped ratio comes in below the lowest stripped ratio among the other three, use that lowest one for the bar. If none of those quarters carried deals, that's his 44.6%, and he gets exactly what he asked for. If they carried some, the cap comes out lower and the bar stays honest.

The rule that matters more than either version is this: write the bar down Monday. The 10-Q is on file. Once we've read Q2's acquired-research line, net of whatever tax effect the filing shows and treated the same way for both quarters, Q2's running costs are a known number. The bar becomes a simple schedule against whatever gross margin Q3 prints. Write that schedule down before anyone sees Q3. For four rounds we've redrawn this bar against report days we'd already seen; let's draw it once against a quarter we haven't. If it looks extreme, we argue about it Monday, not on the morning of the print.

The first threat is something the new door can't see, by design. We strip the cost of buying pipeline out of the earnings test because the test asks whether the franchise is working. Fine. But the deals don't vanish. Q2's $15.4 billion investing outflow came with $23 billion of new liabilities, and the current ratio fell to 1.35. The fundamentals report gave us 1.3 as the level to watch.

So if Q3's acquired-research line is bigger than Q2's, the full position also waits for the 10-Q and a current ratio of at least 1.3. Until then it's an in-between quarter, and the breakout route still works. The condition is narrow and it's the report's own watch level. Without it, the door is blind to the very thing we chose to exclude.

Now the breakout definitions. I accept both, with one fix. He wrote "any close above the line." Pin it to the number. The daily SuperTrend line only ratchets down while the trend is down. The technical report showed that 1217.65 is just the 9/11 bar's midpoint plus three ATRs. A report day that gaps down toward 1060 drags that line into the 1170s or so. Then "a close above the line" fires inside the 1176-to-1197 cluster where every rally since late August has stalled, on a bounce after a weak print.

That's the door we just shut on the green-day close, reopened by an indicator's arithmetic. The trader wrote a number, 1217.65, and it sits above the 1215 rejection high. That's the range top, which was the whole point. "Any later close" is fine. "Above the line" has to mean above 1217.65.

The second threat came out of my neutral colleague's own arithmetic. To show my "everywhere" rule was wrong, he measured a full core against its only price exit. Twenty shares at Friday's close against 979.50 is about $3,300, or 3.3% of the book. He's right that the ruler shouldn't sell those shares. But look at what he found. The plan's standard is 1% per name, and for anyone holding a full position, the risk to the core's only price exit is more than three times that.

In round three I listed our selling rules as the 1090 close, the 1065 backstop, the weekly line and a broken quarter. For holders, that list jumps from a broken quarter straight to a line 14% below. I missed it too, until he put a number on it.

This isn't a remote risk for this stock. LLY fell 23% between its February report-day close and April 29^th this year. And the restore makes it live. We've just agreed holders go back to full size on the first close after the print. That's days before Novo's Q3, the October jobs report and ObesityWeek, where the EloraTZP tolerability data gets its full airing.

Before the print, holders carry the full core through CPI. Now take the macro report's bear case, with real yields through 3% and high-yield spreads through 3.5%. Our vetoes stop new money from averaging down. They do nothing for the core, which sits there with nothing between it and 979.50.

My aggressive colleague's put-spread analogy makes the point for me. He says the restore is the put spread we couldn't buy, so the holder who sold should end up like the holder who hedged. Fine. But the hedged holder's spread expires with the print. The morning after, both own twenty shares with no stop above 979.50. The analogy doesn't show the restored core is protected; it shows neither one is. He's right that insurance shouldn't outlive the event. Protection shouldn't end with it either.

So give the core a stop, at the level the technical report itself names. For holders, it says, "a close below the 200-day is the first real warning to the long-term trend." On a daily close below the 200-day, around 1075 to 1085 through late October, holders trim the core to the size that risks 1% of the book to 979.50. That's about ten shares.

This isn't the ruler selling anything. It's a stop, and we agreed exits are what stops are for; the ruler only sets its size. The trimmed shares come back the way the trader already wrote for tranches one and two after a stop: a reclaim of 1115 with the same confirmations, or a confirmed quarter. That door is already on the page.

Price it. If a slide through the 200-day keeps going to the weekly line, the trim saves about $1,000 on ten shares. If it's a shakeout and LLY reclaims 1115, the round trip costs 30 to 40 points on ten shares, or $300 to $400. It only fires after new money is already out at 1090, so it's the second line of defense, not the first.

The third threat is the first week of November, which every version of this plan walks into with no rule at all. We agreed the rolled slice waits until after ObesityWeek. But the pullback half buys the first pullback within two weeks of the print, and that window runs straight through Novo's results, the jobs report and ObesityWeek. A pullback into the full EloraTZP presentation is exactly what that rule would buy, on the very detail the tape seemed to punish on Friday.

My neutral colleague's ruler measures risk to the closing stop we hold. That's the right measure in a quiet week. It means nothing on a morning when Novo has reported before our open, or payrolls land at 8:30.

My aggressive colleague gave us the principle himself: waiting is cheap when the event is small. So apply it. No new-money buy below 1217.65 in the two sessions before Novo's Q3 or the EloraTZP presentation, the same freeze we wrote before CPI. Restores are exempt, because they're core. Once the events pass, the pullback half and the rolled slice go in on their own rules.

So here's where I land: Buy, as the trader structured it, at the risk the plan already set.

Before the print, nothing changes. The starter fills in its band with no chase. The floor tranche carries every veto, the volume test and the cap on heavy-selling days. The post-CPI checkpoint runs on the agreed terms, with the freezes before CPI and from the FOMC.

On Monday, we read the 10-Q and write the bar down: Q2's acquired-research line, treated the same way for both quarters, with any cap measured on that same basis. We confirm the Q3, Novo and ObesityWeek dates, and pull consensus and the options-implied move. The gap cap is the larger of a 10% move or one and two-thirds times the implied move, marked to market. Excess sits on standing sells into 1176 to 1195 through the morning of decision day. Anything left goes before the 2 p.m. statement, or before the print if that comes first.

After the print, nothing goes in on the report-day close. The full position confirms on $24.6 billion of revenue plus stripped earnings that clear both $9.08 and Q2 restated at Q3's gross margin. If Q3's acquired-research line is bigger than Q2's, it also waits for the 10-Q and a current ratio of at least 1.3.

Otherwise the breakout route decides. That means any later close above 1217.65, the number rather than the indicator's line, on volume above the pre-print average, with the report-day low intact. Every add fits inside 1% of the book, marked to market against the stop we hold, and nothing gets sold because that number grew. No new-money buys below 1217.65 in the two sessions before Novo's results or the EloraTZP presentation. The overweight needs a same-basis beat, a clean 10-Q and a stop that fits, which means next quarter.

Holders restore trimmed shares on the first close after the print that holds the report-day low, closes above 1090 and breaks nothing. They wait for the 10-Q only if costs ran hot and the jump isn't on the acquired-research line. Floor shares come back through the normal doors. Every share whose only price exit is 979.50 gets the 200-day trim to 1% at risk, with the trader's own re-entry rule.

Exits otherwise stay as written: the 1090 close and the 1065 backstop for tranches one and two, no adds below the 200-day, and a full exit below 979.50 or on a broken quarter.

My aggressive colleague closed by saying the plan now loses only amounts we've agreed to. For new money, after this round, I think that's true. For anyone who already owns LLY, it isn't. The core risks more than three times our standard to its only price exit, and the restore we've all signed sends it back to full size right before the busiest week of the quarter. The pullback half buys into that week on a stop that can't see an overnight headline. And the bar that releases the most new money can still be loosened by setting a stripped quarter against unstripped history.

So measure the bar on one ruler and write it down Monday. Make the breakout mean the range top. Let the small events pass before new money goes in. And give every share the firm owns, not just the new ones, a stop at a loss we've actually agreed to take. That isn't a smaller Buy. It's a Buy whose worst case we can state before it happens.

Neutral Analyst¶

Neutral Analyst: Let me start by shrinking this argument to its real size, because I think both of you are fighting harder than the numbers justify. You both accept the Buy, the 1090 stop and the gap cap. Holdings weren't provided, so I'll use the desk example. Everything scales except one thing I'll come to.

Once the gap cap binds, nobody carries more than about eight or nine unhedged shares into the Q3 print. My aggressive colleague's version always gets there. The plan gets there only if the floor tranche fills. My conservative colleague's version, with his extra vetoes, will probably sit at five. So before the print, the real disagreement is three or four shares, about $200 of risk to the stop, plus the CPI and FOMC exposure that comes with them. The bigger questions are how we reach that number and what we do after the print. On both, each of you has something right and something wrong.

Start with Q3, because you both lean on it and neither of you checked the plan's test against our own history. Set revenue aside and take the two bars that translate cleanly to past quarters: gross margin of at least 83%, and costs below gross profit of no more than 50% of revenue. Across the six quarters in the fundamentals report, the two were met together exactly once, in Q2 of 2025. The margin bar was met in two quarters and the cost bar in three.

None of the four quarters behind the report days my aggressive colleague keeps citing would have passed. Q3 of last year narrowly missed both. Q4 missed on margin. This year's Q1 missed on margin. Q2 missed on costs. The stock rose 3.8, 10.3, 9.8 and 4.9 percent on those days anyway.

That cuts both ways. For my aggressive colleague, "take the minimum confirmed thresholds literally" doesn't describe a minimum. An 83% margin together with 50% costs is a combination LLY has delivered once in six quarters. Even on EPS alone, the 33% net margin behind his $9.08 showed up in three of six. That's a coin flip on margins, not "how little has to go right." By our own rules, the likeliest label for Q3 is in-between.

For my conservative colleague, a test that would have kept us out after four straight rallies is a filter, not a forecast. If tranche three depends entirely on it, the plan probably never gets past half size this quarter. Remember that when he stacks more vetoes onto the other routes in.

Then the multiple. Holding 38 times fixed while trailing earnings catch up has already failed once this year in our own data. Before the April report, LLY closed at 848.53 on trailing EPS of $22.95, about 37 times. The quarter was enormous year over year, and the stock jumped 9.8%. But a $3.06 quarter rolled off, trailing EPS jumped 23% to $28.15, and the stock closed near 33 times. Holding 37 times would have predicted about 1,040. It closed around 932. In August the same method came within about 1%, but it overshot both times. This quarter's step-up is about 10%, in between. So 1,253 is the optimistic end of an adequate quarter, not the middle.

But my conservative colleague takes that April multiple of 33 and puts it on Q3 to get 1,080. That's the year's low multiple, set in the one quarter where trailing EPS jumped 23%. This quarter's step-up is less than half that. His 1,080 is a stress test, not a central case. An adequate quarter lands somewhere between his stress case and the aggressive's optimistic one, and real yields pick the spot. That's why the CPI print should drive sizing more than either point estimate.

Valuation works the same way. Each of you took the end of the range that suits you. Suppose I annualize Q2's revenue but use trailing-average margins and costs. Those costs include about one charge-heavy quarter a year, close to the four-in-twelve frequency my conservative colleague counted. I get about $34.40 a share. That's roughly 33 times at 1143: cheaper than 38 trailing, dearer than 27.

And comparing a 3.6% earnings yield to a 2.88% TIPS yield ignores growth. For a business compounding like this, the earnings yield isn't the return. The real lesson is the one both reports give: this is a long-duration stock whose price moves with the discount rate. That argues for staging, not skipping, and not doubling.

Two more for my aggressive colleague. His 2.6-to-2.8-to-1 pairs a range trader's stop with a trend follower's target. If this is a range, the target is the upper band, about 52 points up against 53 down, roughly even. If it's the weekly trend, the stop is the weekly line at 979.50. Then 137 to 150 points of upside against 163 of risk is under one to one. Neither frame gives you 2.7 to 1 from 1143. The only place the range math really works is the floor, which is why the plan waits for it.

On doubling the starter, my conservative colleague is right. The gap cap unwinds the extra shares before the print, so the doubled starter really buys CPI and FOMC exposure, with TIPS 12 basis points from the veto. That isn't really an LLY bet. It's a real-yield bet, and on most books it stacks on top of every other long-duration name you own. And the rate turn my aggressive colleague describes hasn't shown up yet in the series he blames. TIPS is only five basis points off its peak.

The hedging workaround also fails on contract size. One listed option covers 100 shares, roughly $114,000 of LLY. At the desk-example scale, that's more than the whole book and five times the full 1.0x target. You can't put-spread eight shares. A call spread isn't "part of tranche three"; on notional, it's five times the entire position. If your full allocation runs to a couple of hundred shares, options become a real tool, with a live quote and the premium inside the 1%. Below that, you meet the gap cap by selling.

And when he leans on the macro report's line that quality stocks hold up relatively well if credit stress spreads, read the rest of it: the stock can still fall in absolute terms. Our stop is absolute.

Now where he's right, and where I part with my conservative colleague. The OBV veto is broken, and the conservative's own arithmetic shows it. To make his OBV point, he had to strip out one expiration day, 4.54 million shares on a 49-cent gain. A fixed line that one session can move by four and a half million shares can't be a hard veto. From 345.81 million there's about 8 million shares of room above 337.85, which is three or four ordinary down days.

Worse, it measures the wrong thing. A one-day, 4-million-share flush into 1115 would pass it. A four-day drift on normal volume would fail it. The flush is the bearish one. But the test he described in words is a good one: whether the third test comes on heavier selling than the second. So write that test instead. The slide into the floor has to average lighter volume than the 2.44 million shares a day of the slide into 9/11. That keeps his smoke detector and stops it from going off every time someone makes toast.

That matters because of the bigger problem with the conservative version. Each condition in it is reasonable alone: the floor price, the RSI divergence, OBV, TIPS, high-yield spreads, the 10-Q read, the date, and the freezes around CPI and the FOMC. Stacked, they're also correlated. The days LLY reaches the floor are the days rates and spreads are most likely moving against us. So the floor tranche probably doesn't fill.

He says the plan carries up to eight or nine shares into the print. That's only true if the floor fills; under his rules, the likelier number is five. Add a confirmation bar that would have failed after each of the last four reports, and a very plausible path is a quarter-size position into November in a stock this desk rates a Buy. That isn't a staged Buy anymore. It's a Hold waiting for permission.

And where his version does buy, it buys in the riskiest window. Unfilled floor slices roll into tranche three, so up to three-quarters of the position goes in during the two weeks after the print. February's report day gained 10.3% and gave back 7.8% the next session. That quarter wouldn't have passed our test either, but the pattern is the point. A tranche bought after that first close, with its stop just under the report-day low, would likely have been stopped out the next day. Confirmation doesn't remove risk. It moves it to where February showed it can bite.

On "the market isn't paying for good news": Friday's close in the bottom 22% of its range, after trading up to 1164.92, was a real tell, and I take it seriously. But the Jaypirca approval hit around 3:15 Eastern, with forty-five minutes of trading left. Monday is the first full test, and the plan already lets Monday's close decide the starter. Don't convict on one hour, and don't chase on one day.

Where the conservative is right, I'm with him: The 9/30 close is the vote. Charges in four of twelve quarters aren't one-time. The rate relief is thin. Buying at 1165 means 75 points of risk to the stop for about 30 points to the upper band. The Q2 10-Q is already on file, so read it before tranche two. Confirm the Q3 date. Freeze floor fills in the two sessions before CPI and from the FOMC decision through the print. Add the 1065 intraday backstop. Existing holders above the gap cap should sell the excess into a 1165-to-1195 bounce, not on the eve.

As for his warning about splitting the difference, I'm not touching the gap cap. It's arithmetic, and I accept it. What I'm changing is how we reach it, and whether our filters measure what they claim to. So keep the Buy, the 0.25x starter in the 1136.66-to-1151 band from Monday, the 1090 closing stop, the gap cap, and the conservative's 10-Q, date, freeze and backstop rules. Then make four changes.

First, fix OBV as I described. Keep the close back above 1115, RSI above 35.5, TIPS under 3% and high-yield under 3.5% as hard conditions for adding. They're conditions for adding, not reasons to sell shares we already hold.

Second, add one post-CPI checkpoint. It applies on any close between the CPI print and the FOMC decision, if all of these hold: core CPI came in under 0.3% for the month, TIPS is under 3% and high-yield is under 3.5%, and LLY sits above the 1107-to-1118 floor zone but below the 50-day, near 1171 by then. If they do, whatever the starter and floor haven't filled can go in. At the floor itself, the floor rules still govern.

Size the add so total open risk to 1090 stays within the roughly $440, or 0.44% of the book, that the plan already budgets for tranches one and two, and keep unhedged shares under the gap cap. That's not new risk. It's exposure the plan already intended, reached through information instead of a perfect price. If core is 0.3% or more, or TIPS is at or above 3%, nothing more goes in before the print.

That's also my answer to my aggressive colleague's question about what a quarter-size position earns if the floor never comes. Not enough, which is why there should be a second way in. But that way opens after CPI, not today in the lower middle of the range.

Third, make the breakout route explicit after the print. On an in-between Q3 with no broken-thesis trigger, a daily close above 1217.65 on above-average volume releases tranche three, half on that close and half on a pullback, the same as a confirmed quarter. The plan already names that close as an upgrade trigger. Since none of the last four quarters would have passed our confirmation test, the price route has to be able to do the work.

Fourth, keep the rolled-over floor slice out of the first days after the print. Buy tranche three's 0.40x as written. The rolled slice waits until the report-day low has held on a closing basis for five sessions.

So my aggressive colleague is right that this plan can end up owning too little of a stock it likes, and my conservative colleague is right that it can't own too much into a gap. The fix for the first isn't more size today; it's more than one way in. The fix for the second isn't more vetoes; it's vetoes that measure what they claim to. Buy LLY at the risk the plan already set, with entry routes that don't depend on one perfect price or one perfect quarter. Neutral Analyst: Both of you moved this round, so let me bank that first. My aggressive colleague dropped the doubled starter and the option structures and accepted the gap cap. My conservative colleague dropped the compounding argument and took the volume test, the five-session rule, the breakout route and the post-CPI checkpoint. Everyone now agrees on the 1090 close, the 1065 backstop and selling to meet the cap. What's left comes down to two questions: what opens the door after the print, and what we own if LLY runs before CPI. On the first, the data settles it against both of you. On the second, you're each half right.

Start with the door, because that's where the money is. Last round I said none of the four rallied quarters would have passed the plan's margin-and-cost test. It's worse than that. The one quarter in our data that cleared both profit bars, Q2 of 2025, grew revenue 37.6% year over year. That's below the 40% the $24.6 billion bar was built to represent. So on the plan's own definition, the full three-part test passed in none of the last six quarters. Even translated sequentially, it passed only once.

The only quarter that cleared both profit bars is the one that missed the growth bar. That isn't bad luck. This business trades growth, gross margin and spending against each other from quarter to quarter. A test that demands all three at once is waiting for a quarter Lilly almost never prints.

My aggressive colleague's answer is to drop the profit bars and confirm on revenue. My conservative colleague's example settles that. Take $24.6 billion of revenue, an 81.5% margin and costs at 52% of revenue. That trips none of the broken triggers, yet revenue rises 7% while earnings rise 2%.

Revenue isn't quite the given he says it is. Q1 grew only 2.6% sequentially, and Q3 has the hardest comparison of the year. But he's right that revenue is the least uncertain of the three questions, which is exactly why it can't carry the test alone. Confirming on that quarter and putting up to three-quarters of the position to work isn't unlocking a door. It's taking it off the hinges.

But my conservative colleague oversold the case against it. He says the February entry was 23% underwater by April 29^th. It wouldn't have been there. Every version at this table, the plan included, puts the stop just under the report-day low once tranche three goes in. The next session closed 7.8% lower, well below that day's open, so that entry was almost certainly out on day two.

Count the three entries we can price by size, not by number:

February costs about 8%.

August is a small loser: 2% if it's still held, a few points more if the stop took it in September.

April is up about 23% from its report-day close.

Net, that's around ten points or better. It's only three trades. And he's right that April started at 33 times trailing earnings after a 23% fall, a starting point we don't have today. But "one win against two losses" isn't the picture either. Small capped losses and one big gain is what a trend entry is supposed to look like.

So here's what I'd put in its place. Collapse the two profit bars into the one number they were always protecting: net margin, the share of revenue left after every cost. The plan's 83% margin and 50% cost bars together imply 33%. So the test becomes $24.6 billion of revenue and at least a 33% net margin, excluding acquired in-process R&D if the company itemizes it. On $24.6 billion, that's about $9.08 a share. Every broken trigger stays exactly as written, including the 81% gross-margin line. That's the pricing check my conservative colleague wants.

Now run it back over our history:

Q4 of last year passes at 34.4%.

Q1 of this year passes at 37.4%.

Q2 passes at roughly 38 to 41% once the charge comes out, using the fundamentals report's own adjustment. That holds only if the 10-Q shows the charge was acquired research.

Q3 of last year fails at 31.7%.

The $8.12 quarter fails at 29.5%.

So the bar opens for three of the four quarters the market rewarded, and it stays shut on the one real miss anyone has put on the table. That's what a filter looks like.

Exclude the charge for the test, because the test asks whether the franchise is working. Keep it in the valuation, because my conservative colleague is right that four charges in twelve quarters is a cost of doing business.

Then layer his next-close rule on top, which I support. Nothing goes in on the report-day close. The earliest buy is the next close, and only if the report-day low has held. On the three quarters we can price, that combination very likely takes April and sidesteps February.

I'll note the rule rests on one episode, the same small-sample objection he raised against the four rallies. But it costs only one session, so it's worth having. It also exposes a hole in the plan as written. The second half of tranche three buys the first pullback within two weeks, then moves the stop under the report-day low. In February that pullback came the next day, almost certainly below the report-day low. The plan would have bought the second half under its own stop. That half needs the report-day low intact too.

Underneath the overweight sits a question neither of you can settle with what's on the table: is $9.08 a beat? My conservative colleague says 28 times forward means $10.20 a quarter. That's the year divided by four, which assumes Lilly doesn't grow inside the year. My aggressive colleague says $9.08 grows into $40.80 at 8% a quarter, which compounds to about 36% a year.

The plan's own PEG of 1.1 to 1.2 at 28 times implies growth in the mid-20s. On that path, the first quarter needs about $9.40. So $9.08 is in line to slightly light: neither a miss nor a beat. That's enough to finish the 1.0x, because there the question is whether the franchise is intact.

It isn't enough for the 1.25x. The overweight should need a real beat, and none of our reports has the consensus number that defines one. So the overweight needs three things: the consensus number, the 10-Q and a confirmed quarter. A revenue number and a footnote won't do it.

My conservative colleague is also simply right that the post-print buying had no budget, so let's give it one. After the print, total open risk to the new stop under the report-day low stays inside the same 1% of the book. The desk sized twenty shares on a stop about 48 points away, one and a half ATRs. If the report day leaves its low farther below your entry than that, you buy fewer shares, not the same twenty with more risk. The 1.25x only fits inside 1% if that stop is within about 40 points. A wide report day doesn't lock the door. It shrinks what fits through it.

Now the multiple, where you're doing the same thing from opposite ends. My aggressive colleague takes February's report-day close and gets 1,217. My conservative colleague takes February's next close, or April, and gets 1,110 to 1,125. You're each picking which February to believe.

On all four report days the trailing multiple fell, by anywhere from about 1% to about 22%. The 22% was the quarter a charge rolled off. There's no typical. If you insist on a center, the midpoint of your two answers is about 1,170. That's within two points of the August report-day close and a few points from the 50-day. So the central case for an in-between quarter is more of this range. That's why the breakout route exists. It's neither the typical outcome nor a long shot. It's the market grading the quarter we can't grade ourselves.

My conservative colleague made the deeper point himself: the biggest jump in trailing earnings got the smallest move. Trailing arithmetic doesn't price this stock on report day; expectations do. We're missing consensus, and we're missing the one number that would replace most of this guessing: the options-implied move into the print.

We agreed last round that one contract covers a hundred shares and doesn't fit a desk-scale book. But you don't have to trade an option to read one. The gap cap rests on a 10% assumption pulled from four report days. If the options imply about 6%, a 10% stress is a sensible tail. If they imply 9%, then 10% is barely an ordinary report, and the cap is too loose. Set the cap off the market, not off our sample.

On rates, you've each used the same yardstick when it helped and set it aside when it didn't. My aggressive colleague priced CPI at 2% off a six-week average. My conservative colleague showed that average breaking down in the very week real yields peaked. Then he used it anyway to put the floor near 1117 and the next steps at 1094 and the low 1070s. That's not a gotcha. The honest conclusion is that nobody at this table can price what CPI does to LLY.

That cuts both ways. Anything we own before CPI has to be sized as if CPI can take the stop, and the 1% already does that. It also makes the post-CPI checkpoint worth more than either of you is treating it as.

My aggressive colleague's best line this round was that waiting is cheap when the event is small and expensive when it's big. That's the case for the checkpoint. It's how we get toward the cap before the expensive event, using what we learn from the cheap one. And the more we own going in, the less we have to buy in the February window coming out.

So the checkpoint's conditions matter. My conservative colleague is right that "TIPS under 3%" lets a 0.29% core print through even with real yields jumping from 2.88% to 2.97%. But requiring TIPS to close below its pre-print level turns the test from benign into bullish. An in-line core print with real yields up two basis points on an oil headline would fail it. The checkpoint is meant to let in exposure the plan already intended once the event passes without damage.

So use a tolerance. The checkpoint opens only if:

core comes in under 0.3%,

TIPS is under 3% and no more than about five basis points above its close the day before CPI,

and high-yield spreads are under 3.5%.

That last condition dropped out of my conservative colleague's summary, and with spreads 26 basis points from the alarm it belongs back in. Five basis points is about one ordinary day; it's the move from 2.93% to 2.88% last week. That blocks his 2.97% case without failing on noise.

On the floor veto, my conservative colleague has the better argument. My aggressive colleague says the TIPS veto and the floor cancel each other. By his own yardstick, TIPS at 3% puts the stock near 1117. That's a knife-edge, not a cancellation. At 2.99% the floor fills. Past 3%, we're halfway into the macro report's own bear case, and declining to average down there is the veto doing its job.

Now the path my aggressive colleague worries about, where LLY pops on Monday and keeps going. The hole is real, and it's bigger than he described. The starter band is only about 1.25% wide around Friday's close, and the skip line at 1136.66 is about a fifth of an ATR below it. An ordinary down Monday skips the starter and sends its money to the floor. An ordinary up Monday parks it. So a lot of paths run through the checkpoint, and as I wrote it, the checkpoint stops at the 50-day.

But his fix breaks his own rule. He told us he'd wait for CPI but not for the report, and a Monday chase above 1151 isn't waiting for CPI. Monday also hasn't settled the good-news question for either of you. My conservative colleague says the market weighed one tolerability detail over an FDA approval. It never got to weigh them against each other. The tolerability story circulated through Friday's session, and the approval arrived with forty-five minutes left. Monday is the first session that prices both. The plan already lets Monday's close set the starter, so neither of you should be calling the result in advance.

My conservative colleague's objection misses something too. He calls 1165 a worse trade with the same $265 at risk. It's a worse price. But fixed dollar risk means fewer shares: three and a half shares at 1165 carry about 30% less exposure to a CPI or earnings gap than five at 1143. When the dollar risk is fixed, a worse price shrinks the position on its own.

So split the budget by what each slice was for. No Monday chase. At the post-CPI checkpoint, if those conditions pass, the first $265 of unfilled budget, the starter's share, can go in on any close below the daily SuperTrend line at 1217.65. Above that line, the plan's upgrade trigger takes over. Everything else keeps the 50-day ceiling. I wrote that ceiling, and my conservative colleague is right to keep it for the floor money.

The starter was always participation money. The floor slice was always price money. At 1190, $265 buys about two and a half shares. That's what owning a Buy-rated stock costs in the fast-bull path, and it gets bought after CPI rather than on one day of news.

Three smaller things.

First, I'll take my conservative colleague's flush cap: no down day in the slide heavier than about 3.4 million shares, or the floor buy waits for a second close above 1115. But hold it to the standard he used on OBV. He stripped the 9/18 expiration session out of his volume math. October's expiration is Friday the 16^th, a day or two after CPI, right as the pre-CPI freeze lifts. Exclude it from the cap.

Second, the floor route overshoots the gap cap. Starter plus floor is about twelve shares, and the cap is eight or nine. So the plan buys three or four shares at the floor that it has to sell before the print. Put a standing sell on those at the top of the range, 1176 to 1195, so they come off into strength. That's the same way my conservative colleague wants existing holders to trim. Sell at market the day before the print only if that order hasn't filled.

Third, correlation. My conservative colleague's best new argument is that a hot CPI hits every long-duration name on the book the same morning. True, but we don't know the book, and it cuts both ways. LLY is long-duration, but it's also non-cyclical. The macro report expects it to hold up relatively well if credit stress spreads, and in 2022 it rose 32% while the S&P fell 19%. If the rest of your book is long-duration growth, count LLY's pre-print shares against a shared rate budget. If the book is cyclical, LLY is partly the hedge, and the per-name 1% is the limit that binds.

On the balance sheet, you're each quoting a different base. My aggressive colleague compares with a year ago; my conservative colleague compares with last quarter. Both are true. The 10-Q we've all agreed to read Monday tells us which one is the trend.

So here's where I land: Buy, at the risk the plan already set, with my conservative colleague's protections and my aggressive colleague's insistence that the doors actually open.

Before the print, the rules are:

The starter goes in within its band, with no chase.

The floor tranche needs the RSI condition, TIPS under 3%, high-yield under 3.5%, the volume test and the flush cap, with expiration day excluded.

The post-CPI checkpoint uses the conditions I described. The starter's $265 can go in up to 1217.65, and the rest stays under the 50-day.

Floor fills freeze in the two sessions before CPI and from the FOMC through the print.

Read the 10-Q Monday, confirm the Q3 date, and pull consensus and the options-implied move before setting the cap.

Sell the floor tranche's excess into strength.

After the print:

Confirmation uses one earnings bar: $24.6 billion of revenue at a 33% net margin, excluding acquired R&D. The broken triggers stay unchanged.

The breakout route covers an in-between quarter.

Nothing goes in on the report-day close, and the pullback half goes in only above the report-day low.

Total risk to the new stop stays inside 1% of the book.

Existing holders who trimmed rebuy through the same two doors.

The overweight needs a real beat, a clean 10-Q and a stop close enough to fit.

My aggressive colleague is right that a door that never opens isn't caution. My conservative colleague is right that a door that can't stay shut isn't confirmation. This bar would have opened for three of the four rallied quarters, and it stays shut on the one real miss on the table. That gives the firm both. Neutral Analyst: Let me start with what this round settled, because it's a lot. My aggressive colleague gave up the revenue-only door, the Monday chase and the claim that the floor and the TIPS veto cancel each other. My conservative colleague gave up the gross-margin gate, the February overstatement and the borrowing-at-the-peak point. He also took the five-basis-point tolerance and the starter split. What's left is four rules: the confirmation bar, the overweight, freed risk and the gap cap. There's also a fifth that all three of us got wrong two rounds ago. It may matter more to whoever reads this than the other four, and I'll come to it.

Start with the bar, because my conservative colleague landed the best point of the round, and part of it landed on me. He's right that $9.08 was built with charges in, and we're now measuring Q3 with them out. My 33% net margin has the same flaw. It's the plan's charge-inclusive number, and I applied it to charge-free earnings. I'll own that.

But then he wrote two rulers and called it one. His test passes Q3 on GAAP EPS of $9.08. Or, if acquired research comes out of Q3, it passes on matching Q2's underlying $9.70. Run two quarters through it with the same $9.50 of underlying earnings. The clean one has GAAP EPS of $9.50, clears $9.08 and passes. The other carries a dollar-a-share charge, so its GAAP number fails. Strip the charge out and $9.50 misses $9.70, so it fails too. Same business, opposite verdicts, and the only difference is whether Lilly bought something that quarter.

He's the one who told us four charges in twelve quarters is how Lilly does business. His rule makes the business-as-usual quarter clear a bar 62 cents higher. And a clean quarter at $9.30 passes his test while stepping back from Q2 like-for-like. That's exactly what he said a bar must never allow.

Now look at what those 62 cents are. Q2's gross margin was a record 85.8%, 2.4 points above the trailing 83.4%. On $23 billion of revenue, that's about 62 cents a share, the entire gap between your two bars. His $9.70 strips out Q2's cost spike but keeps its record margin. He passed on the top of the fundamentals range because that margin may not repeat, but the bottom of the range has it in too. Normalize both, and Q2 earned about $9.10. That's my aggressive colleague's number, give or take three cents.

Before my aggressive colleague takes a bow, it cuts him just as hard. He keeps that record margin when he values the stock. His 27 to 29.5 times, and his 35 to 36 on trailing earnings, both come from a Q2 with the cost spike stripped out and the record margin left in. Then he drops the margin when he sets the bar. Each of you kept Q2's best feature in whichever number helped your side.

Normalize the same way everywhere, and the stock trades in the low thirties on its run rate. That's roughly where I put it two rounds ago, and dearer than he says. And a flat quarter only has to clear about $9.10, which is easier than my conservative colleague says.

So $9.08 and $9.70 aren't a right number and a wrong one. They're the two ends of a question nobody at this table can answer: was Q2's margin the run rate or a spike?

Above $9.70, the quarter held its ground on any reading, so it confirms. Below $9.08, it stepped back on any reading, so it doesn't. In between, our reconstructions run out. That's where the Street's number should decide, the one we've all agreed to pull Monday. If Q3 lands in the band at or above consensus, it confirms. If it lands below, it's an in-between quarter and the breakout route decides.

And every number gets measured the same way. Q2 and Q3 exclude itemized acquired R&D, and we check whether consensus carries those charges. A Street number with charges in, set against a Q3 with them out, manufactures a beat. That's the same two-ruler mistake in a third place.

There's one more reason not to let either of your histories settle this. My conservative colleague says his rule shuts on last October. That quarter's costs ran 51.2% of revenue, against 47.9% and 48.1% in the quarters on either side. That's the same kind of bump we're calling a charge in Q2. We don't have that 10-Q, so I won't claim it was one. But measured his own ex-charge way, his rule may well have opened there too.

Then his rule passed all four rallies, the same fit to the sample he charged his colleague with. No bar built from four up days can prove it's a filter. That's why the tiebreaker has to come from outside our spreadsheet.

That settles the overweight, and I'll take the hit on my own number. The $9.40 was my reconstruction from a PEG ratio, and it sits below Q2's cost-normalized earnings. A beat that's a sequential decline isn't a beat. So the overweight needs Q3 above both the top of the band and consensus, measured the same way, plus a clean 10-Q. With no consensus, it waits a quarter.

To my aggressive colleague: pulling consensus takes five minutes. You're fighting over a fallback for a case that shouldn't happen. What it guards is the quarter-size above a full position, not the position itself.

On freed risk, my conservative colleague called it pyramiding, but my aggressive colleague capped it at the target. Finishing a position the plan already sized, after a wide report day shrank the first fill, is sizing. My aggressive colleague is right that a wide day should delay the full position, not cancel it. But the conservative's best condition is what makes it safe. The stops on what we already own sit at or above cost first, so the new shares carry the only open risk. Keep that.

Drop the ADX gate, though. Look at when ADX has actually been above 25 in this tape. It happened in the days right after the 8/19 high, and on 9/30, the failed breakout itself. Every reading above 25 since early August came at or just after a top. And we don't have the directional lines to tell an uptrend reading from a downtrend one. A gate that fires at tops is the wrong thing to hang on the one rule that adds risk. Keep his close above 1217.65 instead. That's price confirming direction, which is what the ADX gate was trying to do and can't.

Define the trail too, because his worry about 60-point outside days is real. Trail on closes, under a confirmed higher low, never tighter than one and a half ATRs. That's the stop the desk sized the whole position on. Freed risk only completes the 1.0x. The overweight comes only from its own conditions. Once it's earned, it's sized like everything else: inside the same 1%, with the core's stops at or above cost.

On the gap cap, my aggressive colleague's symmetry sounds fair until you run it through his own evidence. For three rounds he's told us this stock averages a 7.2% move on report day. That's his whole case for holding shares at the close before the print. One and two-thirds times 7.2% is 12%. So a 10% floor isn't my conservative colleague ignoring the market. It's the lenient reading of the aggressive's own sample. He can't argue the stock moves 7% to justify carrying shares in, then size them as if it moves 5.

Add two more things. The macro report flags volatility lagging credit, with the VIX at 16 while spreads widened 51 basis points. And Q3's headline growth will likely be slower than any of the four rallies saw. So the floor stays: the stress is the larger of 10% or one and two-thirds times the implied move. If the implied move comes in at 5%, the whole fight is about one and three-quarter shares at desk scale. That's roughly $145 on an average pop. I'm not asking for 12%, but the floor stays.

Now the one we all got wrong. The trader wrote the cap as open loss plus a 10% gap. For a new buyer that's clear. For an existing holder sitting on a big gain, it isn't. Measured against cost, there's effectively no cap. Measured mark-to-market, the holder cuts a 20-share core to eight or nine. We never said which.

It should be mark-to-market, because a gain given back is still a loss to the book. That's the same logic my conservative colleague used against pyramiding, and it's the honest number.

But look at what we then did to that holder. The trader said to keep the core up to 1.0x. The gap cap gave two tools for the print: put-spread the excess, or sell it and rebuy if Q3 confirms. A hedge keeps the core through an in-between quarter; selling and waiting for confirmation doesn't. At desk scale we took the hedge off the table, rightly, and kept the rebuy rule that came with selling.

My conservative colleague said rebuy on a confirmed Q3 in the first round. I wrote rebuy through the same doors in the second, and all three of us signed it. So on an in-between quarter with no breakout, which is a very live outcome, that holder ends up at about 0.45x with no date for getting back. Nobody argued for halving the core. It fell out of the rules.

The trim is event insurance, not a verdict on the thesis. So the rebuy should ask whether the print broke the thesis, not whether it confirmed it. Trimmed core shares come back on the first close after report day if the report-day low holds and no broken trigger fired. They come back up to the pre-trim count, never above 1.0x, and then the core's own rules govern.

That makes selling behave like the hedge it replaced. New money still goes through the doors. The holder is protected on the night of the print and still owns the stock the morning after.

A few smaller things. On the checkpoint, my conservative colleague is right to recheck the levels on the day we buy: TIPS under 3% and high-yield under 3.5% on that close. At last week's pace, spreads could cover the 26 basis points to the alarm in about three sessions. But the five-basis-point test grades the CPI print, so read it on the CPI close. Otherwise we're grading two weeks of oil headlines and calling it CPI.

On the floor excess, take his deadline and make it symmetric. The freeze already says no buying from the FOMC through the print. So the position is final before the FOMC decision or the print, whichever comes first. The standing sell works the excess down to the cap into 1176 to 1195, and whatever hasn't filled goes before the decision. After that, nothing changes until the print except a stop.

On the flush cap, his expiration test is better than mine: exclude October 16^th only if it trades like expiration.

He also raised a point he didn't finish. ObesityWeek, Novo's Q3 and the October jobs report all land in the first week of November. If the print is around October 30^th, the five-session wait puts the rolled slice right in that cluster. That cluster includes the full EloraTZP tolerability data, the one detail this tape seemed to punish on Friday.

So confirm the ObesityWeek date Monday along with the Q3 date. If it falls inside the window, the rolled slice waits for the close after it. That's not a new veto. It's the same logic as the CPI checkpoint, which my aggressive colleague endorsed: let the cheap event pass before the money goes in.

On rates, you're each reading the same two weeks and seeing your own story. The peak day fits my aggressive colleague's. The two sessions after it fit my conservative colleague's, with yields easing and the stock still slipping. Neither settles anything, which is exactly why we built a checkpoint that does.

On correlation, my conservative colleague is right that calling LLY partly a hedge was too generous for the bear case. There, credit and real yields hit together. But I never said to size LLY above 1%; I said the 1% binds. It's a ceiling, not a target, and we agree.

So here's where I land: Buy, at the risk the plan already set.

Before the print, the 0.25x starter fills on a close in the 1136.66-to-1151 band, with no chase. The floor tranche needs a close back above 1115, RSI above 35.5, TIPS under 3%, high-yield under 3.5%, the volume test and the flush cap. It waits for the print if the 10-Q shows Q2's jump was recurring cost.

The post-CPI checkpoint opens if core comes in under 0.3%. Real yields also have to close no more than five basis points above their pre-CPI level on the CPI close. TIPS and high-yield are rechecked against their limits on the close we buy. The starter's $265 can go in up to 1217.65. Everything else stays under the 50-day, and all of it stays inside the $440. The freezes stand as agreed.

On Monday we read the 10-Q, confirm the Q3 and ObesityWeek dates, and pull like-for-like consensus and the implied move. The gap cap uses the larger of a 10% stress or one and two-thirds times the implied move, measured mark-to-market. The final size is set before the FOMC or the print, whichever comes first.

After the print, nothing goes in on the report-day close. Confirmation needs $24.6 billion of revenue, plus EPS excluding itemized acquired R&D at or above Q2's cost-normalized level. That's $9.70, adjusted by the 10-Q and never below $9.08. Between $9.08 and that level, it confirms only at or above consensus.

Below the band, or inside it with no consensus, the quarter is in-between. Then the breakout route decides, on a next close above 1217.65 with the report-day low intact. The broken triggers stay as written.

The pullback half needs that low intact. The rolled slice waits five sessions, and past ObesityWeek if it falls inside. Open risk stays inside 1%. Freed risk completes the 1.0x only above 1217.65. It also needs the stops on existing shares at or above cost, on a closing trail no tighter than one and a half ATRs. The overweight needs Q3 above both the top of the band and consensus, plus a clean 10-Q, and it's sized inside the same 1%. No consensus, no overweight this quarter.

Existing holders trim to the cap into 1165 to 1195, or before the FOMC. They restore the trimmed shares on the first close after report day if the report-day low holds and nothing broke. Exits are unchanged: the 1090 close, the 1065 backstop and no adds below the 200-day. A close below 979.50 or a broken quarter means a full exit.

My aggressive colleague wanted a door that opens on what the market actually pays for. My conservative colleague wanted one that can't open on a quarter that went backwards. The band does both. It opens when the business held its ground on any reading and stays shut when it slipped on any reading. Consensus settles the part none of us can measure.

And the person who already owns this stock goes into the print protected and comes out still owning it. That isn't splitting the difference. It's making each of your best rules measure what it claims to. Neutral Analyst: Both of you moved again, so let me bank that first. My aggressive colleague accepted the 10% floor on the gap cap, marked to market. He also withdrew the $9.40 fallback, so the overweight now needs a real beat against real consensus plus a clean 10-Q. My conservative colleague conceded that $9.70 mixed two rulers, dropped the ADX gate and accepted the restore in principle. All three of us agree on the checkpoint terms, the expiration test and the ObesityWeek wait.

Four things are left: the door into the full position, the risk ruler, the restore and the deadline. On most of them, one of you has the right diagnosis and the wrong cure.

Start with the door, because it governs the most money. My aggressive colleague caught me fairly. In round three I said $9.08 was enough to finish the full position, because the question there is whether the franchise is intact, and that the overweight should need a real beat. My conservative colleague put it more cleanly that same round: the slice above the full position is the bet that the quarter beat what the market expected. Then last round I let consensus decide inside the band, and both of you went along. That quietly handed the full position to the beat test. I'll own that.

But a green report-day close is the wrong replacement, and my conservative colleague gave the right reason. The next-close rule already applies to every post-print buy. So the only thing the new door adds is a sign test that every report day in our data passed. It can't tell a quarter the market likes from one it hasn't made up its mind about.

He's also right about April. It passes every bar still on the table, so the missed gain my aggressive colleague keeps pricing comes from rules nobody is defending anymore. And you can't lean on a range around 1170 while warning of a re-rating we'll miss. If it's a re-rating, a close above 1217.65 will say so.

His other argument doesn't hold, though. He says the green-day door buys the upper half of the range with a stop in its middle, where ordinary swings take it out. That's true of every door below 1217.65, including the one he's defending. A quarter that beats consensus by two cents and closes at 1170 buys the same shares at the same price with the same stop. We manage where a door fires with size and the stop. What's wrong with the green-day door is what triggers it.

So here's what I'd use inside the band instead. The band exists only because none of us could say whether Q2's record 85.8% margin was the run rate or a spike. Q3 answers that the morning it prints. Take the acquired-research line out of both quarters. Then work out what Q2 would have earned at whatever gross margin Q3 actually reports. Q3 has to earn at least that, and never less than $9.08.

That's my conservative colleague's own principle, no like-for-like step back, on the one ruler he accepted. If Q3's margin falls back toward the trailing average, Q2's bar falls with it, which matches his own view that the record wasn't the trend. If Q3 holds the record, the bar stays near the top. Then an in-band number means spending ran up, and it doesn't confirm.

Because both quarters sit at the same margin, the margin swing mostly washes out. A point of margin costs Q3 about 27 cents a share and lowers the bar about 26 cents, so what's left leans slightly against Q3. The question remaining is the one tranche three exists to answer: did the extra revenue pay for the extra spending? Margin still counts at the $9.08 floor and the 81% line, which is where we already agreed it should.

Put numbers on it. Suppose the 10-Q shows all of the roughly $2.4 billion the fundamentals report estimated was acquired research. Then Q2's underlying costs ran at 44.6% of revenue. A $24.6 billion quarter at an 83% margin passes with costs at about 47% or less. At 48% it earns about $9.63 against a bar of $9.87, and the breakout route decides.

My aggressive colleague's ordinary quarter has last year's 13.1% sequential growth, the same 83% margin and the same 48% costs. It earns $10.17 and passes, because the extra revenue paid for the extra spending. If the 10-Q shows only half the jump was acquired research, the $9.08 floor binds instead. At $24.6 billion and 83%, that means costs at 50% or less, the plan's own cost bar. The more of Q2 we call one-time, the more Q3 has to prove it. My conservative colleague's $8.12 quarter fails either way.

It also fixes something neither of you noticed. Your agreed range of $8.98 to $9.10 averages costs over four quarters. That average includes last October's 51.2%, the bump I flagged as a possible charge, so it isn't quite one ruler either. This test doesn't average anything. It uses Q2's actual costs with the acquired-research line out, from the 10-Q we're reading Monday anyway.

Run the like-for-like part back over reported numbers. It opens on the three quarters before Q2, last October only narrowly. It shuts on Q2, which is the August entry that's underwater today. Once the 10-Q is in, Q2 may well pass with the charge stripped out, so I won't claim six quarters prove it's a filter. Nothing built on six quarters can. What I will claim is that it says no for the reason my conservative colleague gave: spending outran revenue at the same margin. It doesn't depend on whether the stock closed a dollar higher.

Consensus goes back where both of you put it in round three, on the overweight. There, my aggressive colleague's worry about how consensus is calculated costs almost nothing. You're each right about half of it.

On the actual side, it's one adjustment, because acquired research is its own line on the income statement. The consensus side is the hard half. I think my aggressive colleague is right that since 2024 Lilly's adjusted earnings have kept acquired research in. If so, the Street's figure may already carry a known charge, and matching it can take rebuilding. For the full position, that would matter. For the slice above it, the rule is simple: same basis or no overweight, and it waits a quarter.

Now the risk ruler, where my conservative colleague found a real flaw and then overcorrected. He's right that "stops at or above cost" measured risk against what we paid. A stop at cost protects what we paid, not the book. So the shares we already hold count when we decide whether to add. Freed risk folds into that, and I agree.

But he wrote the rule as continuous and everywhere, and both words break things.

Continuous cuts both ways. After August's report, ATR hit 42.72 the next day. Twenty shares on a one-and-a-half-ATR trail at that volatility carry about $1,280. So a continuous rule would sell part of a full position right after a good quarter, just because volatility rose. A fixed stop under the report-day low causes the same problem from the other side. As the stock rises away from the stop, the mark-to-market risk grows, so a continuous rule trims the position for working. Nobody proposed either.

"Everywhere" is worse, and his own deadline argument shows it. He told us the core has no 1090 and no 1065, only 979.50. Twenty shares at Friday's close against 979.50 is about $3,300 of mark-to-market risk, 3.3% of the book. If one ruler really applies everywhere, every holder cuts to about six shares. That's a bigger version of the halving we all just agreed to fix.

So keep one ruler, but give it the right job. Mark-to-market risk to the stop we actually hold limits every add, through every door. It never forces a sale of shares we already own. The stops and the broken triggers do that. The one exception is an overnight event no stop can protect against, and that's the gap cap's job.

Measure to the actual stop, not a notional one and a half ATRs. The plan sized the floor tranche on a 25-point stop, 0.78 ATR, and all three of us kept it. So the full position completes when twenty shares fit inside $1,000 to the stop we have, which means a stop within about 50 points. With a report-day low 60 points away, that's 16 shares now. The rest comes when a higher low brings the stop within range. My one-and-a-half-ATR rule stays what I meant it to be: a limit on how tight a trailing stop can get, not a sizing formula.

He's right about the overweight, though. Twenty-five shares need a stop within 40 points. My trailing-stop floor keeps the stop that far back until ATR is under about 26.7, lower than anything in our data. Two of my rules together quietly made the overweight a next-quarter item. I'd rather own that than loosen either rule, and my aggressive colleague already called caution on that slice cheap.

On the restore, my conservative colleague's scenario is right. A plan that sells new money below 1090 on report day and buys holders' shares at 1065 the next session contradicts itself. So the restore needs a close back above 1090. His 200-day condition is harmless but redundant here, since the 200-day should still sit below 1090 through late October.

But his arithmetic runs backwards. He said restoring at 1065 leaves twelve shares about $1,000 above the core's 979.50 exit, while waiting for 1090 costs only about $300. Restoring at 1090 leaves the same twelve shares about 110 points above 979.50, roughly $1,300. By his own measure, his rule carries more risk to the core's exit, not less. The real reason for the 1090 condition is information. A close back above the plan's own stop says the market has reversed the gap. That's reason enough, and it's the one I'd write down.

How we classify the restored shares matters more than the number. He calls them an add. Suppose they are, and we measure them to 979.50 the way he did. The eight or nine core shares we kept already use nearly the whole 1% at 1090, so not one share can come back. That's the permanent halving again.

The restore isn't an add. It reverses a trim made for the event, back to a position the plan already chose to hold on its own exits. It needs an information test, not a budget test. I'll take his 10-Q wait for the narrow case where costs ran at 54% of revenue or more and the jump isn't on the acquired-research line.

On the floor shares the cap forced out at market, my conservative colleague is right and my aggressive colleague isn't. Those shares were bought knowing they'd be sold before the print, and the trader's plan always said to rebuy on confirmation. Giving them the holders' route back would let the trade that missed its target back in faster than the one that hit it. They come back through the normal doors.

The deadline is the smallest fight left: a handful of shares for a couple of sessions. The date settles most of it, and my conservative colleague's catch is right. October 30^th is a Friday, and every report day in our data fell on a Wednesday or Thursday.

If Lilly reports on the 28^th, the print comes before the Fed decision, and both versions say the excess goes by the close on the 27^th. If it reports on the 29^th, my aggressive colleague's "close before the print" is the Fed-day close. That's the very eve he says he wants to avoid, and GDP lands the same morning as the print. If it slips into the next week, that week holds GDP and possibly ObesityWeek and Novo's results. That's more reason to have decided, not less. Only "the decision or the print, whichever comes first" works under every date.

My aggressive colleague is right about one thing: the Fed doesn't gap us, because it announces while the market is open. So let the standing sell work through the morning of decision day, and sell any remainder before the 2 p.m. statement rather than at the prior close. The order gets its extra hours. And we don't carry shares we've already decided to sell through a decision and a press conference, when a holder's excess has no stop above 979.50.

One last thing, and it's my mistake. I wrote the volume condition into the breakout route in round two and dropped it along the way. My conservative colleague is right to put it back. The breakout route needs a next close above 1217.65 on above-average volume, with the report-day low intact. Volume on an up close shows direction, which ADX couldn't.

So here's where I land: Buy, at the risk the plan already set.

Before the print, nothing changes from what we agreed. The starter fills in its band with no chase. The floor tranche carries every veto, the volume test and the cap on heavy-selling days. The post-CPI checkpoint runs on the agreed terms, and the buying freezes stand.

On Monday we read the 10-Q for Q2's acquired-research line, confirm the Q3 and ObesityWeek dates, and pull consensus and the options-implied move. The gap cap is the larger of 10% or one and two-thirds times the implied move, marked to market. Any excess sits on standing sells at 1176 to 1195 and goes before the decision or the print, whichever comes first.

After the print, nothing goes in on the report-day close. The full position confirms on $24.6 billion of revenue plus EPS, excluding acquired research, that clears two bars: at least $9.08, and at least what Q2 would have earned at Q3's own gross margin on the same basis. Otherwise the breakout route decides, on volume, with the report-day low intact.

Every add fits inside 1% of the book, marked to market against the stop we actually hold, and nothing gets sold because that number grew. Exits stay with the stops, the gap cap and the broken triggers. Holders restore trimmed shares on a close above 1090, with the report-day low intact and nothing broken. Floor shares come back through the normal doors. The overweight needs a same-basis consensus beat, a clean 10-Q and a stop that fits, which probably means next quarter. Exits are unchanged.

My aggressive colleague wants the plan paid when it's right. My conservative colleague wants it wrong only by an amount we agreed to. Both get what they want if each rule does one job.

The door should open on what the quarter earned, not on what the stock did on report day or what the Street guessed. The risk budget should limit what we add, not unwind what we hold. And the restore should ask what the market said after the gap, not treat insurance as new money. That isn't the midpoint between you. It's each of your best ideas, measured the way you each said it should be. Neutral Analyst: Let me bank this round first, because what's settled is now most of LLY's plan.

My aggressive colleague gave up the green-day door. He accepted that shares we already own count against the budget and put 1090 on the restore. He also sent forced-out floor shares back through the normal doors, took the decision-day deadline, and put volume back on the breakout. My conservative colleague took consensus off the full position and dropped the continuous, everywhere version of the ruler. He stopped calling the restore an add, and took the volume definition and the open-ended breakout window.

Five things are left: the ceiling on the bar, the current-ratio gate, what "the line" means, the 200-day trim for holders, and the November freeze. On most of them my conservative colleague has the better of it this round. On one, he has rebuilt the kind of gate he just gave up.

Start with the bar, and let me own my part first. Last round I passed my aggressive colleague's ordinary quarter, with costs at 48% of revenue, against a bar built on stripped costs. That 48% came from round one, when every cost figure we had was reported with deals included. I made the two-ruler mistake before he did. He just made it with a bigger charge.

My conservative colleague's arithmetic is right. Q2's costs below gross profit are fixed at $12.6 billion. So every dollar the filing puts on the acquired-research line is a dollar the running business didn't spend. The size of the charge isn't noise on top of the measurement. It is the measurement.

And the test is gentler than my aggressive colleague makes it sound. It doesn't ask Q3 to grow earnings at all, only not to shrink them at the same margin. With a $3 billion line and an 83% margin, a $24.6 billion quarter can lift running costs about 14% on 7% more revenue and still pass. Now take his ordinary quarter with no deals in it, against that same $3 billion line. Running costs at 48% of $26 billion are up about 30% on 13% more revenue. Failing that quarter isn't a filing punishing the business. It's the test asking the one question tranche three exists for, and the breakout route is still open to it.

But his worry has a real core: one filing shouldn't be able to turn Q2 into a quarter nobody could repeat. My conservative colleague already met that on one ruler, by flooring Q2's stripped cost ratio at the lowest stripped ratio among the other quarters. I'd make two changes.

First, don't stop at the three quarters the Q2 10-Q's columns give us, one of them the depressed first quarter of 2025. The 10-K and last year's Q3 10-Q are on file, so measure all six quarters in our table the same way.

Second, acquired research isn't the only line below gross profit that has nothing to do with the franchise. If the filings break out gains and losses on Lilly's equity stakes, strip those from both quarters too, using the tax effect the filings show. As I understand Lilly's reporting, its own adjusted figures have long set those marks aside. A big gain in Q2 would flatter its cost line exactly the way my aggressive colleague fears, whether or not Lilly bought anything.

Be honest about what that floor costs, though. Lilly's cost ratio has fallen every year since 2023, so even on one ruler the latest quarter will often be the lowest. The floor will sometimes bind on ordinary operating leverage, not just on a fluke, and then it tilts the bar a little toward yes. I can live with that, because the breakout route catches what the bar misses. But nobody should call it neutral.

The most important rule this round is my conservative colleague's: write the bar down Monday. For four rounds, all three of us redrew it against report days we'd already seen, and every redraw leaned toward whoever drew it, mine included. Monday is the last day we can draw it blind. Write down three things: the stripping list, the floor, and the bar against every Q3 gross margin from 81% up. Then nobody touches it.

Now the overreach. My conservative colleague wants the full position to wait for the 10-Q and a current ratio of at least 1.3 whenever Q3's acquired-research line is bigger than Q2's. His diagnosis is fair: stripping deal costs from the test makes the door blind to them, by design. But we already agreed where they show up instead, in the valuation, which keeps the charges in.

And the gate fails the test he used to kill the gross-margin bar. Three of the six balance sheets in our table sat below 1.3: 0.94 at the end of 2023, 1.15 at the end of 2024 and 1.28 in mid-2025. That's the stretch when annual earnings went from $5.80 a share to $22.95. A gate that would have said "not yet" while earnings quadrupled is the gross-margin gate again, moved to the balance sheet.

It also watches the wrong line. Q2's $15.4 billion outflow lined up with a $15.9 billion rise in long-term assets, so most of what Lilly spent was capitalized, not run through acquired research. A trigger keyed to that line can fire on a quarter with a modest charge and sleep through a large acquisition booked as an asset.

The fundamentals report called 1.3 a level to watch, not a level to wait for. Keep it there, and make it part of the clean 10-Q the overweight already needs. The overweight is off this quarter anyway, so the balance sheet gets a full quarter to show us which way it's heading before it touches size.

On the breakout, my conservative colleague is right, and it isn't close. The daily SuperTrend line only ratchets down while the trend is down. Picture a report-day gap to 1060 with a hundred-point true range. That lifts ATR into the high 30s and pulls the line into the 1170s, inside the cluster where every rally since August has stalled. "Any close above the line" would then buy a bounce after a weak print. That's the green-day door my aggressive colleague just withdrew, reopened by an indicator's arithmetic. I read it as a slip, since the same paragraph named 1217.65. Write the number.

Now the biggest item on the table, which my conservative colleague found using my arithmetic. Twenty shares against 979.50 is about $3,300 at risk, 3.3% of the book. Both of you have half of this. My aggressive colleague is right that the restore is the put spread we couldn't buy. My conservative colleague is right that the put spread would have expired with the print too. So the problem was never the restore. From day one, the trader's core had no price exit between the print and a line 14% below. It's live today, for every holder at full size going into CPI.

So I support the 200-day trim, and it's cheaper than my aggressive colleague will think. Say LLY closes around 1080, below the 200-day, before the print. Trimming to 1% at risk to 979.50 leaves about ten shares, and the gap cap at that price is about nine. So before the print, the trim is just the cap's trim pulled forward a week or two when the long-term average breaks. By then the standing sell at 1176 is a hundred points away and wasn't going to fill anyway.

On a gap down through the print, it doesn't bind at all. A capped holder at 1060 has eight or nine shares, and 1% to 979.50 allows twelve. Where it does real work is after the restore, in the November cluster, which is exactly where he aimed it.

My aggressive colleague will say it sells holders at the bottom of a CPI flush. It might. That mistake costs the round trip back to 1115, $300 to $400 on ten shares. The other mistake costs about $1,000 on the same ten shares if the slide reaches the weekly line. And this stock fell 23% between February's report-day close and the end of April. A Buy rating doesn't mean holding full size through what the technical report calls the first real warning to the long-term trend.

It needs three definitions so it doesn't collide with what we've built.

First, it trims once, on the close that breaks the 200-day, marked to market. It's not a ruler that keeps selling as the price moves.

Second, if that close comes before the print, the restore afterward stops at the trim size, even if the cap had already taken the holder below it. Otherwise the restore quietly undoes a trend warning by treating it as event insurance. That's the same confusion we just fixed in the other direction.

Third, the shares the trim sold come back through the trader's re-entry doors: a reclaim of 1115 with the confirmations, or a confirmed quarter. They also come back with the exits that go with those doors, the 1090 close and the 1065 backstop, and they're measured to their own stop. If we stack them on the core's risk to 979.50 instead, our own add rule blocks them forever. At 1115, the ten core shares left already carry about $1,350 to that line, more than 1% on their own, so no re-entry could ever fit. That's the permanent halving we fixed on the restore, rebuilt by the trim. Ten shares against 1090 is about $250, inside the $440 the plan already budgets for tranches one and two.

On the November freeze, I'm with my conservative colleague, with one correction and one repair.

The correction: he says my ruler means nothing on a morning when Novo reports before our open. That overstates it, because the ruler still caps what any add can lose to its closing stop. But he's right that a closing stop can't see an overnight headline, and a two-session pause costs almost nothing.

The repair: the pullback half has a two-week window. A freeze before Novo's results and before the EloraTZP presentation could eat two to four of those ten sessions. A rule meant to delay a buy shouldn't be able to cancel it, so the window extends by however many sessions the freeze takes. And if the presentation date isn't published by Monday, freeze the two sessions before the conference opens.

One small thing on the cap. We're pulling the implied move Monday, three weeks before the deadline, and a straddle read that early mixes the event with weeks of ordinary days. Read it again the session before the deadline and set the cap off that reading. With the 10% floor in place, the later reading can make the cap more accurate, but never looser than the floor.

And here's the risk none of us has named, because we've spent five rounds creating it. This plan now has more conditions than most desks write for a whole book. Plans like this rarely fail on a bad rule. They fail when someone misreads a good one at 7:30 on the morning of the print. So Monday's write-up shouldn't stop at the bar. Put the whole post-print decision on one page: the bar schedule, the stripping list, the cap, the deadline, the doors and the order of exits. Then have someone who argued for none of it check the arithmetic. That's the cheapest risk control in this entire debate.

So here's where I land: Buy, at the risk the plan already set.

Before the print, nothing we agreed changes. The starter fills in its band with no chase. The floor tranche carries every veto, the volume test and the flush cap. The post-CPI checkpoint and the freezes run as written.

On Monday we read the Q2 10-Q, the 10-K and last year's Q3 10-Q, and write the bar down. We confirm the Q3, Novo and ObesityWeek dates, and pull consensus and the implied move. The cap is the larger of 10% or one and two-thirds times the implied move, marked to market and re-read the session before the deadline. Excess works on standing sells at 1176 to 1195 through the morning of decision day. Anything left goes before the 2 p.m. statement, or before the print if that comes first.

After the print, nothing goes in on the report-day close. The full position confirms on $24.6 billion of revenue plus earnings that clear both $9.08 and Q2 restated at Q3's gross margin. Acquired research comes out of both quarters, and so do equity marks if they're itemized. Q2's running-cost ratio is floored at the lowest of the other five quarters, measured the same way.

Otherwise the breakout route decides. That means any later close above 1217.65, the number itself, on volume above the pre-print 20-day average, with the report-day low intact. The pullback half needs that low intact, and its window stretches for any frozen sessions. The rolled slice waits five sessions and until after ObesityWeek. No new money goes in below 1217.65 in the two sessions before Novo's results or the EloraTZP presentation.

Every add fits inside 1% of the book, marked to market against the stop we hold, and nothing gets sold because that number grew. The current ratio stays on the watch list and inside the clean 10-Q the overweight needs, which makes the overweight next quarter's decision.

Holders restore trimmed shares on the first close after the print that holds the report-day low, closes above 1090 and breaks nothing, up to their count before the cap trim. They wait for the 10-Q only if costs ran hot and the jump isn't on the acquired-research line.

Every share whose only price exit is 979.50 gets a one-time trim to 1% at risk on a daily close below the 200-day. If that close comes before the print, the restore stops at the trim size. The trimmed shares return through the trader's re-entry doors, carrying the 1090 close and the 1065 backstop. Floor shares come back through the normal doors.

Exits are otherwise unchanged: the 1090 close and the 1065 backstop for tranches one and two, no adds below the 200-day, and a full exit below 979.50 or on a broken quarter.

My aggressive colleague wants the plan paid when it's right. With a bar drawn blind and a breakout door at the real range top, it can be, without a ceiling borrowed from a different ruler. My conservative colleague wants every share to carry a loss we can name in advance. With the 200-day trim the core finally has one, without a balance-sheet gate that would have sat out the quadrupling of earnings.

What I'd ask of both of you now is to stop adding gates and start writing things down. The quarter will answer on its own schedule. Our job Monday is to decide, before we see it, what each answer means.

V. Portfolio Manager Decision¶

Portfolio Manager¶

Rating: Overweight

Executive Summary: Overweight LLY. The business is compounding fast, but at 1142.85 the stock is fairly valued (~38x trailing, ~31x normalized run-rate), sits mid-range, and faces CPI (~Oct 14-15), the FOMC (Oct 27-28) and an unconfirmed Q3 date, so build toward 1.0x of a standard allocation over 4-6 weeks rather than buying full size now. Buy a 0.25x starter on the first daily close in 1136.66-1151 (no chase); add 0.35x at 1107-1118 only on a close back above ~1115 with RSI > 35.5, 10y TIPS < 3.0% and HY spreads < 3.5% (or via the post-CPI checkpoint); add the final 0.40x no earlier than the close after report day, on either a confirmed Q3 (revenue >= $24.6B and EPS ex acquired R&D >= $9.08 and not below Q2 restated at Q3's gross margin) or a later close above 1217.65 on above-average volume. Into the print, keep unhedged shares to about half the target (open loss plus the larger of a 10% gap or 1.67x the implied move within ~1% of the book); exit new tranches on a daily close below 1090 (1065 intraday backstop), cut full existing positions to 1% of the book at risk to 979.50 on a close below the 200-day (~1,071-1,085), and exit everything below 979.50 or on a broken Q3, over a 3-6 month horizon with a $1,255 target (~+9.8%).

Investment Thesis: Decision: Overweight. The research plan rated LLY Overweight and the trader turned that into a Buy (accumulate) action. All three risk analysts ended at 'Buy at the risk the plan already set,' but what they agreed on is a staged build: 0.25x now, conditional adds, unhedged exposure capped near half the target into the print, and the above-target 1.25x tier deferred to next quarter. On this scale that is Overweight (favorable outlook, gradually increase exposure), not a full-conviction Buy. It is not a Hold either, because no analyst argued for avoiding the stock; the bear case was always 'buy lower or on confirmation.' Direction (the bull side won, uncontested): Q2 revenue was $22.97B (+47.7% YoY, a record +$3.2B QoQ). H1'26 EPS was $16.20 (+73%) and TTM EPS is $29.80 (+95%). TTM operating cash flow is $28.1B (1.05x net income, with a record $10.7B in Q2). Costs below gross profit fell from 63.9% of revenue in 2023 to 49.9% TTM. Jaypirca won first-line CLL/SLL approval Friday with ~45 minutes of trading left, so Monday is its first full test. Weekly (979.50) and monthly (781.18) SuperTrends are up, and price is 6.7% above a rising 200-day (1071.34). Report days moved the stock +3.8%, +10.3%, +9.8% and +4.9%, so owning nothing into a good Q3 has a real cost. Pacing (the cautious side won): at 1142.85 LLY is 38.35x TTM EPS. Normalizing Q2 on one basis (removing both the apparent acquired-R&D spike and the record 85.8% gross margin), the neutral analyst showed Q2 earned ~$9.10, about 31x run-rate; the aggressive analyst conceded this. The research plan's balanced model clears the 9% hurdle by only ~1 point a year. The conservative analyst's tape evidence was the strongest near-term point. In a week with an FDA approval, positive data and two days of easing yields, LLY still fell 3.43% and closed 10/2 in the bottom 22% of an outside day. That followed the 9/30 failed breakout: a 1215.00 high and a 1157.08 close in the bottom 3% of a 1.8-ATR range, on 3.41M shares (~1.5x average). MACD (-2.93 vs a -3.59 signal) is near a bearish cross below ~1150, RSI is 43, and OBV made a lower low (337.85M). At 1142.85, price is only 1.1 ATR above the 1107-1118 floor and 1.6 ATR below the 1194.72 upper band. Macro is unresolved: 10y TIPS are at 2.88% (5bp off the highest since 2008), HY spreads are 3.24% after widening 51bp in six days, the Fed just hiked, and CPI and the FOMC both land before the print. Q3 also faces the year's hardest comparison ($17.6B), so even the $24.6B line prints only ~40% YoY, the slowest in five quarters. Quality flags are real but not thesis-breaking: charges in roughly 4 of 12 quarters, OCF+ICF of -$3.3B in H1'26, liabilities +$23B in Q2, and the current ratio down to 1.35. How the debate was settled: the neutral analyst framed it correctly. Once the gap cap binds, nobody carries more than ~8-9 unhedged shares (desk example) into the print, so the pre-print fight was over 3-4 shares (~$200 of risk). Doubling the starter would mostly buy CPI/FOMC exposure that must be sold before the print. Listed options don't fit desk-scale positions (one contract is ~$114k notional). Both aggressive proposals are rejected. The money is in the post-print rules. There, the neutral analyst showed the plan's original confirmation test (gross margin >= 83% and costs <= 50% of revenue, on >= $24.6B) passed in none of the last six quarters. It would have blocked every quarter the market rewarded, including April's entry, still ~23% higher. I adopt the replacement the debate converged on. Revenue must be >= $24.6B, and EPS excluding acquired IPR&D (and equity-investment marks if itemized) must clear both $9.08 and Q2's like-for-like earnings restated at Q3's reported gross margin. Q2's stripped running-cost ratio is floored at the lowest of the other five quarters measured the same way. This asks the question the final tranche exists for: did the extra revenue pay for the extra spending? The schedule gets written down Monday, before Q3, because every redraw in this debate leaned toward whoever drew it. Rejected: the revenue-only door (the conservative's $8.12 quarter, with revenue +7% and EPS +2%); the green-day door (a sign test all four report days passed); and a current-ratio gate (it would have blocked 2023-25 while EPS quadrupled; 1.3 stays a watch item). Execution, in fractions of a standard allocation (desk example: 1.0x is ~20 shares, ~$22.9k on a $100k book risking 1%): (1) Starter, 0.25x: buy on the first daily close in 1136.66-1151 from 10/5. Don't chase above 1151. A close below 1136.66 first rolls it into the floor tranche. (2) Floor, 0.35x: buy in 1107-1118 on a close back above ~1115 with RSI > 35.5, TIPS < 3.0% and HY < 3.5%. The slide into the floor must average lighter volume than the 2.44M/day slide into 9/11. Any down day heavier than ~3.4M shares requires a second close above 1115; the 10/16 expiration is excluded only if it closes within ~8 points of the prior close. This tranche waits for the print if the 10-Q shows Q2's $3.8B cost jump was recurring. (3) Post-CPI checkpoint: this applies if core CPI is < 0.3%, TIPS closes CPI day no more than 5bp above its pre-CPI close, and TIPS < 3.0% and HY < 3.5% on the buy-day close. Then the starter's unfilled $265 of risk may go in on any close below 1217.65; other unfilled money goes in only between the floor and the 50-day (~1171). Open risk to 1090 stays within ~$440 (0.44% of the book). (4) No floor fills in the two sessions before CPI, or from the FOMC decision through the print. (5) Gap cap: the larger of a 10% gap or 1.67x the options-implied move (re-read the session before the deadline), marked to market. Work the excess on standing sells at 1176-1195, and sell any remainder before the 2 p.m. FOMC statement or the print, whichever comes first. (6) After the print, nothing goes in on the report-day close. On a confirmed Q3, buy half of the final 0.40x (plus any unfilled floor slice) on the next close if the report-day low holds. Buy the other half on the first pullback within two weeks that holds that low, extending the window by any freeze days. The rolled floor slice waits five sessions and until after ObesityWeek. No new money goes in below 1217.65 in the two sessions before Novo's Q3 or the EloraTZP presentation. Stops move to just under the report-day low. Every add must fit within 1% of the book, marked to market against the stop actually held; that limit never forces sales. (7) In-between Q3: hold. Add only on a later close above 1217.65 (the fixed number, not the moving SuperTrend line) on volume above the pre-print 20-day average (~2.3M) with the report-day low intact, or on a confirmed test of 1107-1118 or the 200-day. (8) Broken Q3 means a full exit: revenue < $23.5B, gross margin < 81%, recurring costs >= 54% of revenue, a guidance cut, or, from Q4 on, any non-Q1 quarter adding < $0.5B sequentially. (9) The 1.25x tier needs a same-basis consensus beat, a clean 10-Q and a stop within ~40 points, so it is effectively a Q4 decision. Exits for new tranches: a daily close below 1090 (re-enter only on a reclaim of ~1115 with the confirmations, or on a confirmed Q3), a 1065 intraday backstop, no adds below the 200-day, and a full exit on a close below 979.50. Existing holders: keep the core up to 1.0x, add nothing mid-range, and do not run the range short. Trim to the gap cap into 1165-1195 (or before the FOMC statement). Restore trimmed shares, up to the pre-trim count and never above 1.0x, on the first close after report day that holds the report-day low, closes above 1090 and trips no broken trigger. If costs ran >= 54% outside the acquired-R&D line, wait for the 10-Q first. A full core's only price exit (979.50) is ~$3,300, or 3.3% of the book, away, so I adopt the conservative's one-time trim. On a daily close below the 200-day (~1,071-1,085), cut to 1% of the book at risk to 979.50 (~10 shares in the example). If that happens before the print, the restore stops at the trimmed size. The sold shares return only via a reclaim of ~1115 with the confirmations or a confirmed quarter, carrying the 1090/1065 stops. What changes the call: move toward Buy on a confirmed Q3 backed by the 10-Q, a daily close above 1217.65 on above-average volume, or TIPS falling back toward 2.6%. Move toward Hold or Underweight on any broken-quarter trigger, a close below the 200-day while TIPS > 3.0% or HY > 3.5%, or ObesityWeek/Foundayo data showing falling revenue per patient or poor next-generation tolerability. EloraTZP's 10.8-27% discontinuations, versus 2.9% for tirzepatide, are the live risk. Price target $1,255 (valuation objective, by the Q4 report): calendar-2026 EPS = $8.26 (Q1) + $7.94 (Q2) + $9.08 (Q3 at the confirmation line: $24.6B x ~33% net margin / ~894M shares) + $9.58 (Q4 at ~5.5% sequential growth, the mid-20s annual pace implied by the plan's 1.1-1.2 PEG at ~28x forward) = $34.86. At 36x, that gives ~$1,255. The 36x is today's 38.35x trailing less ~6%. That is the midpoint of the compression seen when trailing EPS stepped up: ~1-2% on the August and February report days, and ~10% after February's next session and in April's stress. It is also close to a straight-line path toward the research plan's 22.5x two-year exit (~35.7x by February). Cross-checks: $1,255 is ~28.6x the following four quarters at the same growth, in line with the ~28x forward the plan cites, so no meaningful re-rating is needed. It sits between the 7/7 high (1247.66) and the 8/19 closing high (1280.34), the breakout setup's targets. It implies ~+9.8% upside against ~-4.6% to the 1090 stop. This is the confirmed-quarter base case. An in-between quarter more likely leaves LLY ranging near ~1,170 (the debate's midpoint). April's 33x on post-Q3 trailing EPS of $32.67 gives ~1,080, the stress case the stop and gap cap exist for. Confidence is medium. All analysts agreed on direction and pacing, and the technical data are verified and internally consistent. But the Q3 date is unconfirmed (10/30 is a Friday, while prior report days fell midweek), and the Q2 10-Q's cost breakdown hasn't been read. The materials also lack consensus, the options-implied move, insider data, a capex split, Foundayo launch figures and Jaypirca's label breadth. Monday checklist: read the Q2 10-Q (plus the 10-K and Q3'25 10-Q) and write the bar schedule. Confirm the Q3, Novo and ObesityWeek dates, and pull consensus and the implied move. Put the full post-print decision on one page, checked by someone who argued for none of it.

Current Price: 1142.85

Price Target: 1255.0

Confidence: Medium

Time Horizon: 3-6 months

Trading Analysis Report: LLY¶

I. Analyst Team Reports¶

Market Analyst¶

LLY (Eli Lilly and Company, NYSE): technical analysis¶

0. Data check¶

1. Indicators chosen and why¶

2. Price structure: a narrowing range after a big rally¶

3. Trend: the timeframes disagree¶

4. Momentum: rolling over¶

5. Trend strength (ADX): mostly a ranging market¶

6. Volatility (ATR and Bollinger Bands)¶

7. Volume (OBV): no sign of accumulation¶

8. Stretch (z-score): nothing is stretched¶

9. Overall read¶

10. Trade setups for LLY¶

11. Risks and gaps¶

12. Summary table¶

Sentiment Analyst¶

1. Source-by-source breakdown¶

2. Cross-source divergences and alignments¶

3. Dominant narrative themes¶

4. Catalysts and risks¶

5. Key sentiment signals¶

News Analyst¶

LLY: Weekly news and macro report (as of 2026-10-03)¶

1. Summary¶

2. Company news (LLY)¶

2.1 Obesity and diabetes drugs: Foundayo and EloraTZP data (positive)¶

2.2 Cancer: Jaypirca approved for untreated CLL/SLL (positive)¶

2.3 Foghorn collaboration ended (neutral for LLY)¶

2.4 Competition: Novo Nordisk did about $4B in two deals (mildly negative, long-term)¶

2.5 Sentiment (bullish but crowded)¶

3. Macro backdrop (FRED data)¶

3.1 The Fed is raising rates again¶

3.2 Bond yields: driven by real yields, not inflation fears¶

3.3 Inflation: led by energy, with core firming slightly¶

3.4 Jobs and growth: few hires, few layoffs¶

3.5 Oil and the Iran war¶

3.6 Risk appetite, the dollar and financial conditions¶

3.7 Prediction markets¶

4. How the macro affects LLY¶

5. Upcoming events (approximate dates; confirm)¶

6. Scenarios¶

7. Takeaways for the trading agent¶

8. Caveats and data gaps¶

9. Key points¶

Fundamentals Analyst¶

LLY (Eli Lilly and Company): Fundamental Analysis Report¶

1. Data coverage and caveats¶

2. Company profile¶

3. Income statement¶

3a. Quarterly trend¶

3b. Annual and trailing-twelve-month (TTM) trend¶

3c. Key watch item: Q2 2026 GAAP earnings didn't keep up with revenue¶

4. Balance sheet¶

5. Cash flow¶

6. Returns and per-share data¶

7. Long-run history¶

8. Valuation framework (the tools provided no price)¶

9. Insider activity¶

10. Fundamental read and what to watch (the trade decision is left to the next agent)¶

Summary table¶

II. Research Team Decision¶

Bull Researcher¶

1. Growth re-accelerated¶

2. The moat widened on three fronts in one week¶

3. The valuation has already absorbed the rate shock¶

Where I expect the bear to push, and why it doesn't hold¶

How I'd own LLY: buy, in stages¶

My challenge to the bear¶

What I concede¶

1. "Routine or one-time": pick one, and growth holds either way¶

2. Q3: your bar sits at Lilly's weakest non-Q1 quarter¶

3. Valuation: your −14% needs a panic multiple on stale earnings¶

4. Rates and this week's tape¶

5. Margins, cash and leverage: widen the window¶

6. Pipeline: the amylin "trap" catches the challenger¶

7. The chart, and a tighter plan¶

Bottom line¶

What I concede¶